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Asthma is a chronic inflammatory pulmonary disease with a significant socio-
economic impact on patients and their family1. The understanding that airway 
inflammation is the key underlying process has led to the early introduction of 
inhaled corticosteroids in guidelines for the management of asthma2"5. Following 
these developments, asthma management in the Netherlands has shifted from 
exacerbation-management to disease management in the last 2 decades. There is a 
high acceptance rate of inhaled corticosteroids and a reduction in emergency room 
visits, hospitalisations and unscheduled GP-visits can be observed. Although 
standards are high in this perspective, Smeele et al demonstrated that prior to the 
start of our ZBA-study presented in this thesis, there still was a substantial group of 
asthma and COPD patients who did not reach the target level of control as stated in 
the 1992 asthma/COPD guidelines6'7. The overall impact on (socio-economic) burden 
of disease is still substantial, as is illustrated in figure 1.1. It demonstrates that 28% 
of Dutch asthma patients over 16 years of age has had lost work or school days in 
the past year due to asthma8'9. Moreover, this percentage is the highest of all 
participating European countries. As is described in chapter 2 of this thesis several 
strategies have been advised and developed to improve outcomes of asthma 
management, but non-compliance could become one of the major factors limiting the 
effectiveness of new and old treatments. Poor compliance with prescribed inhaled 
therapy is an important cause of uncontrolled disease10'11"1'' which in turn is 
associated with an impaired quality of life15,16 and is presumably responsible for three 
quarters of the total costs of asthma1 in the US. Based on differences in the delivery 
of care, cost of uncontrolled disease can be expected to be relatively lower in the 
Netherlands. However, Smeele et al found that more than 20% of all patients with 
asthma or COPD continuously used their bronchodilator for more than twice daily 
and 25% had at least one exacerbation in the last three months7, indicating that 
there is room for improvement. Improving compliance in terms of stressing the 
continuous use of maintenance therapy may not be the most efficient solution. Based 
on current insights it is unclear how long maintenance therapy needs to be 
continued. Additionally there are indications that inhaled steroids can be tapered off 
10 
Figure 1.1: Percentage of patients that has lost work/school days in the past year 
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or stopped during a certain period or at least reduced to the minimal effective daily 
dose that provides adequate control of the disease(17;18). Optimising treatment for 
the individual patient may balance benefits and risks and leads to a more efficient 
and cost effective treatment. Such treatment optimisation can be achieved through 
self-management. In this thesis self-management of asthma is interpreted as a broad 
concept involving aspects of patients taking control of their own disease(19). This 
includes autonomous decision-making, self-monitoring and the use of a written self-
treatment plan(20). Such written self-treatment plan instructs patients to vary their 
dosage and frequency of inhaled steroids, based on self-assessed peak-flow values 
and asthma symptoms. 
Aim of the ZBA-study was to study to what extent self-management based on patient 
education, skills training and a written self-treatment plan results in more efficient 
and cost effective treatment. 
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Components of self management 
Written self-treatment plan 
Instructions in the self-treatment plan are based on the patients' self assessed 
asthma conditions. Such self-monitoring gives patients the opportunity of guidance 
on decisions they make regarding their asthma-treatment and feedback on the 
effects of these decisions. There are two major sources of feedback available for self-
monitoring: peak flow values and asthma symptoms. 
Peak flow measurements can easily be performed by patients and may indicate 
airway narrowing21"26. When related to the personal best value this parameter can 
provide information on both deteriorating and well-controlled asthma. Ideally daily 
peak-flow measurements should provide the most detailed information about asthma 
control. When well-controlled however superfluous information is gathered and 
patients make unnecessary efforts. We therefore advised weekly peak-flow 
measurements. In the presence of alarm symptoms or a drop of peak flow values 
below 80 percent of the personal best value, patients were instructed to change to 
daily measurement of peak flow values and symptoms. 
Based on self assessed changes in peak flow values patients were advised to 
stepwise stop, halve or double their dosage of inhaled steroids. Patients also received 
instructions on when to start a course of oral steroids (30mg prednisolone per day, 
during 1 week). Cut-off points for peak-flow were 80, 60 and 40% of a patients' 
personal best value20. To reduce the number of erroneous decisions a 'decision-delay' 
was introduced when asthma control possibly deteriorated. Asthma treatment had to 
be intensified only if peak-flow values were reduced during at least two out of three 
consecutive days23. Self-management instructions are summarised in detail in Box 
1.1 and the self-treatment diary is shown in Figure 1.2. 
Symptoms were added as an extra indicator of asthma control. Onset of 
deteriorations of asthma control is notorious for a great variety in symptoms and 
peak-flow changes. Symptoms can precede changes in peak-flow on the one side of 
the spectrum, whereas drops in peak-flow without any noticeable symptoms are on 
the other side of the spectrum. When both symptoms and peak-flow are regularly 
assessed, they can act as back-up systems for each other. When asthma is well 
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Box 1.1: Detail of the self treatment plan 
Step-up instructions 
• Peak flow deteriorates <80% PEFR >60% of Personal Best Value (PBV) for 2 out 
of 3 consecutive days: 
double budesonide dosage 
in case of insufficient response within three weeks: again double 
budesonide dosage 
• Peak flow deteriorates <60% PEFR >40% ofPBVfor 2 out of 3 consecutive days: 
increase budesonide dosage to 800 micrograms b.i.d. 
in case of insufficient response within two days: start course of oral 
prednisolone 
and contact your FP 
• Peak flow deteriorates <40% of PBV: 
If sufficient response to bronchodilator: start course of oral prednisolone 
Else: immediately contact your GP 
Step-down instructions 
• Peak flow improves to >40% PEFR <60% of PBV: 
continue the current budesonide dosage until your PEFR is >80% of PBV 
• Peak flow improves to >60% PEFR <80% PBV: 
continue the current budesonide dosage until your PEFR is >80% of PBV 
• Peak flow improves to >80% of PBV: 
halve budesonide dosage when PEFR >80% for a period of six weeks 
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controlled patients are advised to measure their peak-flow once every week in order 
to detect deteriorations without symptoms. When asthma symptoms occur between 
weekly peak-flow measurements, the self-treatment plan gives the advice to initiate 
daily peak-flow measurements to verify if a true deterioration of asthma-control is at 
hand. It is currently believed that waking at night due to asthma and increased use 
of bronchodilator are the most sensitive symptoms of deterioration5. We used these 
symptoms as the first indicators of decreased asthma control. 
Figure 1.2: Self-treatment diary card 
Patient education and skills training 
Self-management has the objective to empower patients with the knowledge and 
skills to treat their own illness. The self-management program studied in this thesis 
was constructed around the concept of shared responsibilities20. It aims at patients 
shifting from reliance on their physician as the one telling them what to do, towards 
feeling more responsible for ones own choices and willingness to explore ones own 
possibilities. The GP has a responsibility for optimising the circumstances under 
which patients can make decisions and in supporting patients in successfully 
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changing their behaviour. Aim of patient education and skills training is to provide 
the asthma patient with information and tools needed for successful performance of 
the self-treatment plan. However, there may be a discrepancy between what the 
patient wants to know on the basis of own interests or previous knowledge and what 
the patient needs to know according to the health professional. As an effort to bridge 
this possible gap between the patients' and the health professionals' agenda patients 
were given a tool to indicate to the GP what they wanted to know themselves about 
their asthma (feedback) and thus influenced the contents of their own asthma 
education. Because of the increased involvement of the patient in his or her own 
education this approach was called tailored education. Specific skills that were 
trained within this tailored education program were inhalation technique and peak-
flow measurement. 
This thesis 
In chapter 2 self-management of asthma in general practice is positioned and 
identified as an area needing additional research. In 1998 basic principles of self-
management were discussed on the WONCA world-conference. The self-
management program studied in this thesis is based on those principles: patient 
education, skills training and a written self-treatment plan. Educating and training 
patients as described above requires changes in the role of GP and patient. Before 
introducing our program in general practice we first explored if patients and general 
practitioners were interested in such treatment strategy. In chapter 3 acceptance of 
self-management by GPs is studied by comparing expectations of Dutch GPs with 
knowledge and experience of British GPs. In chapter 4 acceptance of self-
management by patients is studied. It was hypothesised that asthmatics have a high 
interest in the possibility of reducing their personal dosage of inhaled steroids. But 
subjects using higher doses of inhaled steroids may be more reluctant as dose 
reduction may lead to unwanted loss of asthma control27. Chapter 4 studies the role 
of the dosage of inhaled steroids in the acceptance of self-management by patients. 
In chapter 5 we studied whether our self-management program succeeded in 
incorporating the patients' needs and if this resulted in higher patient satisfaction. 
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In chapter 6 effects on asthma control, quality of life and lost-activity days are 
studied. 
Chapter 7 explores costs and savings induced by the program and their relation with 
successfully treated weeks, quality of life and quality adjusted life years. 
During the course of the ZBA study several other authors have studied effects and 
benefits of self-management. Combined with experiences from our own ZBA-study 
our own and other insights progressed. In chapters 8 and 9 the role and position of 
self-management is discussed based on these proceeding insights and they are the 
preamble to chapter 10 in which the actual conclusions and recommendations of the 
ZBA-study are discussed. 
16 
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Abstract 
On 15 June 1998, a workshop on asthma and chronic obstructive pulmonary disease 
(COPD) was held at the WONCA conference in Dublin. Based on the current 
guidelines for diagnosis and treatment of asthma and COPD, new developments and 
present and future research projects were discussed. Based on these guidelines and 
the research findings, new developments were positioned. The final conclusion of 
this workshop was that there is a need to continue exchanging ideas at an 
international level. So an initiative to start a Scientific Group of Primary Care 
Research within the European Respiratory Society has been taken. 
Introduction 
On 15 June 1998, a workshop on asthma and chronic obstructive pulmonary disease 
(COPD) was held at the WONCA conference in Dublin. The aim of the workshop was 
to discuss present and future developments in the fields of asthma and COPD in 
general practice. This workshop was a joint venture of the British and Irish GPs in 
asthma groups (GPIAG) and the Asthma/COPD in General Practice Research Group of 
the University of Nijmegen, the Netherlands. 
Recent advances in asthma 
An increasing number of guidelines on the diagnosis and treatment of asthma and 
COPD exists1'3"8. Before applying one of those guidelines, an accurate diagnosis is 
essential. Based on data from the DIMCA study9, CP van Schayck (University of 
Nijmegen/Maastricht, The Netherlands) showed that much asthma and COPD still 
remain undiagnosed (20-60%), and that the prevalence of these diseases is 
increasing despite improved treatment. The DIMCA study also shows that 
undiagnosed patients respond positively to inhaled steroids and could be treated and 
diagnosed as asthmatics. As there are as yet no validated primary preventive 
measures, the importance of improving early diagnosis was emphasised. Detection of 
undiagnosed asthma patients is a major challenge for the future. The DIMCA study 
showed that screening the annual decline in forced expiratory volume in one second 
(FEVi) in subjects with chronic cough and shortness of breath may be an effective 
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strategy for tracing undiagnosed asthma or COPD. Whether this approach is cost-
effective has yet to be established. 
M Levy (GPIAG, UK) discussed several methods in use to administer inhaled 
medication for acute asthma. He concluded that spacers may be useful in general 
practice, but scientific evidence is lacking, as present studies investigating the 
usefulness of spacers are not yet applicable for general practice. Another option 
discussed by M Levy was the usefulness of pulse-oximetry to monitor the patient 
during the treatment of an acute asthma attack. Pulse-oximetry, combined with an 
oxygen-driven nebulizer, may be an efficient way to treat acute asthma attacks and 
prevent sudden, life-threatening hypoxaemias. 
The role of long-acting beta-2 agonists was reviewed by D Ryan (GPIAG, UK). Prior 
to their clinical use, fears had been expressed10 about the regular use of beta-2 
agonists, as this appeared to destabilize asthma. Two randomized controlled trials in 
mild to moderate11 and moderate to severe12 asthma demonstrated their efficacy 
when compared to doubling up the dose of inhaled steroids. The measures where 
superiority was observed were improved morning and evening peak flow 
measurements, reduction in rescue use of short-acting beta-2 agonists, and 
reduction in morning and evening symptom scores. An increase in asthma 
exacerbations was not observed in the group using salmeterol. 
A further study13 using a double-blind crossover design demonstrated that when 
patients used a long-acting beta-2 agonist in conjunction with a strict self-
management plan, a reduction of inhaled steroid dose of 17% could be achieved. 
Finally, a year-long study14 examined the effects of adding an inhaled beta-2 agonist 
to both lower and higher doses of inhaled steroids in patients with persisting 
symptoms over a period of 1 year. It found that the addition of long-acting beta-2 
agonists improved both symptoms and pulmonary function without any increase in 
exacerbation rate. In summary, long-acting beta-2 agonists are a useful and effective 
adjunct to treatment in patients whose asthma is not controlled under low-dose 
inhaled corticosteroids. 
Currently, exact positioning for the Leukotriene Antagonist is not entirely clear, but 
current evidence was reviewed by Dr D Price (GPIAG, UK) along with a suggested 
positioning. Leukotriene antagonists clearly improve all clinical end-points in asthma, 
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including FEVi, independent of beta agonists and, at least to some extent, inhaled 
steroids. This would suggest that leukotriene pathways have not been fully treated 
by our more traditional asthma therapies. It was recommended that they may be 
useful for patients failing to respond fully to inhaled steroids and beta-agonist 
therapy. When prescribing leukotriene antagonists, a trial of between 1 week and 1 
month should verify whether patients respond to this class of therapy. 
At the end of this session, Ρ van Grunsven (University of Nijmegen, The Netherlands) 
presented data from the DIMCA study on aspects of compliance. The success of any 
treatment depends on the compliance of patients. Compliance for anti-inflammatory 
treatment was approximately 70% of the prescribed dose during the study period 
and no predictors for compliance could be identified15'16. Most frequently, self-
reported reasons for non-compliance were the absence of symptoms, experiencing 
(or fearing) side-effects and not having the time to take the medication. If treatment 
of early asthma and early COPD is shown to be effective, then non-compliance to 
inhaled steroids may be a major obstacle. Therefore, compliance should regularly be 
assessed during follow-up visits. Repeat education may be an important tool to 
enhance compliance. 
Management of asthma and COPD 
The second session focused of the actual usage of the present guidelines. The BTS 
issued their revised guidelines on the management of asthma1 and COPD8 in 1997; 
one of the changes was the advice to use self-management programmes. Scientific 
evidence of the beneficial effects of these programmes is building up, but questions 
remain on what plans to use and which patient may profit from them most. Β 
Thoonen (University of Nijmegen, The Netherlands) demonstrated that self 
management plans revolve around the increased sharing of responsibilities between 
GP and patient, and introduced the concept of self-managed education. Self-
managed education keeps interests of both GP and patient in mind, and thus 
decreases the specific information needs of patients. As this approach to self-
management of asthma is still under examination, further results will probably follow 
in the near future. 
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R Spelman (GPIAG, Ireland) discussed the usage of current guidelines by the GPs. 
He showed that almost 50% of Irish GPs use asthma guidelines, often locally 
adjusted national guidelines. As these local guidelines take into account the 
accessibility of local resources and prescribed medication, they are often a more 
pragmatic translation of the common guidelines. On the basis of the NHBLI/Gina 
guidelines2, Spelman demonstrated that choosing the proper treatment for patients is 
not always a matter of gradually stepping up. First, a thorough severity assessment 
should be done, and subsequently treatment is started on the appropriate severity 
step. Starting with higher doses (step down regimen) may reduce the overall 
cumulative dosage of (inhaled) steroids, while this may add to the risk of 
overtreating some patients during certain periods. 
C van Weel (University of Nijmegen, The Netherlands) demonstrated that most of 
the statements in various asthma guidelines are also applicable to children. However, 
there are some major differences. One of the specific actions for asthmatic children 
is the monitoring of growth and development. This provides both information of the 
severity of asthma and of possible growth inhibition due to prescribed (anti-
inflammatory) medication. There are specific difficulties when diagnosing asthma in 
children. In contrast with adults, it often takes an observation period of up to three 
years to diagnose childhood asthma. During these 3 years it is difficult to give proper 
advice. Even when asthma is diagnosed, there are some specific therapeutic aspects 
which differ from the adult guidelines. In order to avoid side-effects of anti-
inflammatory treatment, it may be best to prescribe a trial of therapy based on 
symptoms. During the process of diagnosing and treating asthma, it is also important 
to pay attention to the family situation. Barriers to effective treatment may very well 
be not only at the level of the patients but at the level of the parents as well. D 
Bellamy (GPIAG, UK) discussed the present BTS COPD guidelines which were 
recently published in Thorax7. COPD is a very common disease that causes 
considerable morbidity, poor quality of life and 26 000 deaths per year in the UK. 
The diagnosis and management of COPD still is a neglected area, with many primary 
care physicians merely telling patients to stop smoking and suggesting that nothing 
else can be done for them. Smoking is certainly the most important cause of COPD, 
and smoking cessation offers the most effective means of preventing disease 
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progression. However, only 20% of the smokers develop COPD, and at present the 
co-factors that make this group susceptible have not been identified. The guidelines 
propose a more holistic view of treatment. Therapeutic options include 
bronchodilators (the cornerstone of symptomatic improvement in breathlessness, 
wheeze and exercise), corticosteroids, rehabilitation training, long-term oxygen and 
surgery. It is also important to address social problems and treat the secondary 
depression that often accompanies severe COPD. Immunization against influenza 
may help to prevent infective exacerbations. According to the BTS guidelines, goals 
of the management of COPD are: early and accurate diagnosis of COPD, optimising 
symptom control, preventing deterioration of lung function and complications, and 
improving the quality of life. The use of spirometry by GPs is strongly encouraged to 
diagnose and assess the severity of COPD. Patients with moderate or severe COPD 
should undergo a steroid reversibility study to determine whether inhaled steroids 
will be beneficial in long-term management. Long-acting bronchodilators improve 
symptoms and the quality of life, but more studies are needed to fully evaluate their 
use. 
Asthma and COPD research in primary care 
In the third and final session, results from recent research projects and some 
upcoming projects were presented. 
S Cloosterman (University of Nijmegen, The Netherlands) discussed two recent 
placebo-controlled studies on the effects of house dust-mite avoidance measures on 
asthma symptoms, FEVi and peak flow in allergic patients with and without 
asthma17. She concluded that house-dust-mite-impermeable mattress covers were 
capable of reducing the amount of house dust-mite allergen. These reductions were 
followed by improvements in morning peak flow and symptom scores in patients with 
no diagnosed asthma. In patients with asthma, bronchial hyperresponsiveness and 
FEVi did not change significantly. Allergic patients without asthma showed an earlier 
and greater response than allergic patients with asthma. Therefore, house dust-mite 
avoidance measures seem to be more useful and effective in early stages of 
asthma18'19. The underlying mechanism of this phenomenon is still unclear and 
requires further research. 
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The PREVASK study, a new research project to assess whether early prenatally 
started interventions may lead to preventive effects on the development of asthma in 
infants was presented by H Schönberger (University of Maastricht, The Netherlands). 
He presented data from general practice which suggest a genetic predisposition for 
developing asthma. Many of the relevant risk factors are often already known to the 
GP and are easily recordable. Exposure to these risk factors may lead to the 
expression of genetic predispositions and might well be preventable. In the PREVASK 
study, the effects of reduction of exposure will be evaluated the next few years. 
G van den Boom (University of Nijmegen, The Netherlands) presented a cost-
effectiveness study based on the DIMCA project20. Screening of subjects from the 
open population during a maximum of 12 months traced approximately 20% of the 
open population with undiagnosed asthma or COPD. The costs per detected case 
were US$ 564, which is relatively little compared with other screening programmes. 
Treatment was initiated for these patients and the effects and costs will be evaluated 
in the near future in a cost-benefit analysis. Screening of a population followed by 
treatment of newly diagnosed patients will always incur extra expense. It is 
important to weigh up these costs against the gains in health and quality of life - a 
so-called cost-effectiveness study - to support medical decisions and health policies. 
One of the recent developments in the treatment of COPD patients is treatment with 
/V-acetylcysteine as an anti-oxidant drug. The effectiveness of this therapy on 
relevant parameters such as decline in FEVi, exacerbation rates and quality of life is 
still unknown. W Gorgels (University of Nijmegen, The Netherlands) demonstrated 
the supposed anti-oxydant effects of yV-acetylcysteine and the design of the recently 
started COOPT study. This 3-year study compares the efficacy of /V-acetylcysteine 
and fluticasone diproprionate in a placebo-controlled design among 600 COPD 
patients recruited from at least 30 general practices. 
The final speaker of this workshop was M Levy, who presented the effects of training 
practice nurses in an asthma training centre. Training practice nurses improved the 
organisation of asthma management and increased confidence in patients in the 
advices given. Practices with trained nurses used self management plans more 
frequently. One of the negative effects, however, was that compliance to follow up 
visits was dramatically reduced. Although the data presented came from a relatively 
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small study, the results did show relevant changes in the organization and 
management of asthma in general practice, so M Levy concluded that the effects of 
training nurses on practice management needed further addressing. 
Conclusion 
This international initiative to make an inventory of present and future developments 
in the management of asthma and COPD was of great value. There proved to be a 
clear concensus on the place of some new developments in the treatment of asthma 
and COPD in general practice, such as the use of long-acting bronchodilators and 
leucotriene antagonists. It was concluded that priorities of research in these fields 
are the detection of unknown patients, further placement of non-steroid anti-
inflammatory treatment and the effects of self-management. As all guidelines 
promote the usage of spirometry, further research on the implementation of this 
technique in general practice needs to be promoted. 
Although relevant differences in the various national guidelines are present, 
comparison of these guidelines showed that there is an increasing convergence in 
ideas about how chronic airway diseases should be treated. Asthma and COPD have 
a high prevalence in general practice, and the majority of patients are treated by the 
GP. Therefore, it is important that current guidelines also take into account general-
practice-based evidence. The present and future research projects presented in this 
workshop clearly showed that research in general practice can and will provide this 
scientific evidence. In order to prevent redundancy, it is important that these 
research efforts are well co-ordinated at an international level. The final conclusion of 
this workshop therefore was that there is a need to continue exchanging ideas at an 
international level. The WONCA conference offers a good opportunity for this 
purpose. Another possibility is to form a Scientific Group of Primary Care Research 
within the European Respiratory Society, as this also provides an easy interface 
between primary and secundary respiratory care. An initiative to start such a 
Scientific Group has been taken already, and we would welcome any national group 
of GPs or individuals to join this initiative. 
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Abstract 
Objectives. Self-management of asthma is becoming more and more widespread. 
The implementation of this treatment strategy requires changes in the role and 
attitude of the GP. These changes may be hindered by obstacles both expected and 
experienced. As self-treatment of asthma is more common in the UK, comparison 
between UK and Dutch GPs provides a good opportunity to identify possible 
obstacles in general practice to the implementation of self-treatment of asthma with 
inhaled corticosteroids. 
Methods. We carried out a qualitative descriptive study with self-administered 
questionnaires and interviews. Questionnaires were sent to 500 randomly selected 
Dutch GPs. Interviews were held with 20 Dutch and 25 British GPs in order to acquire 
more in-depth information. The outcome measures were attitude towards, 
knowledge regarding and experiences with self-treatment of asthma; organizational 
requirements; and expectations of consequences of self-treatment in general 
practice. 
Results. The Dutch and British GPs investigated have a positive attitude towards self-
treatment of asthma. Though knowledge about self-treatment is present among a 
majority of the GPs, self-treatment by patients is not yet as common in The 
Netherlands as it is in the UK. Nineteen per cent of the Dutch GPs had experience 
with a written peak-flow-based self-treatment plan related to the usage of inhaled 
steroids. According to our findings, present expected obstacles are probably mainly 
of organizational kind, such as the availability of time, money and materials. 
Conclusions: There is a positive attitude towards the implementation of self-
treatment plans in general practice, problems relating to certain identified obstacles 
need to be addressed. There is a need to define which patients might profit from 
self-treatment, and further proof of both the clinical effectiveness and the cost-
effectiveness of self-treatment needs to be acquired. 
Background 
In the last decade, interest in self-treatment of asthma has increased and several 
studies with different self-treatment strategies have been published. After the first 
positive results of a self management plan in the United Kingdom, published by 
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Beasley et al. m 19891, others also found clues that self-management and self-
treatment programmes may lead to improvement of patients' outcomes2 6. Some 
researchers, however, found more moderate results or even little or no evidence for 
beneficial effects of self-treatment programmes7 9. Most of the positive research has 
been done among out-patient populations and attenders at accident and emergency 
departments, so results may be not applicable to general practice. Furthermore, as 
there are great differences between designs, outcome parameters and contents of 
the self-management programmes used, it is difficult to compare the results, but at 
least components such as patient education and peak-flow assessments are felt to 
have some proven value3,4,10. 
Guidelines for asthma treatment in the UK and the US have emphasized the use of 
self-management plans1113, but guidelines for general practice in The Netherlands 
have not thus far advised the use of such plans on a broader scale14. The use of self-
treatment plans among Dutch GPs is therefore less common. Implementation of 
effective self-treatment plans in general practice might require a change in the role 
and attitude of the GP. Instead of 'prescriptor' the GP becomes educator and coach. 
Objectives 
Self-management of asthma seems to be an effective way of managing asthma, and 
present evidence may justify a change in treatment strategy. Before implementing 
this change in treatment, the obstacles to this change should be identified15. The 
purpose of this paper is to assess if GPs are willing to make these changes and what 
obstacles they might encounter during these changes. As self-treatment of asthma is 
already more common in the UK, comparison between UK and Dutch GPs provides a 
good opportunity to assess the obstacles encountered and expected when 
implementing self-treatment in general practice. The following questions were 
explored: 
- What is the present knowledge of self-treatment of asthma among Dutch GPs' 
- How do Dutch GPs use self-treatment plans at present? 
- What are the attitudes of Dutch GPs towards the implementation of asthma self-
treatment? 
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- Do Dutch GPs have realistic expectations about the implementation of self-
treatment plans in comparison with their more experienced UK colleagues? 
- What are the experienced obstacles and problems regarding the implementation 
of asthma self-treatment in general practice in the UK and in The Netherlands? 
Methods 
In the literature there are several definitions for self-treatment and self-
management. In this study we used the following definition: self-treatment of 
asthma means that patients vary their dosage and frequency of inhaled steroids 
based on peak-flow values and/or asthma symptoms, as described in a written plan. 
We consider this form of self-treatment to be a component of the broader concept of 
asthma self-management16. 
This study was conducted in two phases: first, questionnaires were sent to 500 
randomly selected Dutch GPs. The questionnaires provided information from a large 
group of GPs. However, as they contained mainly closed questions, they were not 
the most suitable instrument for gaining proper insight into the opinions of the GPs. 
So, secondly, 20 Dutch GPs and 25 British GPs were interviewed in a standardized 
way. 
Questionnaire phase 
A random selection of 500 GPs across all of The Netherlands received a 
questionnaire. After 1 month a reminder was sent to non-responders. GPs were 
asked to report reasons for not responding to the questionnaire on a separate form, 
in order to investigate a possible recruitment bias. As no previous instrument was 
suitable, a structured, closed-end-question (multiple choice), 20-item questionnaire 
for postal distribution and self-completion was designed specifically for this study. 
Face validity was examined by discussion with clinical colleagues. The following GP 
characteristics were studied: age; type of practice: solo, duo, group, health centre, 
else; urbanization: >30 000 inhabitants, <30 000 inhabitants, rural; and membership 
of Dutch College of General Practitioners. In relation to research questions 1 and 2, 
we asked for familiarity with self-treatment plans (yes, no, a little; symptom-based 
versus peak-flow-based; with inhaled bronchodilators and/or with inhaled steroids). 
34 
Information about attitudes and expectations was provided by the following items: 
possible advantages and disadvantages of self-treatment plans; reasons for not 
applying self-treatment plans; attitude towards self-treatment plans (useful, 
because...; not useful, because...); willingness to implement self-treatment plans 
(eager to, probably want to, don't know yet, probably not, not); reported possible 
obstacles. Data were analysed using the SAS 6.07 under CMS statistical package. 
Interview phase 
Twenty of the Dutch GPs who returned the questionnaires were also interviewed in 
their practices. As it is obviously that familiarity with self-treatment of asthma is 
needed in order to have an opinion about it, these 20 GPs were randomly selected 
from among those GPs who mentioned being familiar with the concept of self-
treatment of asthma. Additionally, 25 GPs in the Tyneside area of North-East 
England, selected as broadly in favour of proactive asthma care by one of the 
authors (KJ), were interviewed about their attitudes and experiences with self-
treatment of asthma. The interviews with the Dutch and British GPs utilized a 
standard set of questions. The contents of the interview are summarised in table 3.1. 
Table 3.1: Contents of the interviews 
Concept of self-management of asthma 
personal definition; commonness of self-management; enthusiasm about self-
management; advantages and disadvantages 
Experiences with self-management: 
years of experience; number of patients with self-management; organisational 
obstacles; necessary equipment. 
Attitude towards self-management: 
is self-management a meaningful alternative for patients and for the GP; motives to 
start using self-management; willingness and capability of patients to perform self-
management. 
Organisational conditions 
how was self-management introduced; received instructions prior to introduction; 
time investment for GP and practice nurse; consequences for the number of 
consultations, prescribed medication, financial resources, available time and the role 
of the practice nurse 
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Results 
As the interviews were designed to obtain more elaborate information about the 
same subjects who completed the questionnaire, results are presented 
simultaneously. Where relevant, the source of the information will be specified. 
The overall response rate to the questionnaire was 59%. Of the 500 questionnaires 
originally sent out, 287 (57%) were suitable for further analysis. Six forms were not 
completed at all, and 207 forms were not returned. Of these 207 non-responders, 47 
GPs in total gave 63 reasons for not responding. The most common reason for not 
responding was lack of time (90% these 47, see table 3.2). 
Table 3.2: Reported reasons for not responding to the questionnaire (more than 
one reason possible; 47 GPs, 63 answers) 
Reason given No. Of GPs % 
Lack of time 42 90 
No experience with self-treatment 9 20 
Not willing to co-operate 5 10 
Personal reasons 5 10 
Disagreement with design 2 5 
Table 3.3 shows some of the characteristics of the GPs who returned the 
questionnaire. When comparing the type of practice characteristics with figures from 
the Dutch Institute for Primary Care Research (NIVEL), the sample should in this 
extent be representative of all Dutch GPs28. One hundred and three (36%) GPs 
reported to be very (well) familiar with the concept of asthma self-treatment, 141 
(49%) were somewhat familiar with it, and 43 (15%) had never heard of this self-
treatment concept. 'No experience with self-treatment' was reported by 20% of the 
non-responders as a reason for not responding. Presuming that the group of non-
responders with no experience with self-treatment is comparable with the responders 
that had never heard of this self-treatment concept (15%), there might have been 
some recruitment bias. One hundred and fifty-three (65% of GPs with some kind of 
experience, 53% of total responders) of the GPs had experience with self-treatment 
with inhaled steroids, based on asthma symptoms, whereas 45 (19% of GPs with 
36 
some kind of experience, 16% of total responders) had experience with peak-flow-
based programmes. 











Small town (<30 000 inhabitants) 



























In both the questionnaire and the interview, Dutch GPs reported several possible 
advantages of self-treatment in various areas: for patients, prescribing, health costs 
and GPs. Reported advantages for patients were an increase in self-efficacy, higher 
patient satisfaction and greater independence and responsibility. Self-treatment 
programmes could lead to a better control of the disease as a consequence of earlier 
recognition of symptoms and less doctor-induced delay in treatment. Patients might 
suffer fewer and milder exacerbations; furthermore, as a consequence of better 
control, the long-term effects of asthma might be reduced. More efficient medication 
usage may lead to fewer side effects and perhaps better compliance. From an 
economic point of view, fewer medical consultations in both primary and secondary 
care may be needed, together with less use of additional medications. Although GPs 
expect that the implementation of self-treatment plans initially will take up more of 
37 
their time, in the long term, as a result of better asthma control, self-treatment 
might lead to a reduction in emergency visits and intercurrent visits to the GP and 
thus save time. 
Disadvantages 
The Dutch GPs felt that as self-treatment requires specific knowledge, skills and 
patient awareness, this approach is only possible for a selected group of patients. 
These requirements may well result in extra GP workload for the teaching of self-
treatment programmes to patients. Also a lower contact frequency could lead to less 
medical control of the disease. Misinterpretation of symptoms and wrong treatment 
decisions by patients could lead to an increased delay in seeking medical help and a 
consequent more rapid decline in lung function. The long-term influence of self-
treatment on the course of asthma is still unknown. At the medication level, self-
treatment programmes could result in overtreatment or undertreatment and 
decreased compliance. In economic terms, more complications may well lead to an 
increased need for treatment and medical resources, with an attendant rise in health 
care costs. In the interviews with British GPs most of the GPs explained that they had 
not (yet) encountered any of these negative effects. 
Willingness to implement self-treatment plans 
Sixty-eight GPs (24% of total responders) did not promote self-treatment of asthma 
with inhaled steroids for one or more reasons. Their stated reasons for not applying 
self-treatment are summarized in table 3.4. Most of the GPs reported that they had 
never really thought about the implementation of self-treatment, or did not know 
how to start with the implementation of self-treatment plans. Among the GPs who 
reported self-treatment with inhaled steroids to be useful (164, 57%), almost 90% of 
the GPs were more or less willing to start self-treatment (see table 3.5). This is 51% 
of the total numbers of responders. 
Reported obstacles 
Of the above 164 GPs, 41 (25%) thought that there would be no consequences for 
daily practice in commencing asthma self-treatment, but reported expected obstacles 
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Table 3.4: Reasons for not applying self-treatment with inhaled steroids 
(n=68, 24% of total responders; more than one reason possible) 
Reason No. % 
Never thought about using self-treatment 
Difficult to make a start 
I do not (don't) know how to apply self-treatment 
No benefit for the patient 














Table 3.5: Willingness of GPs to start with self-treatment of asthma 
(if thought to be useful; n=164) 
No. % 
Eager to start 
Probably wants to start 
Doesn't know yet 
Will probably not start 











by the remainder were: availability of time, availability of necessary materials (peak-
flow devices, diary cards, etc), delegation of tasks and the role of the practice 
assistant or nurses, and changes needed in the role of the GP. During the interviews 
with the British GPs some experienced obstacles were reported that need to be taken 
into account when implementing self-treatment of asthma in general practice. These 
obstacles were mainly of a practical nature. Necessary materials (e.g. peak-flow 
devices, diary cards) need to be available. At the start of the implementation of self-
treatment, an extra time investment is needed. Later on, as reported by the GPs, this 
time investment will be paid back, because of a decreasing number of emergency 
visits and consultations. Tasks need to be clearly divided among the GP and the 
practice nurse, and both need to use the same protocol of care. The lack of such a 
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clearly described protocol was reported as one of the obstacles. Setting up a so-
called asthma clinic was reported as a good solution to overcome most of the 
organizational problems. 
We also studied the relationship between knowledge of self-treatment of asthma, 
age, type of practice, earlier experiences with self-management of diabetics and the 
willingness to start implementing self-treatment. The only relationship we found was 
a positive association between the familiarity of the GP with the concept of self-
treatment of asthma and his/her willingness to start implementing such self-
treatment (see table 3.6). 
Table 3.6: Relation between knowledge of and willingness to start with self-
treatment. 
Don't Probably 
Eager to start May start know if not start Not start 
Knows self-treatment very well 40 15 1 1 1 
Has heard of self-treatment 31 59 8 6 0 
Has never heard of self- 0 1 1 0 0 
treatment 
Discussion 
Our results indicate that 57% of the Dutch GPs in our sample have a positive attitude 
towards the implementation of asthma self-treatment plans in general practice. Many 
have at least some knowledge about this innovation in care, but experience with the 
use of self-treatment is more limited. When comparing the expected disadvantages 
of the Dutch GPs with the experienced disadvantages of the British GPs, Dutch GPs 
may overestimate the possible disadvantages of self-treatment of asthma. On the 
other hand they do have a realistic understanding of the potential obstacles in 
primary care which need to be overcome in the more widespread promulgation of 
self-treatment, and their views in this area are echoed by the experiences of the UK 
GPs interviewed. 
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The increasing prevalence of asthma, among other factors, has also led to an 
increased burden of asthma morbidity17"20. Since the majority of asthma 
management for both acute and chronic episodes occurs in general practice21'22, it is 
important that the community care of this common disease is optimized. The 
publication of numerous consensus-based guidelines on asthma management over 
the last decade has been a welcome advance11'12, as has been the more recent 
production of evidence-based documents23. Proof of the effectiveness of such 
guidelines has gradually appeared, but there has often been insufficient focus on the 
organizational aspects of asthma care outside hospitals. 
The development of asthma self-management plans has to some extent mirrored 
that of guidelines. Some original hospital-based experience indicated that they may 
be beneficial1, and their use, particularly in the UK, then became widespread. 
Further community-based research has followed quite slowly, but some at least of 
the literature now indicates benefits for patients2,5'24. 
Some important lessons have emerged from earlier experiences. First, showing 
beneficial outcomes of such care has proven to be difficult, and present-day research 
findings are not all in favour of self-management. Secondly, it is still unclear which 
patients might profit most from self-management programmes, but there are 
indications that these plans do not necessarily apply to all patients. For example, 
self-treatment based on peak-flow meters is not suitable for all patients and 
symptom-based self-treatment programmes are, under certain circumstances, 
equally effective as peak-flow-based programs7'25. 
If the potential advantages of asthma self-treatment are to be realized in the 
community, there is a need for clear guidelines, describing how to implement self-
treatment of asthma in general practice and defining the patients that might profit 
from self-treatment. Current differences in available self-treatment plans need to be 
regularized26. In the interviews with the British GPs, the need for a clear division of 
tasks and a useful protocol of care was expressed. Organizational requirements are 
likely therefore to play crucial roles in delivering optimal asthma care. A recent UK 
publication by Neville et al. underlines the possible influence of practice organization 
and audit on clinical outcome measures in general practice asthma care27. 
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Clearly, interest in self-treatment programmes among Dutch GPs is increasing. 
Knowledge and attitude towards self-treatment of asthma do not seem to be 
obstacles for the implementation of self-treatment programmes. However, training 
practice assistants or practice nurses and GPs, and reorganizing general practice in 
order to implement a self-treatment programme take time and money. Resources of 
potential benefit to patients with asthma could be wasted if strict attention to 
training of practice assistants or nurses and the production of efficient protocols is 
not given. 
As a consequence of this study, a self-treatment programme tailored to Dutch 
general practice will be developed and further research to assess the clinical and 
cost-effectiveness of this self-treatment programme initiated. 
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Abstract 
Objective: Asthma self-management is a generally accepted effective treatment 
strategy for asthma patients. Acceptance by patients may be a barrier for successful 
implementation. In this study, the role of inhaled steroids in starting asthma self-
management is described. 
Design: Cross-sectional explorative study. 
Setting: General Practice. 
Subjects: 283 adult steroid-requiring asthma patients were invited by their GP to 
participate in a self-management programme. 
Main outcome measures: In a multivariate logistic regression model, the relation 
between baseline dosage of inhaled steroids, occupational status, age and sex as 
independent variables and willingness to participate as dependent variables was 
explored. 
Results: Of all invited, 148 (52%) were willing to participate. Subjects not using 
inhaled steroids were least willing to participate (43/143 = 30%). Subjects with low 
doses of inhaled steroids (<400 meg daily) were most willing to participate (44/54 = 
81%). Unemployed asthmatics had a higher tendency to participate than patients 
with a regular job. 
Conclusion: Acceptance of self-management by patients is not a limiting issue in 
promoting self-management of asthma in general practice. High acceptance in 
patients taking low or intermediate doses of inhaled steroids makes general practice 
the most appropriate setting for self-management. A selection procedure is 
recommended. 
Introduction 
A key component of asthma guidelines is educating the patient. The finding that 
education should not be administered without an action plan, self-monitoring and 
regular review1 has led to the introduction of self-management programmes. Several 
randomised controlled trials have demonstrated that self-management of asthma is 
beneficial from both the perspective of both GPs and the patients2;3. 
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When implementing self-management, there are certain barriers (time investment, 
division of tasks, materials) that may be encountered by GPs, and setting up an 
asthma clinic can be a good solution in overcoming these problems4. To make this 
implementation process more efficacious, identification of all patients who may profit 
from self-management and selection of those willing to participate in such treatment 
strategy are the first steps. 
One of the key components of asthma self-management is tapering off inhaled 
steroids. Fear and dislike of inhaled steroids are described as playing a role in 
compliance5'6. It is likely that asthmatics have a high interest in the possibility of 
reducing their personal dosage of inhaled steroids. On the other hand, subjects using 
higher doses of inhaled steroids may be more reluctant as dose reduction may lead 
to unwanted loss of asthma control7. This paper studies the role of the dosage of 
inhaled steroids in the introduction of self-management in general practice. Based on 
findings from a pilot study we included age and sex in this study too8. 
During the initial recruitment we observed that lack of time due to work was one of 
the most frequent reasons for non-participation. Employment or study thus may be a 
barrier for patients to participate so this factor was included as well. 
Patients and methods 
In this cross-sectional explorative study, 23 GPs first identified all asthma patients 
requiring inhaled steroids aged between 16 and 60 years from their practice 
population. The information sources used were problem list codings (based on the 
International Classification of Primary Care), prescription data from practice records 
and the local pharmacist and annual influenza vaccination campaign lists. All selected 
patients were invited to participate in a self-management programme consisting of 
three initial education and training visits, regular (weekly or daily) self-assessment of 
symptoms and peak flow and adjustment of inhaled steroids according to their self-
assessed asthma condition. Patients could indicate their willingness to participate by 
returning an enclosed form to the investigators. Patients who did not return the form 
were classified as not willing to participate. For patients who refused to participate, 
or did not respond to the invitation, the following data were provided anonymously 
by the subject's GP: age, sex, dosage of inhaled steroids and occupational status. 
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Patients willing to participate were invited to a lung function laboratory where they 
were checked for in- and exclusion criteria, as defined in table 4.1 and data on age, 
sex, dosage of inhaled steroids and occupational status were collected. 
Table 4 .1: In- and exclusion criteria 
Inclusion criteria: 
Treated for asthma by the GP 
and age between 16 and 60 years 
and FEVi more than 40% of the predicted value and more than 55% of predicted 15 min 
after inhalation of 800 pg salbutamol or 6 weeks after inhalation of 800 pg 
budesonide twice daily 
and reversibility FEVi (after bronchodilation with 800 pg salbutamol MDI or 8 weeks 
treatment with 800 pg budesonide twice daily) of at least 10% of the predicted value 
or PC20 histamine <= 8 mg/ml 
Exclusion criteria: 
• Smoking history of 15 or more pack years 
• Serious other diseases than asthma with a low survival rate 
• The patient has had exacerbations during a period of 1 month before the start of the 
study 
• Other diseases which influence bronchial symptoms and/or lung function (e.g. 
decompensatio cordis, sarcoidosis) 
• The patient is unable to inhale medication correctly or to measure and record their 
peakflow adequately and it is unlikely that this can be taught. 
Analysis 
The dependent variable in this study was willingness to participate (yes/no). 
Independent variables were 'usage of inhaled steroids', Occupational status', age and 
sex. Usage of inhaled steroids was defined as: none, low dose (<400 pg daily), 
intermediate dose (between 400 and 800 pg daily) and high dose (>800 pg daily). 
Based on presumed differences in effectiveness and deposition the dosage of a dry 
powder inhaler was halved to obtain equipotent dosages with metered dose 
inhalers9. The cut-off points for fluticasone were <125, between 125 and 250 and 
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>250 pg daily for low, intermediate and high doses, respectively. Occupational status 
was defined as being unemployed versus having a regular (part time) job or study. 
Each of the factors was first studied univariate using the Pearson chi-square test for 
categorical variables and the Student's t-test for age. All factors with an alpha <0.05 
were included in a multivariate logistic regression by stepwise forward inclusion of 
each separate factor and all first-degree interactions between factors identified. The 
log-likelihood method was used with a threshold of 0.05 for inclusion of each factor. 
Analysis was performed using the SPSS 9 software package10. 
Results 
A total number of 283 patients were invited by their GPs and 148 (52%) were willing 
to participate. In table 4.2, the relation between use of inhaled steroids and 
willingness to participate is summarised. The percentage of non-participants is 
relatively high in subjects not using inhaled steroids (although they should) and there 
is a reciprocal relationship between dosage of inhaled steroids and willingness to 
participate (Pearson chi square 61.94, p<0.0001). Based on the selection criteria 
defined, all selected patients should require inhaled corticosteroids. However, 143 
(51%) of all selected patients were not using inhaled steroids at the time of 
selection. Within this group, 43 patients (43/143 is 30%) were willing to participate. 
From all patients who did use inhaled steroids, 105 out of 140 (75%) were willing to 
participate. 
Table 4.2: Willingness to participate and the dosage of inhaled steroids (Pearson 
chi-square=61.94, p<0.0001) 
Willing Not willing 
to participate (%) to participate (%) 
43 (30) 100 (70) 
44 (81) 10 (19) 
43 (78) 12 (22) 
18 (58) 13 (42) 
148 (52) 135 (48) 
No inhaled steroids 
Low dosage of inhaled steroids 
Intermediate dosage of inhaled steroids 
High dosage of inhaled steroids 
Total no of subjects 
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The relation between occupational status and willingness to participate is outlined in 
Table 4.3. Unemployed subjects have a higher tendency to participate (Pearson chi 
square 16.32, p<0.0001). 
The mean age of participants and non-participants were 38 and 36, respectively 
(p=0.078, t-test). Within the female group, 95 of 181 subjects (53%) were willing to 
participate, within the male group this was 53 out of 102 (52%) (Pearson chi square 
0.01, p-value = 0.932). 
Table 4.3: Willingness to participate and occupational status (Pearson chi-
square= 16.320, p<0.0001) 
Willing Not willing 
to participate (%) to participate (%) 
Unemployed 37 (69) 17(31) 
Regular job or study 89 (55) 73 (45) 
Unknown 22 (33) 45 (67) 
Total no of subjects 148 (52) 135 (48) 
Based on the above findings, a multivariate logistic regression model was tested with 
dosage of inhaled steroids, occupational status and age. Usage of inhaled steroids 
and occupational status were statistically significant independent determinants of 
willingness to participate. There were no significant interactions. Table 4.4 gives the 
results of the tested model. 
Discussion 
In this study, dosage of inhaled steroids and occupational status were identified as 
independent factors associated with willingness to start asthma self-management. In 
general, half of all invited asthmatics are willing to participate. 
In a focus group study exploring views of asthma patients on self-management, 
Jones et al. found that 34 out of 35 patients stated that these plans were not 
relevant for them personally11. This is in contrast to our results and to findings by 
Paterson et al.12, who interviewed 120 patients from a nurse run asthma clinic in 
general practice. The majority of patients interviewed were in favour of asthma care 
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Table 4.4: Relation between dosage of inhaled steroids, occupational status and 
willingness to participate: multivariate logistic model 

















95% confidence interval 
4.70 - 23 88 
3.82 - 18 35 
1 33 - 7.04 
0.19-0 84 
0.17-0 91 
aiming to teach people to manage their asthma for themselves. Additionally, in a 
Dutch outpatient clinic population willingness to participate in a self-management 
programme was 68%13. This comes close to our findings that the participation rate 
was 75% within the group of subjects already using inhaled steroids. 
The finding that willingness to participate is lower in patients with high dosages of 
inhaled steroids supports our hypothesis that these patients are truly steroid 
dependant. Other studies have shown that discontinuation of inhaled steroids is 
often accompanied by exacerbations7. On the other hand, there is a substantial 
group of patients in whom periodic treatment14,15 or at least dose reduction7 has 
proved possible. 
One of the most striking findings in our study was that 51% of invited patients did 
not use inhaled steroids, although they should, on the basis of the criteria defined. 
These criteria were based on national guidelines for general practice1617, which are 
in this respect comparable to international guidelines3,18. Willingness to participate 
appears to be associated with prescription of inhaled steroids. This is an important 
finding, which may be explained by selection criteria used in this study. GPs were 
instructed to include all patients possibly requiring inhaled steroids in their invitation 
list. Based on information sources used, GPs could not properly estimate the need for 
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inhaled steroids in all cases. As patients who were not willing to participate did not 
visit the lung function laboratory we could not verify their actual need for inhaled 
steroids. It is justifiable that patients who can do without inhaled steroids are 
unwilling to participate. Although it seems obvious that these subjects will be least 
willing to participate, this may be an oversimplification. Willingness to participate 
may also depend on reasons for not using inhaled steroids (e.g. steroid resistance, 
non-compliance) and whether these can be modified or not. 
Another factor identified in this study was the role of occupational status. The finding 
that occupational status was not always known to the GP hampers interpretation of 
our findings. If the unknown group consists of a relatively high number of 
unemployed subjects, the difference found might decrease or even disappear. If 
there is a relatively high number of subjects with a regular job or education, the 
difference observed could become even more prominent. Based on our findings, the 
initial observation that patients with a regular job were more reluctant to participate 
in a self-management program seems true, but generalisation to all asthma patients 
is uncertain. 
In our study, we may have underestimated willingness to participate, because two of 
our exclusion criteria: the presence of exacerbations one month prior to the study 
and the presence of other diseases that influence bronchial symptoms. Earlier studies 
indicate that patients are more accessible for a new treatment strategy closely after 
having had an exacerbation and in the presence of comorbidity19. Especially for 
patients unjustly not using inhaled steroids, willingness to participate may have been 
higher had patients with a recent exacerbation been included. 
This study certainly does not cover all possible factors influencing the willingness of 
patients to participate in self-management programmes. However, factors identified 
in this study are all easily accessible for the GP, making them relevant for a quick 
assessment. Based on our findings, we recommend the procedure summarised in 
Table 4.5 to select and invite patients possibly interested in self-management in 
general practice. 
Finally, results from this study show that most patients are interested in self-
management plans. Acceptance of guided self-management plans by patients is 
therefore not a limiting issue in promoting the usage of self-management of asthma. 
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Assess current steroids 
STEP 3 STEP 4 
Assess need for 
inhaled steroids Advised action 
Information sources: 




No inhaled Not required 
steroids 
No further action 








High dosage Earlier reduction No further action 
failed 
Dosage reduction First discuss dose 
might be reduction 
possible 
Patients on low or intermediate dosages of inhaled steroids were most willing to 
participate. As this group is predominantly treated in general practice, high 
acceptance of self-management in this category of patients makes general practice 
the most appropriate setting for this treatment strategy. 
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Abstract 
This paper studies the effects of patient education, tailored to individual needs of 
patients as part of an asthma self-management program. A tailored education 
program was designed which took into account individual information needs of 
patients by using a feedback instrument. Totally 98 steroid dependent asthmatics 
entered the tailored education program, 95 patients received usual care. Outcome 
measures were information exchanged and patient satisfaction. Study duration was 6 
months. Patients in the tailored education group showed a significant reduction in 
information need (p=0.005). Patient satisfaction increased from 87.9 to 93.7 in this 
group while this did not change in the usual care group (p=0.000). Use of this 
tailored education program improved the GP-patient interaction within the context of 
a clinically effective asthma self-management program. Findings from this study may 
be applicable to other chronic conditions as well. 
Introduction 
Management of chronic diseases has changed during the last few decades. Especially 
the introduction of evidence based guidelines caused a shift from symptom based 
management towards disease management1^. Specific aspects of chronicity like 
relapse prevention, maintenance therapy and scheduled follow-up have led to 
changes in the long-term outcome of chronic diseases. But the apparent gap 
between effectiveness and efficacy demonstrates that other factors than adequate 
diagnostics and therapy may determine the success of chronic disease management. 
One factor that remains underestimated in most studies is the role of the patient in 
terms of adherence to any given treatment program or advice. A suitable tool to alter 
adherence is appropriate patient education combined with skills training and a self 
treatment plan5"9. A major problem regarding patient education however is the 
discrepancy between what the patient needs to know according to the health 
professional and what the patient wants to know on the basis of own interests or 
previous knowledge. Patient education aimed at improving compliance is often based 
on the aforementioned 'need to know' basis and has the potential risk of becoming 
yet another way of pursuing professional objectives10. This makes it obvious that 
patient-education should be tailored to individual needs. 
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One of the chronic conditions in which success of a structured disease management 
plan depends greatly on adherence and involvement of patients is asthma. Previously 
to this study 28 relevant topics ('need to know') for asthma education were identified 
by a panel of GP's, based on a Delphi consensus procedure11. As part of an asthma 
self-management plan a stepwise education program was designed, based on these 
topics. This asthma self-management program improved quality of life and asthma 
control12'13. In terms of cost-effectiveness it proved to be a dominant treatment 
strategy14. Patients were given a tool to indicate to the GP what they wanted to 
know themselves about their asthma (feedback) and thus influenced the contents of 
their own asthma education. Because of the increased involvement of the patient in 
his or her own education this approach was called tailored education. The objectives 
of the tailored education program were to provide asthma education as defined by 
the Delphi procedure and to meet the specific information need of the patient as 
well. To find out if this could be achieved we studied if use of feedback by patients 
led to a decrease in information needs of patients. We also investigated if the 
education program led to changes in satisfaction of patients with the treatment of 
asthma as provided by their GP. 
Methods 
Study design 
Main outcome measures of the education program were changes in patient 
satisfaction and the information need of patients. The design of the study is 
schematically summarised in figure 5.1. 
A total number of 19 practices participated in this study. Self-management 
intervenes in the interaction between health care professionals and their patients. To 
prevent contamination within family practices it was therefor considered important 
that all patients in each practice received the same treatment. Randomisation thus 
took place at practice level. 
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Figure 5.1: Schematic representation of the trial comparing the effectiveness of a 














Usual care Patsat Patsat 
Edul..4: Scheduled education sessions 
PatSat: Patient Satisfaction questionnaire 
Inclusion of patients 
GPs selected all known asthma patients from their own practice population. Patients 
had to be aged between 16 and 60 years and had to have a need for inhaled 
corticosteroids, based on criteria from national guidelines on the treatment of 
asthma[15]. At the lung function laboratory patients were checked for in- and 
exclusion criteria, which have been described in detail elsewhere[16]. Permission was 
given by the local medical ethical committee. 
Tailored education and usual care 
The tailored education program consisted of four individual sessions by the GP: an 
initial session of 30 min and three repeated education sessions of respectively 20 min 
and 2 sessions of 10 min. As indicated in figure 5.1 all sessions took place within a 
period of 3 months. Topics that had to be discussed in each consequent session were 
written down in a protocol for the GP. GPs received this protocol together with oral 
instructions before the start of the study. After completion of all four sessions 
according to the protocol, the following topics had been discussed with the patient: 
mechanisms and causes of asthma, skills training (peak-flow measurement and 
inhalation technique), pharmacological and non-pharmacological treatment and 
instructions on when and how to stepwise stop, halve or double the dosage of 
inhaled steroids. These issues are already advocated by guidelines. In this study, all 
issues were systematically presented to all patients and their individual feedback was 
incorporated. Ten minutes before each subsequent session, the patient completed a 
feedback form. This is a list with 31 topics concerning asthma that was written in 
common language. The patient could indicate if he or she had received any 
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information at all about each topic, whether this information was sufficient, or if 
additional information was required. One of the obligatory items in the protocol for 
the GP was to make an inventory of and to discuss the needs of the patient, as they 
were indicated on the patient list. It was left to the responsibility of the GP if he or 
she discussed the topic immediately or postponed discussing the topic to a later 
session, as long as the latter was made explicit towards the patient. 
In the usual care group GPs were instructed to treat all asthma patients according to 
current local guidelines2'15. At the start of the program one visit at the GP office was 
scheduled in order to provide standardised instructions to patients on use and 
dosage of their inhaled steroids (budesonide 200 μg Turbuhaler ®). 
Measures 
Changes in information needs were measured by comparing the counts per patient of 
items with answer categories 'I know all I need to', 'I want to know more' and 'I did 
not receive any information' before the first and the third repeated education 
session. As these counts were normally distributed differences were tested by a T-
test for paired samples. 
The need for additional information was also studied for each separate topic. Before 
the first and the third repeated education session the percentage of patients 
indicating a need for additional information for each answer category was calculated. 
Confidence intervals (CIs, 95%) were calculated for the differences in these 
percentages to test for statistically significant changes in information need. Handing 
over a list of topics concerning asthma in itself stimulates the need for additional 
information in patients. Therefore, the need for information was not assessed within 
the usual care group in order to avoid induction of information needs. 
Patient satisfaction was measured before the start of the study. To minimise the 
effects on patient satisfaction due to the extra time spent on educating the tailored 
education group (Hawthorne effect), patient satisfaction was measured again 3 
months after finishing the tailored education program. This was 6 months after the 
start of the study (figure 5.1). To assess if patients were satisfied with the care given 
by the GP a 20-item questionnaire was derived from the CEP-questionnaire17"21. This 
CEP-questionnaire was especially designed to measure the patients' opinion about 
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several aspects of the treatment provided by their GP. The CEP-questionnaire 
includes nine dimensions of general practice care. Of those dimensions only 'medical 
care', 'relation and communication' and 'information and advice' were used, as they 
were seen as the most relevant in relation to the contents of the education program. 
Satisfaction for each item was measured on an ordinal scale from 1 to 6 points 
(l=least satisfied, 6=most satisfied). To measure patient satisfaction, first a principal 
components factor analysis was performed on all 20 questions. One factor containing 
all 20 questions explaining 54% of variance was identified. As the correlation for all 
variables in this factor was at least 0.6 an overall score was calculated by adding the 
scores of each individual question. This overall score was used to measure changes 
in patient satisfaction. All questions were also compared separately to identify which 
items specifically changed. There were no significant differences in baseline 
satisfaction scores. Therefore, the difference in scores at the start of the study and 
after 6 months were compared. Changes in mean satisfaction score of at least 0.5 for 
each item within one of both groups were considered relevant. As no previous 




After the selection procedure 214 eligible patients were included, 104 in the usual 
care group and 110 in the tailored education group. In the tailored education group 
seven patients did not start with the program and five patients decided to stop 
during the education program. As a result 98 patients completed the education 
program. In the usual care group eight patients did not start and one patient decided 
to stop, leaving 95 patients. Baseline characteristics of patients completing the 
tailored education program are summarised in table 5.1. Interviews with participating 
GPs after the selection procedure did not reveal any possible selection-bias in terms 
of excluding patients on other reasons than the study criteria. 
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Table 5.1. Baseline characteristics of study subjects1. 
Self-management Usual care 












(PCzo-histamine, geometric mean) 
': Figures are means (SD) unless stated otherwise. 
FEVi=forced expiratory volume in one second in litres 
a
 missing data - SM 2; DC 1 
" missing data - SM 17; UC 14 
c
 missing data - SM 1 
Changes in information need 
Table 5.2 summarises changes in information needs based on each answer category. 
There was a statistically significant reduction in the number of items with answer 
categories 'I want to know more' and 'I did not receive any information'. Additionally, 
there was a statistically significant increase in the number of items with answer 
category 'I know enough'. 
Table 5.3 summarises the number of patients asking for additional information for 
each separate topic after the first visit. The reduction in percentage of patients 
needing additional information after 3 months is also summarised in table 5.3. All 
items showed a significant decrease in the need for additional information except 
'Training of peak flow measurement'. Remarkable are the pronounced interests in 
the prognosis of asthma and the effects of asthma medication. Also, remarkable is 
39.6 (11.2) 39.3 (12.0) 0.859 
34/64 40/56 0.394 
5.8 (4.5) 5.7 (4.5) 0.881 
21.0 (16.5) 18.1 (14.3) 0.232 
2.80 (0.66) 3.00 (0.76) 0.044 
2.99 (0.67) 3.20 (0.77) 0.051 
84.0 (13.1) 86.9 (14.2) 0.141 
90.0 (12.1) 92.6 (12.9) 0.135 
1.10 1.05 0.144 
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the lack of interest in peak-flow measurement, which is one of the cornerstones of 
our asthma self-treatment plan. 
Table 5.2: Changes in information need for each answer category 
Mean number of items per patient (95% confidence interval) for each 
answer category 
'I didn't receive any 
'I want to know more' 'I know enough' information' 
(p=0.005) (p=0.001) (p=003) 
Before first repeated 
5.9(5.0-6.9) 20.0(18.6-21.4) 4.0(3.1-4.9) 
education session 
Before third 
repeated education 0.7(0.3-1.1) 25.6(23.5-27.6) 1.0(0.4-1.7) 
session 
Table 5.3: Changes in the number of patients needing information per topic 
Reduction in 
information need 
between first and 
Need for third repeated 
information at first education session 
repeated education (% change with 
TOPIC 
Prognosis of asthma 
Side effects of inhaled steroids 
How and why to change dosage of inhaled 
steroids 
Only long term effect of inhaled steroids 
Role of patient platforms 
session 








37 (26 - 48) 
41 (29 - 53) 
31 (20 - 42) 
29 (19 - 39) 
27(17-37) 
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Relation between physical exercise and 
symptoms 
Effect of long-acting bronchodilators 
Effect of short-term bronchodilators 
Hyperreactivity and personal triggers 
When and how to take prednisone tablets 
Nature, cause and prevention of allergy 
Effects of oral steroids 
Occupational advice and role of a company 
doctor 
Effects of inhaled steroids 
Nature, cause and prevention of exercise 
induced asthma 
Sanitation at home 
Possible causes of asthma 
Goals of asthma management 
Possible reasons for referral to specialist 
Importance of proper inhalation technique 
Importance of influenza vaccination 
Effects of (passive) smoking 
Additional medication 
Basic characteristics of asthma 
Mechanism of shortness of breath 
Importance of regular follow-up 
Information about intracutaneous allergy test 
Information about lung-function test 

























26 (16 - 36) 
24 (16 - 34) 




16 (8 - 27) 
17 (9 - 26) 
18 (10 - 26) 
16 (7 - 24) 
13 (6 - 20) 
11(2-19) 
14 (6 - 23) 





10 (2 - 17) 
8 (2 - 15) 
6(1-11) 
7 (2 - 13) 
6(1-11) 
4 (0 - 8) 
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Patient satisfaction 
The overall scores for the patient satisfaction in both groups are summarised in table 
5.4. As this table shows, both within the tailored education group and between the 
tailored education and the usual care group significant changes occurred. Questions 
with both statistically and clinically significant improvements in patient satisfaction 
were: 'Did your GP convince you of the importance of taking medicines?', 'Does your 
GP help you to deal with your disease(s)?', 'Do you know enough of your disease to 
manage at home?', 'Did your GP convince you to follow his/her advice?', Does your 
GP pay attention to the consequences of your disease in daily life?', 'Does your GP 
involve you in looking for an explanation of your symptoms?', 'Does your GP reassure 
you with regard to your symptoms?' and 'Does your GP perform no more tests than 
necessary'. 
Table 5.4: Patient satisfaction scores before and 6 months after the education 
program*. 
Before program After six months 
(95% confidence interval) (95% confidence interval) 
Tailored education 87.90 (80.09 - 89.11) 93.69 (89.63 - 97.76) 
Usual care 84.26(80.10-88.42) 84.23(80.16-88.30) 
*: Patient satisfaction scores: 0 means least satisfied, 120 means most satisfied on all items 
Discussion and conclusion 
Discussion 
Results of this study show that GPs are able to reduce the information needs of 
asthma patients using feedback of information needs, resulting in a higher patient 
satisfaction. This is also reflected in the decrease of the need for additional 
information as described for each separate item in table 5.3. 
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A similar approach was tested by Cegala et al ; . They provided patients with tools 
to make a systematic inventory of their information needs combined with a 
communication-training booklet. They demonstrated that this approach was capable 
of improving information seeking behaviour of patients and compliance. In our study 
we added an information checklist for patients to assist them in making an inventory 
in their information needs. This was based on the presumption that this checklist 
notifies patients of the existence of all possibly relevant topics as interest in certain 
topics needs to be preceded by the awareness of their existence. Thus, the role of 
GPs in educating asthma patients is to increase the awareness of the existence and 
importance of certain information. Next, it may depend on the relevance to the 
patient if the presented topic deserves further discussion. 
Additionally, it must be notified that information needs as indicated by patients 
should not be used as a touchstone of their actual knowledge. One of the 
cornerstones of our self-treatment plan is the regular (daily - weekly) assessment of 
peak flow values. From our data it appears that patients have a remarkable low 
interest in this topic, which does not change throughout the education program. 
Other topics that are associated with (self) management, like the importance of an 
adequate inhalation technique and effects of (passive) smoking show the same 
pattern. This either means that patients believe they know enough about these 
topics, or they are not interested in them. As patients record their information need 
for the first time after the baseline visit to the GP a baseline need for information 
may already have been fulfilled. For the afore-mentioned topics over 75% of the 
patients indicated at the first repeated education session that they had sufficient 
information about these topics. Therefore little room is left to improve or to induce 
any need for additional information. So interest for these topics is low because 
patients thought they already knew enough about these items. This does not imply 
that patients are in fact well-informed about these issues and it should be left to the 
professional responsibility of the GP to verify if knowledge of the patient is sufficient 
indeed. Especially as interest in subjects like peak-flow measurement and inhaler 
technique is notoriously low in patients. As is shown in table 5.3 the information 
need of patients is highest for items related to personal fears and concerns like 'the 
prognosis of asthma' and 'side effects of inhaled steroids'. These findings confirm our 
67 
hypothesis that patients and health care providers are likely to have diverging 
agendas. In our study, providing patients with tools to elucidate their own needs and 
demands was associated with an increase in patient satisfaction. Our results are 
comparable to findings by vd Borne and co-workers24 who tested a similar approach 
in an outpatient clinic setting. It also supports the findings from Little et al25. They 
showed that communication aimed at understanding the patients' needs and worries 
is an important domain of patient centeredness. Patient and GP have a shared 
responsibility in managing the patient's asthma. The patient is responsible for 
focusing the GP to his or her needs, and the GP has the responsibility to enhance 
patients in expressing their own needs and to make patients aware of topics that are 
potential interest. As was demonstrated by Galefoss and Bakke such a patient 
centered approach is also beneficial from the GPs' perspective in terms of improved 
compliance and a reduction in the need for short acting bronchodilators6. We believe 
that systematically and actively involving patients in clarifying their personal needs 
does increase the patient's involvement in the management of his or her asthma and 
that this sharing of responsibilities is a prerequisite for effective (asthma) self-
management. 
Taking the results of the patient satisfaction questionnaire into account it is 
reasonable to assume that asthma patients do feel more involved and that 
adherence may increase. A change of 0.5 point on the answering scale was 
considered as relevant. Several questions related to the teaching of self-management 
improved almost an entire point. Our data show that asthma patients are especially 
more satisfied about the explanation of their medication and the feasibility of advises 
given by the GP. This is also reflected in effects of our self-management program on 
asthma-specific quality of life (AQLQ). Improvements in the emotions domain were 
both statistically and clinically relevant, indicating that patients felt less insecure 
about the impact of asthma on their daily life12. 
Conclusion 
Educating and motivating patients is crucial for a successful self-management 
program25. Before effective treatment will be feasible, ownership of the treatment 
plan is essential - in particular ownership by patients10. This implies that their needs, 
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demands and expectations must be taken into account. Findings from this study 
show that the needs of the patient can be taken into account in a satisfactory way 
within the context of asthma self-management. Following the tailored education 
approach, the interaction between the GP and the patient improved. 
Implications for practice 
Using materials for systematically taking into account the patients' needs may 
enhance shared decision-making by balancing the patients' and the GP's perspective 
in a more patient centered approach27. Consequently, the checklist for patients that 
was used in our self-management program has been made available through the 
Internet by the Dutch Asthma Foundation (www.astmafonds.nl). 
The basic principles used in this program are not disease specific. Although the 
contents of the education program are disease specific, the concept of shared 
responsibilities and self-management as an other approach of the doctor-patient 
relation is not, so beneficial findings from this study may very well be applicable to 
other chronic conditions like diabetes or chronic heart failure. 
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Abstract 
Background: Aim of this study was to assess the effects of a self-management 
program in general practice on asthma control, quality of life and lost-activity days. 
Methods'. Nineteen general practices were randomly allocated to usual care (DC) or 
self-management (SM). Asthma patients were included after confirmation of GP 
diagnosis. Follow up was two years. Patients kept diary cards and visited the lung 
function laboratory every six months. Outcomes were number of successfully treated 
weeks and limited activity days, asthma specific quality of life, FEVi, FEVi-
reversibility, PC2o-histamine and amount of inhaled steroids. 
Results: 214 patients were included (104 DC / 110 SM). Selected patients were 
predominantly female (62%). Mean percentage of successfully treated weeks per 
patient in the DC group was 72% (74 per 103 weeks) versus 78% (81 per 105 
weeks) in the SM group (p=0.003). The average number of limited activity days was 
1.2 (95% CI 0.5; 1.9) for self-management and 3.9 (95% CI 2.5; 5.4) for usual care. 
The estimated increase in asthma quality of life score was 0.10 points per visit in the 
UC group versus 0.21 points per visit in the SM group (p=0.055). FEVi, FEVi-
reversibility and PC2o-histamine did not change. There was a saving of 217 puffs in 
favour of the SM group (p<0.05). 
Conclusion: Self-management lowers the burden of illness as perceived by the 
patient and is at least equally effective as asthma treatment usually provided in 
Dutch primary care. Self-management is a safe basis for intermittent therapy with 
inhaled corticosteroids. 
Introduction 
Asthma is a chronic inflammatory pulmonary disease which has a significant socio-
economic impact on patients and their family1. The understanding that airway 
inflammation is the key underlying process has led to the early introduction of 
inhaled corticosteroids in the management of asthma2'5. Despite these guidelines and 
increasing insights asthma morbidity is still considerable. Poor compliance with 
prescribed inhaled therapy is an important cause of uncontrolled disease6"10. Poor 
control of asthma is associated with an impaired quality of life11'12 and is presumably 
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responsible for three quarters of the total costs of asthma1. Therefore it is likely that 
improving compliance will lead to improvements in asthma control and quality of life. 
Low compliance results in underuse of (medication) care, but asthma is also 
characterised by overuse, in particular of inhaled medication. Overuse of inhaled 
steroids may increase the number of unwanted side effects, without additional 
benefits. There are indications that inhaled steroids can be tapered off or stopped 
during a certain period13 or at least reduced to the minimal effective daily dose that 
provides adequate control of the disease14. Optimising treatment for the individual 
patient may balance benefits and risks and leads to a more efficient and cost 
effective treatment. Mild asthmatics treated by their General Practitioner may be very 
suitable patients for intermittent therapy15, providing adequate control of their 
asthma is maintained. Implementing guided self-management takes a considerable 
effort16 and studies on effectiveness and use in General Practice are needed. As most 
published studies were effective in more severe asthmatics or in patients with 
frequent exacerbations, the question rises if guided self-management may also be 
effective in milder asthmatics. Loss of asthma control occurs less frequently and 
there is lower impact on quality of life17, leaving limited room for improvement. Aim 
of this study was to determine if guided self-management can provide a safe 
treatment strategy for asthma patients in General Practice. 
Methods 
Practices 
Nineteen General Practices participated in this study. Stratified cluster randomisation 
was performed, based on the type of practice (solo, duo, group), the number of 
identified asthmatics (above or below the median number (14) of identified 
asthmatics) and use of computerised prescription (yes, no). 
Selection of patients 
GPs selected asthma patients aged between 16 and 60 years using problem list 
coding (ICPC), prescription data from practice records, the annual influenza 
vaccination campaign list, and prescription data provided by the local pharmacist. 
75 
Selected patients received an invitational letter from their GP. Patients willing to 
participate were checked by the investigators for the exclusion criteria as defined in 
Box 6.1. Those eligible for the study were invited for assessment in a lung function 
laboratory. Inclusion criteria are summarised in Box 6.1. Patients with a 
prebronchodilator FEVi less than 80% of predicted were treated with 800 pg 
budesonide bid during a six weeks run in period. 
Box 6.1: In- and exclusion criteria 
Exclusion criteria: 
• Smoking history of 15 or more pack years 
• Serious other diseases than asthma with a low survival rate 
• The patient has had exacerbations during a period of one month before the start of the 
study 
• Other diseases which influence bronchial symptoms and/or lung function (e.g. 
decompensatio cordis, sarcoidosis) 
• The patient is unable to inhale medication correctly or to measure and record their 
peakflow adequately and it is unlikely that this can be taught. 
Inclusion criteria: 
Treated for asthma by the GP 
and age between 16 and 60 years 
and FEVI more than 40% of the predicted value and more than 55% of predicted 15 
minutes after inhalation of 800 pg salbutamol or 6 weeks after inhalation of 800 μg 
budesonide twice daily 
and reversibility FEVi (after bronchodilation with 800 μg salbutamol metered dose inhaler 
or 8 weeks treatment with 800 pg budesonide twice daily) of at least 10% of the 
predicted value or PC20 histamine <= 8 mg/ml 
Study medication 
All included patients were treated with budesonide 200 meg/dose dry powder inhaler 
(Turbuhaler®). In the self-management group patients were educated to change 
their dosage of inhaled steroids according to a written self-treatment plan (Box 6.2). 
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Box 6.2: Summary of the self-treatment plan. 
Step-up instructions 
• Peak flow deteriorates <80% PEFR >60% of Personal Best Value (PBV) for 2 out of 3 
consecutive days: 
double budesonide dosage 
in case of insufficient response within three weeks: again double budesonide 
dosage 
• Peak flow deteriorates <60% PEFR >40% of PBV for 2 out of 3 consecutive days: 
increase budesonide dosage to 800 micrograms b.i.d. 
in case of insufficient response within two days: start course of oral 
prednisolone 
and contact your FP 
• Peak flow deteriorates <40% of PBV: 
If sufficient response to bronchodilator: start course of oral prednisolone 
Else: immediately contact your GP 
Step-down instructions 
• Peak flow improves to >40% PEFR <60% of PBV: 
continue the current budesonide dosage until your PEFR is >80% of PBV 
• Peak flow improves to >60% PEFR <80% PBV: 
continue the current budesonide dosage until your PEFR is >80% of PBV 
• Peak flow improves to >80% of PBV: 
halve budesonide dosage when PEFR >80% for a period of six weeks 
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In the usual care group the daily dosage was determined by the patients' GP 
according to the national guidelines for treatment of asthma18'19. Both groups 
received regular inhalation instructions. 
The self-management program and usual care 
The self-management program started with four individual training visits at the GP 
office within a period of three months. These visits consisted of tailored education20 
and instructions on how to use a personalised written self-treatment plan. Patients 
weekly recorded morning and evening peak flow values and the presence of asthma 
symptoms. Three alarm symptoms were defined: waking at night because of asthma 
(yellow zone), use of bronchodilator >4 times a day (red zone) and increased 
dyspnea without exertion (purple zone). In the presence of alarm symptoms or a 
drop of peak flow values below 80, 60 or 40 percent of the personal best value, 
patients were instructed to start daily measurements of peak flow and symptoms. 
Self-treatment instructions for budesonide and oral steroids (30mg prednisolone per 
day, during 1 week) are summarised in Box 6.2. After the training visits biannual 
control visits were recommended over a follow-up period of 21 months. At each 
control visit GP's checked the patients' performance of the self-treatment 
instructions. It was left to the initiative of the GP and patient if and when these 
control visits took place. Training of inhalation technique and peak-flow 
measurement was repeated at each visit. 
In the usual care group GPs were instructed to treat all asthma patients as usual, 
which is for most GPs according to the national guidelines of the Dutch College of 
Family physicians18'19, which are largely comparable to most international guidelines, 
but which do not include self-management thus far. At the start of the program one 
visit at the GP office was scheduled to instruct patients on use and dosage of their 
inhaled steroids (budesonide 200mcg Turbuhaler ®). 
Outcome measures 
Main outcome measures of this study were asthma control, asthma specific quality of 
life and lost activity days. Asthma control was defined with the following parameters: 
percentage of successfully treated weeks; changes in post bronchodilator FEVi 
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(800mcg salbutamol mdi through spacer); changes in reversibility of FEVi as 
percentage of the predicted value and the changes in PCzo-histamine. 
Post bronchodilator FEVi, reversibility and asthma specific quality of life were 
measured at baseline and each 6 months over a period of two years. PC20-
histamine21 was measured at baseline and after two years. 
A successfully treated week was defined as a week in which acceptable asthma 
control in terms of perceived dyspnea was maintained. Patients in both groups 
weekly recorded dyspnea on a modified Borg-scale, ranging from 0 (no dyspnea) to 
10 (maximally severe dyspnea)22. The median dyspnea score of all individual 
recordings was considered as cut off point between successfully and unsuccessfully 
treated weeks. Weeks with a dyspnea score equal to or below this cut-off point were 
counted as successful. To correct for differences in the number of recorded weeks, 
successfully treated weeks were standardised to the percentage of recorded weeks. 
An example of this procedure is graphically summarised for one patient in figure 6.1. 
In addition to the dyspnea scores patients weekly recorded the number of days 
during the last week with limited activities due to asthma. 
Asthma specific quality of life was measured using the Asthma Quality of Life 
Questionnaire (AQLQ) by Juniper et al11'12. An individual increase of 0.5 point of the 
overall score or one of the domain scores was considered a minimal clinically 
relevant improvement (MCRI). 
Secondary outcome measures were the number of puffs budesonide used, the 
number of dose equivalents of short acting bronchodilators, short courses of oral 
prednisolone, antibiotics and GP-diagnosed exacerbations. The number of puffs 
budesonide used was counted at each laboratory visit by substracting the number of 
remaining dosages in each turbuhaler issued from the total number of dosages 
prescribed over the past period. The amount of short acting bronchodilators was 
based on the weekly recordings of patients. Based on presumed differences in 
deposition between metered dose inhalers and dry powder inhalers, dry powder 
inhaler dosages were halved to get dose equivalents23124. Short acting 
bronchodilators were thus converted to equipotent doses of either salbutamol or 
ipratropium metered dose inhaler in micrograms per day. 
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Exacerbations were recorded by GPs at each (scheduled and unscheduled) visit. GPs 
recorded if there was an exacerbation according to their own professional judgement 
(based on symptoms, peak-flow and increased use of bronchodilators). Short courses 
of prednisolone and antibiotics prescribed were recorded as other indicators of 
exacerbations. 
Figure 6.1: Calculation of successfully treated weeks for patient 09303 (usual 
care group). 
No of registered weeks: 104 
Median dyspnea score: 3 
No of weeks with dyspnea < median dyspnea score: 64 
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The power calculation for determining the trial size was based on the asthma quality 
of life questionnaire. A between group change of 0.5 point was considered clinically 
relevant. Based on multilevel analysis, we assumed an average inclusion of 10 
patients per practice and an interclass correlation of 0.02. With an observed standard 
deviation of 0.9, a power of 90% and an α of 0.05 (two sided), 17 practices with a 
total number of 170 patients were needed. When taking a drop-out rate of 20% after 
inclusion into account, 213 patients had to be initially included. 
Analysis 
Outcome parameters were evaluated on an intention to treat basis and by repeated 
measurement techniques25. A random coefficient linear model with an autoregressive 
error structure (multilevel model) was performed on post BD FEVi and AQLQ. 
Reversibility FEVi (% predicted value) was analysed in a non-linear model. Baseline 
values, age, sex and smoking were entered as possible confounders. All analyses 
were performed using the PROC MIXED procedures by SAS26. PC20 values (2log 
transformed) were compared with a students-T-test. If there was a significant 
difference over time in any quality of life domain, the proportions of subjects with a 
relevant change (MOD) were compared too by Chi-square tests. Amounts of 
medication used in both groups and the percentages of successfully treated weeks 
were compared with a T-test when normally distributed and a Mann-Whitney U test 
when not normally distributed. 
Results 
Table 6.1 represents the characteristics of participating practices in both treatment 
groups. The flow chart in Figure 6.2 summarises the number of patients. During the 
pre-treatment phase 15 patients dropped out of the program and an additional 5 
patients dropped out before the first follow-up measurement. Therefore 193 patients 
(98 self-management) were included in the intention to treat analysis. Baseline 
characteristics of patients included in the intention to treat analysis are listed in table 
6.2. There was no difference in pre and post BD FEVi when corrected for age and 
sex. There were higher numbers of patients with asthma attacks during the previous 
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6 months and patients requiring pre-treatment in the self-management group. 
Asthma specific quality of life was lower in the self-management group for the 
activities and emotions domains. 
Table 6.1: Practice characteristics 
Type of practices 
Solo 
Duo 
More than 2 GPs 
Total 




















The mean percentage of successfully treated weeks per patient in the self-
management group was 78% (95%-CI 75.1-80.6; 81 per 105 recorded weeks) 
versus 72% (95%-CI 68.8-74.8; 74 per 103 recorded weeks) in the usual care group. 
During follow-up 79% of self-management and 62% of usual care patients reported 
one or more limited activity days. When all patients were included, the mean number 
of limited activity days was 1.9 (95% CI 0.7; 3.2) for self-management and 6.0 (95% 
CI 2.6; 9.4) for usual care. Closer examination identified two distinct outliers in the 
usual care group with 142 limited activity days and 69 limited activity days, 
respectively. One of the outliers had a period of several months with frequent but 
short episodes of sick leave due to asthma, the other a three-month episode of 
uninterrupted sick leave. In both cases, irritant exposure in the workplace explained 
the high counts. Because of the clear work-related cause and the disproportionate 
impact of these two outliers on the group average we decided to exclude subjects 
above the 98th percentile from the final calculations in both groups. 
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This resulted in an average number of limited activity days of 1.2 (95% CI 0.5; 1.9) 
for self-management and 3.9 (2.5; 5.4) for usual care. 
Table 6.2: Baseline characteristics of study subjects included in the intention to 
treat analyses. Figures are means (SD) unless stated otherwise. 
Self-management Usual care ρ value 








requiring pre-treatment with budesomde9 
% with asthma attack(s) in previous 
FEV, as % of predicted value 
Before bronchodilatoH1 
After bronchodilator 
FEV, reversibile (%)b (median) 
PostBD - preBD/predicted 
Bronchial hyperresponsiveness 
PC20 geometric mean 
Initial dose of inhaled steroids 
none 
6 months 
Low (<400 meg daily, or equivalent) 
Intermediate (>=400 and 
equivalent) 
High (>=800 meg daily or 






<800 meg daily, or 
equivalent) 
FEVi=forced expiratory volume in one second in litres; 



















5 3 (1.03) 
5.3(1.10) 
5.4 (0.872) 
FVC=forced vital capacity 
: and after bronchodilator/ predicted FEV, 
• pre-treatment consisted of 6 weeks budesomde 800 micrograms BID 





5 7 (4.5) 
22 (23%) 
31.6% 
86 9 (14.2) 
92.6 (12.9) 



























a) missing data - self-management 2; usual care 1 
b) missing data - self-management 2, usual care 2 
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Figure 6.2: Flow chart of patients 
224 not willing to 
participate 
40 excluded at 
laboratorv 
8 did not start 
1 dropped out 
before 








11 usual care (24 GPs) 
8 self-management 
Usual care 
368 selected by GP 
104 patients included 
^ 




283 selected by GP 
98 intention to 
treat analysis 
135 not willing to 
participate 
38 excluded at 
laboratorv 
7 did not start 
5 dropped out 






Lost to follow-up: 
3 
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As demonstrated in figure 6.3, the post bronchodilator FEVi showed an estimated 
decline rate of 0.048 L per year in the self-management group versus 0.026 L per 
year in the usual care group (p=0.239). There were no between-group differences in 
estimated decline-rate for FEVi-reversibility and PCzo-histamine. 
Figure 6.3: Mean changes from baseline in post bronchodilator FEVi(L) with 
standard errors. 
-Self managemenl - •• - Usual care 
Changes from baseline in overall AQLQ-score are summarised in figure 6.4. Based on 
repeated measurements analysis the estimated increase in overall asthma quality of 
life score was 0.10 points per visit in the usual care group versus 0.21 points per visit 
in the self-management group (p=0.055). Changes in quality of life were also 
estimated for each of the sub-domains: emotions, activities, symptoms and 
environment. There only was a significant change between both groups in the 
emotions domain (0.02 points per visit in the usual care group; 0.20 points per visit 
in the self-management group; p=0.006), which is summarised in figure 6.5. To 
verify if statistically significant changes in quality of life were clinically relevant, we 
compared proportions of subjects with individual changes of at least 0.5 points. In 
the emotions domain 41% of patients from the self-management group had an 
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Figure 6.4: Mean changes from baseline in quality of life with standard errors 
-Self managemenl - *· - Usual care 
Figure 6.5: Mean changes from baseline in quality of life with standard errors, 
emotions domain. 
-Self managemenl - * - Usual care 
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increase of at least 0.5 point versus 23% of patients in the usual care group (Chi 
square=8.811, p=0.012). 
Mean budesonide usage was 1680 puffs per patient (95% CI 1538; 1822) for self-
management and 1897 puffs per patient (95% CI 1679; 2115) for usual care, 
indicating a saving of 217 puffs per patient. 
With a median amount of 97 (168 IQR) micrograms per day of short acting beta-2 
bronchodilators in the self-management group versus 69 (340 IQR) micrograms per 
day in the usual care group, there was no statistically significant difference between 
both study groups (p=0.711, Mann-Whitney-U). In the self-management group there 
was a median of 12 (28 IQR) micrograms per day of ipratropium versus 35 (114 
IQR) micrograms in the usual care group (p=0.607, Mann-Whitney-U). 
Table 6.3: Indicators of exacerbations. 
(Between group comparison using Mann-Whitney-U test) 
Self- Usual Care 
management 
Exacerbations per patient per two years (p=0.678) 
No (% within group) with 0 exacerbations 
No (% within group) with 1 exacerbations 
No (% within group) with 2 exacerbations 
No (% within group) with 3 exacerbations 
No (% within group) with 4 or more exacerbations 
Oral prednisolone courses per patient per two years 
(p=0.015) 
No (% within group) with 0 courses 
No (% within group) with 1 course 
No (% within group) with 2 courses 
No (% within group) with 3 or more courses 
Courses of antibiotics per patient per 2 years (p=0.643) 
No (% within group) with 0 courses 
No (% within group) with 1 course 
No (% within group) with 2 courses 




























Table 6.3 summarises the indicators of exacerbations. There were no differences in 
the number of GP diagnosed exacerbations and the number of antibiotics. There was 
a statistically significant higher number of courses of oral prednisolone in the guided 
self-management group (p=0.015, Mann-Whitney-U). 
Discussion 
Findings from this study indicate that asthma control improved in the self-
management group in terms of a higher number of successfully treated weeks and 
fewer limited activity days. There were no major changes in the lung function 
parameters. Based on initial levels of pre- and post bronchodilator FEVi, the 
observed reversibility and initial dosage of inhaled steroids, included patients were a 
representative sample of mildly to moderately severe asthmatics5'18'27. In the self-
management group there was a slight improvement in asthma specific quality of life 
with a clinically relevant improvement in the emotions domain, indicating that 
patients in the self-management group felt less worried or insecure about the 
influence of their asthma on daily life. GPs did not diagnose more exacerbations, but 
the number of oral prednisolone courses was higher in the guided self-management 
group. 
Thus far there are few randomised controlled trials to the effects of guided self-
management programs in family medicine. As in our study most of these studies 
show limited reductions in symptoms or improvements in lung function and quality of 
life. Hoskins et al showed reductions in morbidity in terms of hospital admission, 
(emergency) consultations, oral steroid courses and emergency nebulisations. But 
due to possible selection bias superiority of self-management plans could not be 
proven28. Their results suggest that improvements in clinical and morbidity 
parameters are indeed less likely to occur in mild asthmatics. This was also 
concluded by Jones et al, but they may have failed to show results due to the small 
number of subjects29. On the other hand neither of these studies found that self-
management caused unwanted loss of asthma control or increased morbidity. In our 
study we observed a significantly higher number of patients requiring one or more 
courses of oral steroids in the self-management group. Based on instructions in the 
self treatment plan patients could start an oral course of prednisolone independently, 
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so patients routinely were prescribed one prednisolone course at the third 
educational session. As there are strong indications that GPs accidentally recorded 
these prescriptions as true oral prednisolone courses overregistration may have 
occurred. An other explanation for the higher number of prednisolone courses may 
be the higher number of patients with an asthma attack in the previous six months 
and the higher number of patients requiring pre-treatment at the start of the study in 
the self-management group. This may indicate that asthma control in the self-
management group initially was worse than in the usual care group. This is also 
reflected in a lower baseline quality of life. During the study changes in post BD 
FEVi, FEVi reversibility and PC20 did not differ in both groups. In the light of these 
findings the higher number of oral steroid courses in the self-management group can 
be attributed to a baseline between-group difference in asthma control. Additionally 
the use of oral steroids can be biased by instructions in the guided self-management 
program. Subjects in the self-management group were explicitly instructed about 
when to take oral courses of prednisolone. In this light the increased number of 
prescriptions may indicate either overtreatment or the self-treatment instructions 
worked as planned. In instances with more severe loss of asthma control adequate 
treatment was initiated without unnecessary delay, which is consistent with the 
increased number of successfully treated weeks and the lower number of lost-activity 
days. 
The number of successfully treated weeks is an indicator of the burden of asthma as 
perceived by patients. It is based on perceived changes in dyspnea instead of the 
perceived levels of dyspnea. Patients constantly experiencing the same high levels of 
dyspnea may thus have a relatively high number of successfully treated weeks. 
Presuming that the pre treatment phase did result in the highest achievable level of 
asthma control, constantly high symptom levels only are an indicator of experienced 
asthma severity, not asthma control. Subjects with increased weekly variations in 
perceived dyspnea levels will consequently have a lower number of successfully 
treated weeks. Accordingly the increased number of successfully treated weeks in 
the self-management group suggests less loss of asthma control in this group. 
Observed changes in quality of life were statistically significantly different in favour of 
the self-management group. The magnitude of these gains however is limited. At 
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baseline quality of life was high in both groups. This may have left little room for 
improvement. The finding that the observed baseline differences in quality of life 
scores completely disappeared after 24 months may indicate that quality of life has 
been maximised in both groups. 
Based upon our findings we conclude that self-management of asthma is at least 
equally effective as asthma treatment usually provided in Dutch primary care. Self-
management of asthma provides a safe basis for intermittent therapy with inhaled 
corticosteroids and lowers the burden of illness as perceived by patients. 
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Abstract 
In this randomised controlled economic evaluation we compared guided asthma self-
management with usual asthma care according to guidelines for Dutch family 
physicians. 19 family practices were randomised, 193 stable adult asthmatics (98 
self-management, 95 usual care) included and followed for 2 years. We hypothesised 
that introducing self-management would not compromise asthma control and cost 
would be equal or lower than in usual care. Patient-specific cost data were collected, 
preference-based utilities assessed, and incremental cost per quality-adjusted life 
year (QALY) and successfully treated week gained calculated. Self-management 
patients gained 0.039 QALYs (95%CI 0.003; 0.075) and experienced 81 (95%CI 78; 
84) successfully treated weeks in two years time; the corresponding figures for usual 
care were 0.024 (95%CI -0.022; 0.071) and 75 (95%CI 72; 78). Total cost was 
€1084 (95%CI 938; 1228) for self-management and €1097 (95%CI 933; 1260) for 
usual care. Self-management patients consumed 1680 (95%CI 1538; 1822) puffs 
budesonide, usual care patients 1897 (95%CI 1679; 2115). Mean productivity cost 
due to limited activity days was €213 lower in self-management patients. When all 
costs were included, self-management was cost-effective on all outcomes. The 
probability that self-management was cost-effective relative to usual care in terms of 
QALYs was 52%. We conclude that guided self-management is a safe and cost-
effective alternative approach compared to asthma treatment usually provided in 
Dutch primary care. 
Introduction 
Asthma is a chronic respiratory disease affecting people of all ages. In western 
countries, 4 to 6% of the adult population have a physician-confirmed diagnosis of 
bronchial asthma1'2. Compliance with prophylactic inhaled corticosteroid treatment is 
poor in many asthma patients, thus limiting its effectiveness3,4. Because the cost of 
asthma for society are largely due to the consequences of uncontrolled disease, it is 
presumed that the cost could be significantly reduced if disease control is improved5. 
Using a comprehensive approach generally consisting of education and training, 
written action plans and periodic supervision, health professionals may try to improve 
knowledge, practical skills, decision-making responsibility and, ultimately, disease 
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control in their asthma patients6;7. A recent systematic review including twenty-three 
trials concluded that self-management programs are able to improve health 
outcomes in adult asthma if they include self-monitoring and are accompanied with 
written action plans and regular medical professional review8. However, the trials 
included in this meta-analysis have been conducted mainly in selected (secondary 
care) patients. 
When competing for scarce health care resources it is not sufficient to determine the 
effects of asthma self-management programs solely in terms of health outcomes. It 
is also important to analyse whether the cost of introducing self-management 
outweigh the -potential- subsequent savings in health care utilisation and 
productivity Cindirect') costs, the latter resulting from fewer days of limited activities 
and incapacity for work9. If the savings do not outweigh the investments, it is 
essential to assess whether the additional -or incremental- cost of a self-
management program can be justified by the health gains. 
Meanwhile, several asthma guidelines recommend self-management10'11 and health 
professionals and asthma patients themselves seem to appreciate the contemporary 
approach12"14. A number of economic evaluations on asthma education and self-
management have been published15"26 but most authors have confined themselves to 
separate descriptions of costs and health effects without directly assessing their 
relationship by calculating summary ratios. Essential methodological shortcomings 
were the absence of a control group receiving an appropriate comparator treatment 
and a too short duration of follow-up. None of the published economic studies 
included instruments to assess preference-based utilities (e.g., quality-adjusted life 
years (QALYs) or similar universal outcome measures) as is currently recommended 
for all economic evaluations27;28. Moreover, only a part of the studies used written 
action plans, which seems to be a prerequisite for a successful treatment result8. 
This paper reports a state-of-the-art economic evaluation of a guided self-
management program for adult asthma patients treated in Dutch primary care. We 
compared the self-management program with the 'best' generally available medical 
treatment for asthma Cusual care') according to asthma treatment guidelines for 
family physicians29130. Beforehand, we did not expect substantial differences in health 
outcomes because medical care for asthma patients is already of a high standard in 
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the Netherlands, with asthma-related hospital admissions and deaths almost 
becoming rare events31. Therefore, the main objective of this evaluation was to 
investigate whether a family practice based self-management program for adult 
asthmatics provides an efficient treatment alternative in terms of health care 
utilisation and absence from work, without asthma control being compromised. 
Methods 
Study design 
The study was a randomised controlled parallel group multi-centre clinical trial. 
Nineteen (19) Dutch family practices (49 family physicians) were randomly allocated 
to guided self-management or usual care. Randomisation was stratified on type of 
practice, number of asthmatics initially identified from the practice records and use of 
a computerised prescription system. Duration of follow-up was two years per patient. 
Self-management and usual care were fully pursued by the family physicians, no 
other health professionals were involved. The study protocol was approved by the 
medical ethical committee of the University Medical Centre St Radboud. Patients 
gave written informed consent before study entry. The first subject entered the 
study in March 1996, the last subject completed the study in June 1999. 
Participants 
The 49 family physicians involved in the study selected asthmatic subjects aged 16-
60 years who were to be treated with inhaled steroids according to national 
guidelines30'31. Identification of subjects was based on the following information 
sources: problem list coding (International Classification of Primary Care (ICPC): 
R96); prescription of inhaled steroids or bronchodilators from practice or pharmacy 
records; and the annual influenza vaccination campaign list. Subjects willing to 
participate were included if (1) PC20 (provocative dose of histamine causing a 20% 
drop in FEVi) <8 mg/ml and/or reversibility of FEVi >9% of the predicted value after 
800 micrograms salbutamol aerosol administered by spacer; (2) smoking history <15 
packyears; (3) not currently treated by a chest physician; (4) able to communicate in 
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the Dutch language. Eligible patients with an initial FEVi <80% of the predicted 
value were pre-treated with budesonide 800 micrograms b.i.d. during 6 weeks. 
Guided self-management and usual care 
All participants were prescribed budesonide administered by multi-dose dry powder 
inhaler (Pulmicort Turbuhaler®, 200*200 microgram, Astra Zeneca BV, Zoetermeer, 
the Netherlands) by one of the investigators (BT). Participants received new 
budesonide inhalers and handed-in used inhalers during half-yearly visits to the 
pulmonary function laboratory. The patient's own family physician was responsible 
for regulating the dosage scheme at study entry. Family physicians were not 
restricted in prescribing non-steroid lung medication in either group, apart from 
cromoglycates and nedocromil being prohibited during the trial. Bronchodilators were 
preferably prescribed on an as-needed basis, if necessary at all. 
Self-management patients received education and training of skills on an individual 
basis from their family physician. Training consisted of four visits to the practice 
scheduled within a period of 3 months. Subsequent control visits for the remaining 
follow-up period of 21 months were recommended, but it was left to the initiative of 
the family physician and patient if and when these visits took place. Training tools 
consisted of (1) a detailed manual for the physicians describing the educational 
topics to be discussed during the consecutive training sessions and instructions on 
how to teach patients self-management skills (i.e. peak flow measurement, proper 
inhalation technique, completing the self-management diary, application of self-
treatment guidelines); (2) checklists for patients and physicians to assess and record 
specific information needs of patients; (3) two booklets of the Dutch Asthma 
Foundation, one containing general information about asthma, the other information 
about asthma medication; (4) diaries containing self-treatment guidelines, also used 
for data collection. Self-management patients were equipped with a portable peak 
flow meter (Asmaplan+, Vitalograph Ltd., Buckingham, UK) and instructed to 
measure morning and evening peak expiratory flow rates once a week and record 
the best of three attempts in their diary. Self-treatment guidelines were based on 
peak flow values and severity of respiratory symptoms (figure 7.1). Detailed 
information on the exact contents of the education program and self-treatment 
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Figure 7.1: Summary of step-up and step-down instructions for self-management 
patients regarding the use of budesonide. 
Step-up instructions 
• PEFFt deteriorates <80% PEFR >60% of PBV for 3 consecutive days: 
double* budesonide dosage 
in case of insufficient response within three weeks: again double* budesonide 
dosage 
• PEFR1 deteriorates <60% PEFR >40% of PBV for 3 consecutive days: 
increase budesonide dosage to 800 micrograms b.i.d. 
in case of insufficient response within two days: start course of oral 
prednisolone 
and contact your family physician 
• PEFR1 deteriorates <40% of PBV for 3 consecutive days: 
immediately contact your family physician 
Step-down instructions 
• PEFlt improves to >40% PEFR <60% of PBV: 
continue the current budesonide dosage until your PEFR is >60% of PBV 
• PEFR' improves to >60% PEFR <80% PBV: 
continue the current budesonide dosage until your PEFR is >80% of PBV 
• PEFft improves to >80% of PBV: 
halve budesonide dosage when PEFR >80% for a period of two weeks 
* if no budesonide was used at the time of deteriorating peak flow, the patient should commence with the lowest dose 
(200 microgram b ι d.) Patients were not allowed to double their dosage of budesonide anymore once the maximum dosage of 
800 micrograms b.i.d. had been reached 
+ either morning or evening value 
PEFR: peak expiratory flow rate 
PBV: personal best value 
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guidelines have been published elsewhere33. Usual care physicians were instructed to 
adhere to the asthma treatment guidelines issued by the Dutch College of Family 
Physicians in 199229 and to the revised guidelines issued in 199730. Usual care 
patients did not receive peak flow meters, nor were they instructed on how to adjust 
their dosage of budesonide. 
Clinical effectiveness 
Clinical effectiveness was evaluated on the basis of asthma control parameters and 
quality of life. Asthma control was expressed as the number of successfully treated 
weeks in two years follow-up, changes in post-bronchodilator FEVi (forced expiratory 
volume in one second), changes in FEVi reversibility as percentage of predicted 
value, and changes in PCzo-histamine33. Asthma-specific quality of life was assessed 
using the interview-administered 32-question Asthma Quality of Life (AQLQ) 
questionnaire34. This instrument assesses four domains: (1) asthma symptoms; (2) 
limitation of activity; (3) emotional dysfunction and (4) responses to environmental 
stimuli, respectively. An overall score as well as separate domain scores were 
calculated. 
Economic evaluation: data collection and resource valuation 
A societal perspective was adopted for the economic evaluation. Patient specific 
resource use was measured in natural units if possible. Resource use was valued in 
monetary terms by multiplying the units consumed with the cost per unit. Three 
major cost categories were distinguished: program implementation, direct health 
care, and productivity Cindirecf) costs. The specific cost components can be read 
from tables 7.3 and 7.4. 
Data regarding bronchodilators and other prescribed non-steroid asthma medication, 
over-the-counter medication and limited activity days were extracted from the diary 
cards. A limited activity day was defined as any day on which a patient could not 
perform his or her usual (paid or unpaid) daily activities. Consumption of budesonide 
was assessed by counting the remaining puffs in the inhalers returned and by 
registration on the diary cards. We considered the puff counts as the most reliable 
source of information for estimating budesonide consumption36. Patient out-of-pocket 
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cost on house dust mite allergen avoidance measures and smoking cessation 
attempts were assessed retrospectively by an ad hoc questionnaire. Family 
physicians reported details of asthma-related consultations, medication prescriptions, 
influenza vaccinations, referrals and diagnostic procedures on study report forms. 
Completeness of consultation data was verified after a patient had completed study 
participation. 
The first-choice source for resource unit valuation was the sum charged by family 
physicians to privately insured patients (including V.A.T. and a mark-up for 
administrative expenses). Secondary sources were annually updated drugs and 
diagnostic indexes35,36 and recent recommendations regarding cost analysis37 (all 
issued by the Dutch College of Health Insurance), study expense accounts and 
patient questionnaires. The human capital approach28 was adopted to value limited 
activity days. An individual hourly wage based on the gross monthly income and the 
number of hours of disbursed work was calculated for all participants in paid 
employment. The resultant average gross hourly wage (€9.53) was subsequently 
used to convert all limited activity days (eight hour workday) into monetary terms, 
regardless of the employment status or income of individual participants. All 
resources used were valued in Dutch guilders and converted to Euros (€). For 
conversion to US$, costs in € should be multiplied by a factor 0.912, based on the 
2000 Purchasing Power Parities as issued by the Organisation for Economic Co-
operation and Development (www.oecd.org). Purchasing Power Parities are the rates 
of currency conversion that equalise the purchasing power of different currencies, 
thus eliminating differences in price levels between countries. Costs nor effects were 
discounted for time preferences. 
Cost-effectiveness analysis: outcome measures 
We performed a 'Reference Case' cost-effectiveness analysis as recommended by 
Gold et al27 as well as secondary cost-effectiveness analyses. With the term 
Reference Case we refer to an analysis in which the direct health care cost, program 
implementation cost and productivity cost of patients are included. Outcome for the 
Reference Case analysis was defined in terms of quality-adjusted life-years (QALYs). 
In order to calculate QALYs, preference based utilities were assessed at baseline and 
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half-yearly at the lung function laboratory. An interval rating scale ranging from 0 to 
1 was used for this purpose, 0 being equal to death and 1 being equal to perfect 
health38. Participants first marked a standardised (hypothetical) reference health 
state on the rating scale and subsequently their own perceived health state. 
The number of successfully treated weeks served as the main outcome for secondary 
cost-effectiveness analyses9. Successfully treated weeks were defined on the basis of 
recorded scores for shortness-of-breath in the diaries (modified Borg interval scale, 
scoring 0 = no shortness of breath; 10 = maximal shortness of breath)39. Any given 
week with a score higher than the individuals' median score over the total follow-up 
was considered as an unacceptable low level of control of asthma symptoms and 
therefore counted as i//7successful. Subtracting this figure from the individual's total 
number of recorded weeks resulted in the proportion of weeks being treated 
successfully, which was eventually standardised to the number of successfully 
treated weeks per two years (104 weeks). Next to successfully treated weeks, the 
number of patients with a minimal clinically important difference (MCID) in quality of 
life between the baseline and final visit was studied as a secondary outcome. MCID 
was defined as a within-subject improvement of 0.5 unit on the overall AQLQ or 
domain scores34. 
Statistical analysis 
Patients were included in the intention-to-treat analysis if they had been present at 
the first follow-up visit at the pulmonary function laboratory after 6 months. Although 
distributions of resource units were skewed to the right for most cost components, 
arithmetic means and f test based ninety-five percent confidence intervals (95% CIs) 
were calculated to compare self-management and usual care groups41. Within-group 
cost differences between the first and second study year were analysed by paired, 
between-group differences by unpaired f test. QALYs were determined by calculating 
the area-under-the-curve (time*rating scale score) for each individual participant. 
Mean costs and effects were multiplied by a constant of 100 in order to standardise 
for inequalities of group sizes. Because of that, cost-effectiveness results reflect a 
situation in which two groups of one-hundred patients each would receive either self-
management or usual care. Consequently, the cost-effectiveness ratios of the AQLQ 
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data should be interpreted as the incremental cost or net savings to improve quality 
of life in one patient. A treatment was qualified to be 'dominant' when this particular 
treatment was both more effective and less costly than the alternative27. Secondary 
analyses were performed by calculating cost-effectiveness ratios with exclusion of 
the productivity cost. 
The SAS statistical software package (SAS Institute Inc., Release 6.12 for Windows, 
Gary, NC, US) was used for statistical analyses. With regards to the incremental cost 
per successfully treated week, a 95% CI was determined based on Fiellers 
theorem43. In order to express uncertainty in the estimated incremental cost per 
QALY, Data for Health Care software (Data Pro, Treeage Inc., Williamstown, MA, 
US) was used to generate graphical representations of the cost-effectiveness plane 
and accompanying two-dimensional 90% and 95% confidence intervals. This was 
done using Monte Carlo simulation by drawing 1000 random samples with size 
n=100 each from the actual cost and QALY study data from the two comparator 
groups. Each point in the resulting scatterplot represents the incremental cost-
effectiveness ratio of one iteration of the Monte Carlo simulation. A diagonal line 
intersecting the origin of the plot simplifies identification of points for which the 
incremental cost-effectiveness ratio of self-management versus usual care is less 
than, or equal to, a a priori specified societal 'willingness-to-pay'limit44 (λ) to gain 
one additional QALY. Arbitrarily, λ was set on €22,500. A graphical representation 
Cacceptability curveO of the probability that a particular intervention is cost-effective 
over a range of increasing values for λ was generated45. This bayesian approach of 
the stochastic analysis provides information relevant to health care decision making. 
Results 
Study population and clinical effects 
Ninety-eight (98) self-management and 95 usual care patients were included in the 
intention-to-treat analyses (figure 7.2). Treatment groups did not differ on general or 
clinical characteristics at baseline, apart from a higher proportion of patients 
reporting a recent episode of aggravated asthma symptoms and lower AQLQ scores 
in the self-management group (table 7.1). Fourteen (14) self-management patients 
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Figure 7.2: Flow chart of recruitment and drop out of study participants. 
224 not willing 
to participate 
40 excluded at 
laboratory 
• 8 did not start 
• 1 drop out 
before first 
follow up visit 
Withdrawn 9: 
• Lost to follow-
up. 2 
• Other reason: 7 
Randomisation of family 
practices: 
11 usual care (24 family 
physicians) 
8 self-management 
(22 family physicians) 
Usual care 





intention to treat 
86 completed trial 
Self-management 
283 patients selected 
by physicians 
98 
intention to treat 
135 not willing 
to participate 
38 excluded at 
laboratory 
7 did not start 
5 drop outs 
before first 
follow up visit 
85 completed trial 
Withdrawn 13: 
• Lost to follow-
up· 3 
• Other reason· 10 
and 16 usual care patients did not use bronchodilator medication during the study. 
Twelve (12) self-management and 5 usual care patients used a long-acting beta2-
agonist, theophyllines were used by 3 self-management patients only. The course of 
the pre- and post-bronchodilator FEVi did not differ between groups, nor did FEVi 
105 
reversibility or PC20 · The mean number of successfully treated weeks in two years 
time was 81 (95% CI 78; 84) for self-management and 75 (95% CI 72; 78) for usual 
care (table 7.2). This corresponds with a statistically significant gain of 6 successfully 
treated weeks in two years in favour of self-management. In the self-management 
group 17% (95% CI 10; 24) more participants showed a MCID on the AQLQ 
emotions domain compared to usual care. No statistically significant differences were 
observed for the activities, environmental and symptoms domains, or the total AQLQ 
score. 
Cost analysis 
The total implementation cost of the self-management program amounted to €189 
(95% CI 179; 199) per patient (table 7.3). Time invested by family physicians and 
purchase of peak flow meters constituted the major part of the implementation cost 
(60% and 16%, respectively). Mean budesonide usage was 1680 puffs (95% CI 
1538; 1822) or €414 for self-management and 1897 puffs (95% CI 1679; 2115) or 
€467 for usual care, indicating a saving of 217 puffs or €53 per patient during the 2-
year follow-up (table 7.4). Converted to the level of budesonide inhalers, 0.5 inhalers 
per year were saved by self-management patients. Cost of short-acting 
bronchodilators were significantly lower for self-management, but this difference was 
largely compensated by the higher cost of long-acting beta2-agonists and 
theophyllines in this same group. During the study, 30 (31%) self-management and 
10 (11%) usual care patients took domestic house dust mite avoidance measures 
(Relative Risk = 1.7, 95% CI 1.3; 2.2). Consequently, mean cost of domestic house 
dust mite allergen avoidance measures were significantly higher among self-
management patients (€193 i/ersz/s€109 for usual care, p=0.0015). Although the 
cost of influenza vaccinations comprised only a marginal proportion of the total direct 
cost, there were significantly more vaccinations in the self-management group (table 
7.4): 46 (47%) self-management and 27 (28%) usual care patients received at least 
one influenza vaccination during follow-up (Relative Risk = 1.5, 95% CI 1.1; 1.9). 
There were more referrals to chest physicians among self-management than among 
usual care patients: 9 (4.6%) and 1 (0.6%), respectively (p=0.011). No asthma-
related emergency unit visits or hospital admissions were reported. 
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Table 7.1. Baseline characteristics of the study population by treatment group. 






Full-time or part-time job (%) 







Duration of asthma* (years) 
Subjects with asthma attack(s) in previous 6 months 




Lung function parameters 
FEVi post-BD % of predicted value 
Median FEV, reversibility* (%) 
PQo geometric mean 
Utilities and quality of life 
Utilities 
Median Own health state' 
Median 'Reference health state' 
Quality of life 
Overall AQLQ score 
AQLQ activities domain 
AQLQ emobons domain 
AQLQ symptoms domain 
AQLQ environment domain 
Self-management 
















5 0 (IQR 8.6) 
1.20 
0.80 (IQR 0.15) 







(n = 95) 















5.4 (IQR 6.8) 
0.97 
0 80 (IQR 0 16) 
0.40 (IQR 0.20) 
5 7 (0.77) 



























missing in 17 self-management and 14 usual care patients 
missing in 14 self-management and 19 usual care patients 
difference between FEVi % predicted before and after bronchodilator 
Asthma Quality of Life Questionnaire 
forced expiratory volume in one second 
forced vital capacity 
inter quartle range 
Table 7.2. Average and incremental effects of self-management and usual care in 
adult asthmatics. 
Results of the Reference Case analysis are printed in bold figures. Increments are 




Number of successfully treated weeks 
(95% CI) 










Incremental* effect of 
self-management in 
100 subjects treated 





Proportion of subjects with MCID: 
AQLQ total score' 
(95% Q) 
AQLQ emotions domain' 
(95% CI) 
AQLQ activities domain' 
(95% CI) 
AQLQ symptoms domain' 
(95% CI) 
































* self-management minus usual care 
t final AQLQ measurement was missing in 2 self-management and 6 usual care patents 
AQLQ: Asthma Quality of Life Questionnaire 
MCID' minimal clinically important difference 
QALY: quality adjusted life year 
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Table 7.3. Breakdown of the implementation cost of the self-management 
program for 98 adult asthmatics treated for two years in eight family practices 
Component of cost 
Preparation 





Application of self-management program 
Educational and self-management aids 
Peak flow meters 
Education sessions: 



























Total implementation cost 













* set· all materials necessary to educate and tram one patient, ι e information brochures, self-management diaries and 
information feedback forms 
t based on the average gross hourly wage of all employed participants 
Sources used for unit valuabon 
[a] Guidebook for Cost Investigation (Dutch College of Health Insurance, reference 39) 
[b] retail prices (index year 2000) 
[c] study-specific inquiry by quesbonnaire 
Mean direct health care cost aggregated to €809 (95% CI 683; 934) for self-
management and €798 (95% CI 682; 914) for usual care (table 7.4). 
Seventy-nine percent (79%) of self-management and 62% of usual care patients 
reported one or more limited activity days at some point during follow-up. The mean 
number of limited activity days was 1.9 (95% CI 0.7; 3.2) for self-management and 
6.0 (95% CI 2.6; 9.4) for usual care, corresponding with mean productivity cost of 
€144 and €462, respectively. However, closer examination of the productivity cost 
data identified two distinct outliers in the usual care group with productivity cost of 
109 
€10,831 (142 limited activity days) and €5,263 (69 limited activity days), 
respectively. One outlier had a period of several months with frequent but short 
episodes of sick leave due to asthma, the other a three-month episode of 
uninterrupted sick leave. In both cases, irritant exposure in the workplace explained 
the high productivity cost. Because of the clear work-related cause and the 
disproportionate impact of these two outliers on the average productivity cost in the 
usual care group, we decided to exclude subjects above the 98th percentile of the 
productivity cost distribution from the final cost calculations in both groups. This 
resulted in an average number of limited activity days of 1.2 (95% CI 0.5; 1.9) for 
self-management and 3.9 (2.5; 5.4) for usual care, corresponding with a €213 
productivity cost saving for self-management (table 7.4). We consider the 
productivity cost without the outliers as the main results. 
The sum of direct health care and implementation costs amounted to a difference of 
€199 (95% CI 70; 328) in favour of usual care (table 7.5). The between-group 
difference in the total cost of €13 was not statistically significant (p=0.906). 
Analysing the cost for the first and second year separately showed that, as expected, 
the major part (91%) of the program implementation cost was spent during the first 
study year (figure 7.3). A significant reduction of the productivity cost from the first 
to the second year was observed for self-management (p=0.036) but not for usual 
care (p=0.487). During the second year the total cost per patient were €147 
(p=0.0013) lower in the self-management group. 
Reference Case cost-effectiveness analysis 
The course of rating scale scores is given in figure 7.4. The mean number of QALYs 
gained during the two year follow-up was 0.039 (95% CI 0.003; 0.075) for self-
management and 0.024 (95% CI -0.022; 0.071) for usual care (table 7.2). This 
would imply that in 100 patients with asthma, self-management is associated with a 
gain of 1.5 QALY (95 % CI -1.4; 4.4) relative to usual care. In terms of cost-
effectiveness, self-management dominated usual care (table 7.6). Uncertainty 
around the incremental cost per QALY point estimate is depicted in figure 7.5. This 
scatterplot shows that the uncertainty around the cost-effectiveness estimate is 
large. In other words, the dominance of self-management cannot be firmly 
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established. This is supported by the cost-effectiveness acceptability curve (figure 
7.6): regardless of the societal willingness-to-pay, the probability that self-
management is cost-effective relative to usual care is approximately 52% when a 
prior probability of 50% is assumed. 
Figure 7.3. Cost analysis for the first and second year of follow up of self-
management and usual care patients. 
The cross-hatched area In the grey section of each bar represents the patient out-of-pocket 
cost for domestic allergen avoidance measures. 




o J — I 1 1 1 1 1 1 
Year 1 Year 2 Year 1 Year2 
D Direct health care cost • Program implementation cost D Productivity cost 
between-group difference in total cost for year 2 (unpaired f test) 
within-group difference in productivity cost between year 1 and year 2 (paired itest) 
within-group difference in indirect cost between year 1 and year 2 (paired f test) 
Table 7.4. Mean and incremental program implementation, direct health care and 
productivity cost (€) of self-management and usual care per patient per two 
years. Figures in the black bars are the mean cost per cost category 
Self-management (n=98) Usual care 
(n=95) 
Component of cost 
Source for Units (95% CI) 
unit valuation 
Cost (€) Units (95% CI) Cost(€) 
I nc remen ta l 
cost (€) " 
Program implementation cost 
(see table 2 for details) [a b c] 




Short-acting bronchodilators (doses) 




Other asthma medication' 
Influenza vaccinations (number) 
Physiotherapy (courses) 
Allergen avoidance measures 
Other resources 
Family physician consultations (number) 
Chest physician consultations (number) 
Diagnostic procedures' 
Emergency room visits (number) 
Hospital admissions (number) 
98 189 







































































( 6 , 66) 






























+ 8 4 
Productivity cost 
Limited activity days (days) ! [c] 
Subtotal direct cost: 
1.2 (0.5, 1.9) 




( 6 8 3 , 9 3 4 ) 








- 2 1 3 
- 2 1 3 
Total cost: 1 0 8 4 (938, 1228) 1097 (933, 1260) -13 
b o t h p r e s c r i b e d a n d o v e r - t h e - c o u n t e r m e d i c a t i o n 
t p u r c h a s e o f h o u s e d u s t m i t e i m p e r m e a b l e m a t t r e s s covers, s m o o t h f l o o r s , special v a c u u m cleaners a n d air c leaning 
e q u i p m e n t 
* cost o f var ious p u l m o n a r y f u n c t i o n a n d a l lergy tests, chest X-rays a n d s p u t u m c u l t u r e s 
§ h ighest t w o p a t i e n t s w e r e e x c l u d e d in b o t h g r o u p s (see t e x t ) 
II s e l f - m a n a g e m e n t m i n u s usual c a r e 
N/A. n o t appl icable 
Sources used f o r u n i t v a l u a t i o n : 
[a] Guidebook for Cost Investigation (Dutch College of Health Insurance, reference 39) 
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[b] retail prices (index year 2000) 
[c] study-specific inquiry by questionnaire 
[d] sum charged by family physicians to privately insured patients, including administrative expenses 
[e] Pharmacotherapeutic Compass (Dutch College of Health Insurance, reference 37) 
[f] Diagnostic Compass (Dutch College of Health Insurance, reference 38) 
Figure 7.4. Mean changes in rating scale scores for self-management and usual 
care groups adjusted for baseline level. 
Vertical bars are standard errors. The grey area between the two lines represents the 
difference in QALYs between treatment groups*. 
0 05 -i 
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because not all participants had their laboratory visits scheduled at exactly 6,12, 18 and 24 months, the visual 




Secondary cost-effectiveness analyses 
When productivity cost were excluded, the incremental cost per QALY of self-
management relative to usual care was €13,267 (table 7.6). Self-management 
dominated usual care with regard to successfully treated weeks and the proportion of 
patients with a MOD in quality of life. Without the productivity cost, the incremental 
cost-effectiveness ratio was €33 (95% CI 4; 99) to gain one successfully treated 
week due to self-management (table 7.6). Cost-effectiveness ratios based on the 
cost per patient with a MCID in quality of life preponderantly pointed to self-
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management as the dominant treatment, regardless of the inclusion or exclusion of 
productivity cost (table 7.6). 
Table 7.5. Average and incremental cost (€) during two years of self-management 
and usual care in adult asthmatics. 
Results of the Reference Case analysis are printed in bold figures. A plus sign indicates an 
expenditure due to the self-management program, a minus sign a saving 
Cost components 
Direct Program Productivity 
health care implementation 
Self-management Usual care 





























| and •indicate the cost components included in the calculations of mean costs 
' self-management minus usual care 
95% CI. ninety-five percent confidence interval 
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Figure 7.5. Scatterplot of 1000 modelled incremental cost per QALY estimates. 
The table shows the proportion of iterations in the respective quadrants and compartments. 
Observations in compartments C^ C2 and C3 indicate cost-effectiveness of self-management 
The diagonal dashed line represents the societal willingness-to-pay (€22,500 per QALY, 
arbitrarily chosen). Inner and outer ellipses represent 95% and 90% confidence intervals, 
respectively). 
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Table 7.6. Incremental cost-effectiveness ratios for asthma self-management 
relative to usual care during two years follow-up. 
Cost are in Euros (€). Results of the Reference Case analysis are printed in bold figures. 
Incremental cost per QALY gained 
Incremental cost per successfully treated week gained 
Observed incremental cost for one patient to experience a MCID, 














AQLQ+ total score 
AQLQ emotions domain 
AQLQ* activities domain 
AQLQ* symptoms domain 
+ 



















dominant: treatment both more effective and less costly than the alternative treatment 
uncertainty in the Reference Case cost per QALY estimate is depicted in figure 5 
final AQLQ measurement was missing in 2 self-management and 6 usual care patients 
Asthma Quality of Life Questionnaire 
minimal clinically important difference 






95% CI: ninety-five percent confidence interval 
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Figure 7.6. Acceptability curve reflecting the probability that asthma self-
management is cost-effective relative to usual care given a societal willingness-
to-pay (λ) value 
2500 5000 7500 10000 12500 15000 17500 20000 22500 
Willingness to pay limit (€) for the incremental cost per QALY (€) 
Discussion 
This paper reports the economic evaluation of a family medicine based asthma self-
management program, with 'usual care' according to Dutch asthma treatment 
guidelines as the comparator treatment. In summary, the results were as follows. 
Net savings in favour of self-management were observed in some of the direct health 
care cost components (i.e., use of budesonide and short-acting bronchodilators) and 
productivity Cindirecf) cost. When all costs were included, a mean net saving of €13 
in favour of self-management was observed (not statistically significant). Despite the 
investment necessary for program implementation, the total cost for the self-
management group were significantly lower during the second year of follow-up. The 
Reference Case cost-effectiveness ratio pointed to self-management as a cost-
effective treatment option: self-management dominated usual care (i.e., was more 
effective and less costly). However, the graphical evaluation of uncertainty around 
the cost per QALY estimate showed that the observed dominance of self-
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management could not be firmly established. Overall, the secondary analyses based 
on successfully treated weeks and patients with a clinically important improved 
quality of life pointed to self-management as the dominant treatment option. When 
productivity cost were ignored, self-management was no longer dominant in the 
secondary analyses (€13,267 to gain one QALY and €33 to gain one successfully 
treated week). 
Some comments on the studies' methodology need to made before further 
discussing our findings. First, a disadvantage of using rating scales to value health 
states (and subsequently estimate QALYs) is that these instruments do not take risk 
avoidance and uncertainty about future health outcomes into account. Therefore, 
rating scale utilities tend to produce higher quality weights then other techniques 
such as time-trade-off and standard gamble methods46. Moreover, rating scale scores 
appear to be not a true interval scale of preference for certain health states. 
Unfortunately, in the current study we did not include a standard gamble or time-
trade-off instrument. The mean number of QALYs in both treatment groups may 
have been overestimated because of this, but the incremental difference between 
the groups is probably valid. However, one should keep this point in mind when 
comparing our QALY results with external information from other studies. 
We did not randomise individual asthma patients but family practices. The reason for 
doing so was to avoid potential 'contamination' of the usual care group by family 
physicians who had to practice both usual care and self-management simultaneously 
in different patients. Whereas in the clinical evaluation a multilevel analysis was used 
to address possible dependency in clustered observations induced by this kind of 
randomisation34, some influence on the cost data cannot completely be ruled out. For 
instance, prevailing habits and preferences in prescribing bronchodilators by family 
physicians may have biased the results for this cost component to an unknown 
extent. The same argument holds for the promotion of influenza vaccination among 
asthmatics. 
The baseline level of quality of life scores was higher in usual care patients, possibly 
leaving less room for improvement in this group. The comprehensive clinical 
evaluation of the data showed that the differences in AQLQ scores existing at 
baseline gradually disappeared during the 2-year follow-up period, which may 
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indicate that quality of life was maximised in both groups . However, the 
observation that self-management patients experienced significantly more 
successfully treated weeks implies that the self-management program also had an 
independent effect, regardless of the health status differences present at baseline. 
As a consequence of our study design, we cannot be sure which component of the 
self-management program in particular was responsible for the observed effects and 
savings: the (expensive) educational efforts made by the family physicians or the 
(relatively inexpensive) guidelines for self-monitoring and self-treatment. There is 
some evidence that addition of self-treatment guidelines to an asthma education 
program does yield extra effects in terms of health outcomes44. 
We have previously looked at the generalizability of our study population48. 
Evaluation of the recruitment process showed that patients who use a low or 
intermediate dosage of inhaled steroids were more likely to participate in the study 
than patients on a high dosage or patients who did not use inhaled steroids at all 
(although, according to our national treatment guidelines30,31, they should have). 
Moreover, patients in paid employment were more likely to refrain from participation 
than those not in paid employment. 
Regarding the cost analysis, several points need to be addressed. The most 
important expenditure necessary to implement the self-management program was 
the time spent by family physicians to educate and train their asthma patients (€113 
per patient on average). Delegation of this task to, for instance, nurses specialised in 
respiratory care could reduce these cost considerably. Assuming delegation would 
not diminish program effectiveness, any reduction in the implementation cost would 
obviously affect cost-effectiveness ratios in favour of self-management. Another 
advantage of transferring the actual pursuance of self-management training to other 
professionals would be the diminished impact on the (already) high workload of 
family physicians. Targeting the self-management intervention to patients with a 
high likelihood of treatment success could also enhance overall efficiency, although 
at this time it is unknown how these patients could be identified beforehand. 
One of the most remarkable findings in this study was that the introduction of self-
management led to substitution of particular cost components with other 
components. For instance, the financial saving due to reduced budesonide usage and 
less limited activity days in the self-management group was outweighed for the 
greater part by the extra out-of-pocket cost for domestic allergen avoidance 
measures, and, although to a much lesser extent, more influenza vaccinations and 
referrals to chest physicians. These favourable 'side effects' of the self-management 
program are probably explained by the emphasis put on the importance of healthy 
behaviour (i.e., allergen avoidance, influenza vaccination, smoking cessation) during 
the education sessions. The higher out-of-pocket cost for domestic allergen 
avoidance measures in the self-management group may be due to specific contents 
of our educational program. 'Nature, cause and prevention of allergy or allergic 
symptoms', 'Hyperreactivity and personal triggers', and 'Allergen avoidance measures 
at home' were three of the 31 educational topics the family physicians discussed with 
their participants. One previous study has reported that asthma education may be 
effective in promoting house dust mite avoidance measures in patients with 
moderate to severe asthma49. The extra attention focussed on self-management 
patients as a consequence of the intensified doctor-patient relationship may have 
influenced the higher referral rate observed in the self-management group. 
We observed significant differences in the use of asthma medication between self-
management and usual care patients, especially for budesonide. This difference 
suggests a more efficient use of prophylactic medication due to self-management, a 
finding inconsistent with previously reported higher compliance rates regarding the 
use of inhaled steroids after introducing self-management4,50. However, use of the 
term 'compliance' may be inappropriate when it comes to evaluation of self-
management in patients with asthma. After all, the essence of the approach is to 
fine-tune the use of inhaled steroids to the actual need as determined by self-
monitoring, without a prescribed (fixed) daily dose. For this reason, we anticipated a 
reduced consumption of inhaled steroids in the intervention group beforehand, 
although it has been shown that self-management patients do not always adhere to 
their personalised self-treatment guidelines4. 
The main objective of any self-management program is to attain a longwearing 
behavioural change in patients with regard to their disease. Once accomplished, this 
effect could be expected to persist for a longer period of time. Although in the 
current study we had to limit the time horizon to a maximum of two years, there was 
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a tendency towards further productivity cost reduction during the second year of 
follow-up. Because we had no cost data from the years before the study at our 
disposal, we can only speculate on how the observed productivity cost for the first 
and second year related to the annual productivity cost before the study. However, 
both Mühlhauser et aP and Trautner et aP have shown that significant changes 
from the pre-study situation may indeed be achieved. Moreover, findings reported by 
Trautner et aP agree with our observation of a progressive reduction of productivity 
cost between the first and second year in self-management patients: they observed 
a 5% reduction in the number of days of absence from work during the first year, 
but an 18% reduction during the third year. This suggests that savings in 
productivity cost resulting from asthma self-management are retained in the long 
term. 
Several other authors have reported significantly lower productivity cost due to self-
management as
 We||17"19;22;23;26;27. The estimated savings from these studies range 
from 25 to 70% of the productivity cost observed in control patients. It should, 
however, be kept in mind that these studies were performed in populations with 
varying asthma severity, with diverse control groups, in different countries and with 
different methods used for valuing productivity losses. Since there is no consensus in 
the literature as to what method is most suitable for valuing productivity losses, we 
applied the widely used human capital approach. An alternative method would have 
been the more advanced friction cost method as proposed by Koopmanschap etat7. 
The basic idea of this method is that the amount of production lost due to disease 
depends on the time-span organisations need to restore the initial production level. 
This 'friction period' is likely to differ by location, industry, firm and category of 
worker, making the method rather complex. Had we used the friction cost method, 
our estimate of productivity cost would probably have been lower, as has been 
demonstrated for other health care programs48. 
It is generally recognised that a large proportion of the total cost of asthma is 
derived from treating the consequences of poor asthma control, such as emergency 
room use and hospitalizations5. Therefore, improved asthma control is likely to 
reduce the number of acute asthma-related hospital admissions as well as the 
productivity costs resulting from the admission itself and recovery time after 
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discharge. Although several authors have reported reductions in use of hospital 
services due to self-management, hospital admissions did not occur at all in our 
study and can therefore be no explanation for the lower number of sick days 
observed in self-management patients. Thus, the effect of self-management on 
asthma-related limited activity days appears to be more subtle in mild patients with 
adequate asthma control, like the patients involved in the current study. We 
conclude that guided self-management is a safe and cost-effective alternative 
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'Equipping people with asthma with the tools they need to manage their condition is 
as important as writing the correct prescription,' according to the United Kingdom's 
National Asthma campaign. Guided self management has an established place in 
asthma guidelines and recommendations1'2. Yet the reality of every day asthma care 
is quite different from that which the guidelines suggest, as shown by Jones et al in 
this issue (p 1507).3 Even among general practitioners in an academic setting, 
asthma remains underdiagnosed and poorly treated,4 despite increased awareness of 
the condition. Professionals perceive asthma as a lifelong problem, but patients 
discontinue treatment after a few years or do not consult health professionals at all.5 
General practitioners and nurses have an important role in implementing self care 
programmes. However, Jones et al report that patient self management and transfer 
of responsibility from professional caregivers received a lukewarm response at best 
from general practitioners, practice nurses, and patients. This is particularly striking 
among nurses, who are generally valued for their ability to implement protocols, 
including encouraging self care. This response could be related to specific 
characteristics of the programme, but more probably it signals a development in 
primary care nursing in which nurses are no longer prepared only to follow 
instructions but wish to act using their professional judgement. There are indications 
that nurses need specific asthma qualifications to provide the best possible care for 
patients with asthma. Robertson et al found that nurses with advanced qualifications 
in asthma provided self management plans significantly more frequently.6 Ownership 
of guidelines is essential to guaranteeing implementation, not only for general 
practitioners but also nurses. 
The nurses in the study by Jones et al believed strongly that guided self 
management plans might do more harm than good as these plans would 'increase 
the likelihood of patients falling into bad habits'. The nurses believed that self 
management plans were appropriate for just a few patients: the ones who were 
already almost fully compliant with their treatment regimens. The nurses' lack of 
faith in the effectiveness of self management plans and their reluctance to hand over 
responsibilities to the patient contradict the very basis of self management. The 
objective of self management is to empower patients with the knowledge and skills 
they need to treat their own illness. A first step towards this is to have patients share 
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responsibility for their treatment with their caregivers.7 But empirical data on asthma 
care can only serve to indicate the breadth of the differences. For example, a general 
practice based screening programme in the Netherlands found that about 75 % of 
those with mild asthma and 65 % of those with moderately severe asthma who were 
eligible for treatment were reluctant to visit their general practitioner or to comply 
with follow up7'8; most of the patients studied did not consider themselves ill.9 In the 
study by Jones et al patients stated that they were not interested in guided self 
management plans, describing themselves as 'already self managing competently' 
and 'behaving responsibly'. This reflects self reliance more than competent self 
management according to guidelines. 
It also indicates a failure to integrate the personal and the medical dimensions of 
medical care10 - that is, the integration of the medical agenda with the patient's 
perspective. Self management schemes have to combine the best of these two 
elements, but sharing responsibilities implies that patients as well as medical 
professionals should determine the goals of treatment. Ownership of a management 
plan is an important precondition to effective treatment for both patients and health 
professionals. It is not a question of whether guided self management is effective or 
should be implemented, but rather the challenge is to accept that patients are 
managing their care one way or another and that we need to create opportunities to 
clarify how medical input can enhance their personal situation. Cooperation is the 
key to bridging the gap between the efficacy and effectiveness of asthma care. 
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Abstract 
The reality of every day asthma care differs substantially from guidelines. The fact 
that better possibilities for asthma care do not result in a better outcomes remains 
an enigma and harms professional pride. Patient self-management has been 
presented as a tool to improve outcome of care. Based on published work thus far, it 
can be concluded that self-management of asthma can be beneficial from both the 
family physicians' and the patients' perspective and, under certain conditions, proves 
to be an efficient method of incorporating both interests. Health professionals play 
an important role in implementing self-care, but several barriers should be solved 
first: attitudes of health professionals and patients need to shift towards shared 
responsibilities and be patient-centered and organization of care should change 
accordingly. As reviewed in this article, the typical features of self-management of 
asthma may provide the means to overcome these barriers. 
Introduction 
Guided self-management has an established position in asthma guidelines and 
recommendations1'2. Yet, the reality of every day asthma care differs substantially 
from these guidelines, and under-diagnosis and under-treatment remain high, even 
under optimal academic primary care3, and despite the fact that family physicians are 
increasingly aware of this problem4. 
Patient-related factors are important in under-diagnosis and under-treatment: 
patients appear reluctant to consult for chronic, persistent respiratory symptoms5 or 
discontinue treatment that was prescribed for long-term use after a short while. In 
particular, there is resistance to pharmacological treatment6: this has been reported 
in as many as 75 % of patients with mild asthma and in 65 % of those with 
moderately severe asthma. Additionally, most patients consider themselves as not 
being ill3;6. 
This information in itself is not new for family physicians and nurses, but it conflicts 
fundamentally with professional concepts of 'good' asthma care, which focuses on a 
pro active approach and the effective prevention of symptomatic episodes of asthma. 
This makes it difficult to apply the knowledge of patients' perceptions in a 
constructive way in regular care. 
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The fact that better possibilities (e.g. inhaled corticosteroids, patient education 
materials, leukotriene antagonists) do not always result in better outcomes remains 
an enigma and harms professional pride. Patient self-management has been 
presented as a tool to improve the outcome of care, assuming that improved 
knowledge, self-efficacy and patients' attitudes would enhance compliance with 
professional treatment schemes7. But the discrepancy between what is possible from 
a professional perspective and what is desired from the patients' perspective makes 
this an over-simplification. Based on this model, 'self-management' as mere 
compliance enhancement could easily become yet another way of pursuing 
professional objectives by other means. In other words, it is the physician who wants 
the patient to become compliant to the physicians' treatment scheme, instead of the 
patient becoming motivated to take and maintain control by himself. 
The findings of Jones et al8 that patients, family physicians and nurses are less than 
enthusiast to use and promote self-management plans under these conditions may 
not come as a surprise. Nurses in particular are generally valued for their ability to 
implement protocols and promote patient involvement, so this is in our view an 
important signal from primary care. At the same time, it is sound professional 
judgement that the basic concept of current asthma care, including the contribution 
of self-management, must be reconsidered before effective treatment will be 
feasible. 
The implementation of self-management can benefit from experiences associated 
with the implementation of other care innovations - for example, the introduction of 
treatment guidelines. These experiences have underlined that ownership of a 
treatment plan is essential, and this must also be true for self-management 
guidelines. All involved should experience this feeling of ownership; the interesting 
concept of 'self-management' makes it explicit that this includes, in particular, the 
ability of patients to take ownership of the guideline or plan. Their needs, demands 
and expectations must be taken into account, this will allow for a better 
understanding of why they cannot subscribe to the professional norms of asthma 
care. Understanding and cooperation are the first steps in eventually closing the gap 
between what is possible and what can be achieved in practice. 
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No guideline can reconcile what is incompatible. However, when it is explicitly clear 
where a patient and provider might differ, then at least informed decisions can be 
made and differences of opinion understood. This also allows for a re-evaluation of 
treatment decisions in a late phase. Based on this viewpoint, the key feature of self-
management is the change to patients fully sharing responsibility of treatment with 
their caregivers9, based on a common frame of reference. It is in this context that 
health professionals play an important role in implementing self-care, although some 
barriers may be encountered. Interviews with British GPs suggest that these 
obstacles are mainly of a practical nature10 Necessary materials (e.g. peak flow 
devices, diary cards) need to be available and an extra investment of time is required 
when initiating a self-management program, including the setting up of an asthma 
clinic and dividing tasks between all the health professionals involved. Absence of a 
clear protocol of care to support this proved to be one of the most important 
obstacles in implementation of these programs. Practitioners should therefore look 
for evidence of the effectiveness of self-management under circumstances where 
these issues are addressed and the barriers taken care of. We will review and 
summarize the benefits and essential elements of self-management on which such 
protocol of care can be based. 
Benefits of self-management 
The first publications regarding self-management of asthma date from the late 1970s 
and studies, including those of self-medication, started in the 1980s11"17. Table 9.1 
summarises the most important results of various trials published since this date. 
These studies have indicated that self-management programs are capable of 
reducing hospital admissions and emergency room visits in outpatient clinics and 
emergency departments. Days off work can be reduced and quality of life has been 
improved. One recent study demonstrated that having an asthma action plan was 
associated with a 70% reduction in the risk of asthma-death18. 
Thus far, there are few randomised controlled trials evaluating the effects of guided 
self-management programs in family practice, which raises the question of whether 
guided self-management may also be effective in patients with mild asthma. Loss of 
asthma control occurs less frequently in this group and there is less impact on quality 
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of life . Consequently, the room for improvement of a self-management program is 
limited. Hoskins et al demonstrated reductions in morbidity in terms of hospital 
admission, emergency consultations, oral steroid courses and emergency 
nebulizations; however, because of possible selection bias, the superiority of self-
management plans could not be proven20 Their results suggest that improvements in 
clinical and morbidity parameters are indeed less likely to occur in patients with mild 
asthma. Jones et al. Also reached this conclusion, although their failure to 
demonstrate superiority of self management may be due to a lack of statistical power 
to detect minor changes in a population with relatively little room for improvement21. 
Based on published work thus far it may be concluded that, under certain conditions, 
self-management of asthma is beneficial from both the family physicians' and the 
patients' perspective and proves to be an efficient method of incorporating both 
interests. 
Table 9.1: Effects of asthma self management programs 
1st author/ 
pub year 
Snyder et al. 
(16) 
Beasley et al. 
an 
Bailey et a l . ( 3 0 ) 
Setting / patients 
97 asthmatics with at least 
mild asthma, selected 
through advertisements; 
no previous self 
management 
36 asthma clinic 
outpatients (aged 14-60y); 
initial mean ΡΒΛ 75.6 % 
of predicted value. 
225 asthma patients (aged 
>18y) with mild to severe 
asthma attending a 
university pulmonary 
Self-management program 
Two 2.5-hour group asthma 
education sessions. Compared 
with a waiting list group 
Three sessions over 3 months, 
including skills training. Peak 
flow based, with a stepwise 
doubling of inhaled steroids / 
oral prednisolone. No control 
group. 
One-on-one 1-hour counselling 
session with telephone follow-
up at 2 and 4 weeks. Patient 




knowledge, reduction in 
frequency of asthma 
attacks 
6-months follow-up: 
increased FEV!, FVC (both 
% predicted value), 
reduction in nocturnal 
waking and lost 
productivity. Reduction in 




increased inhaler skills and 
adherence to inhaler 




D'Souza et al. 
(31) 
Allen et al. (32 ) 
Ignacio-Garcia 
etal. ( 3 3 ) 
Setting / patients 
mediane clinic. 
69 Maori patients (aged 
14-65 y) with moderate to 
severe asthma 
116 patients (aged 18-
65y) with moderate to 
severe asthma responding 
to newspaper 
advertisements 
70 asthma clinic 
outpatients (aged 14-65y), 
recruited at attendance 
Self-management program 
cognitive skills, positive 
attitude and enhanced 
compliance. Compared with 
usual care 
Instructed by doctors in the 
study team at a community 
clinic. Peak flow and symptom 
based, stepwise doubling of 
inhaled steroids / oral 
prednisolone. 8-weeks before 
compared with 16 weeks of 
self-management. No control 
group 
Hospital-based program with 4 
once-weekly small group 2.5 
hour education sessions 
focussing on asthma 
management skills and 
behaviour. Compared with 
control group. 
One individual 30-min 
education session. Peak flow 
based, with stepwise doubling 
of inhaled steroids / oral 
prednisolone. Compared with 




in previous 7 days. 
Decrease in episodes of 
cough/shortness of breath 
and asthma interference in 
daily life. Decreased 
emergency departmentt 
visits. 
After 16 weeks' self-
management: 12 % 
increase in mean peak 
flow. Reduction in night 
awakenings, days out of 
action and unscheduled / 
emergency visits. Increase 
in the number of patients 
prescribed inhaled 
corticosteroids and a 
decrease in those solely 
using oral bronchodilators. 
1-year follow-up: 
improved asthma 
knowledge. Reduction in 




improvements in the 
number of exacerbations, 
physician consultations / 
emergency room visits, 
days lost from work, days 
on antibacterials and 
mean peak flow values. 




Kotses et al. 
(34) 
Taitel et al. (35) 
Jones et al (21) 
Ayres /1996 
(36) 
Setting / patients 
76 patients (aged 27-70y) 
with asthma. 
76 patients (aged 27-70y) 
with asthma Cost-benefit 
analysis 
127 patients (aged 15-
40y) predominantly with 
mild asthma, from 25 
family practices 
125 outpatients with 
persistent mild to 
moderate asthma (aged 
>17y) 
Self-management program 
Seven 90-minute once-weekly 
small group sessions, including 
skills training and education. 
Asthma management 
behaviour regulated through 
environmental cues. 
Compared with a waiting list 
control group for the first 6 
months, and the period prior 
to self-management 
(before/after design) for the 
16-20 month follow up 
Seven 90-minute once-weekly 
small group sessions, including 
skills training and education. 
Asthma management 
behaviour regulated through 
environmental cues. 
Compared with a waiting list 
control group for the first 6 
months, and the period prior 
to self-management 
(before/after design) for the 
16-20 month follow up 
Two education sessions over 2 
weeks. Peak flow based, with 
stepwise doubling of inhaled 
steroids / oral prednisolone. 
Compared with usual care. 
Peak flow based, stepwise 
doubling of inhaled steroids / 
oral prednisolone. Compared 
with physician-managed 
Outcomes 
variability, and use of 
inhaled fenoterol and 
prednisone 
Short-term (6 months)· 
reduction in asthma 
symptoms and physician 
visits Improved asthma 
management skills and 
cognitive abilities Long 
term (16-20 months): 
reduction in frequency of 
asthma attacks and use of 
medication. Improved 
cognitive measures and 
management skills. 
Cost-benefit ratio of 
1·2.28 
26-weeks follow-up. no-
between group differences 
in lung function, 
symptoms, quality of life 
and prescribing costs. 
Reductions in sleep 
disturbance, daytime 
symptoms and activity 










Klein et al. ( 39 ) 
Setting / patients 
906 asthma patients 
attending 159 family 
physicians 
115 outpatients with mild 
to moderate asthma 
162 outpatients (aged 18-
76y) with newly diagnosed 
asthma 
245 outpatients with 
moderate to severe 
asthma 
Self-management program 
regime based on the same 
criteria. 
Peak flow based, stepwise 
doubling of inhaled steroids / 
oral prednisolone. Compared 
with usual care. 
Peak flow based, stepwise 
doubling of inhaled steroids / 
oral prednisolone. Compared 
with usual care 
Intensive patient education, 
skills training and supervision 
Peak flow based, stepwise 
doubling of inhaled steroids / 
oral prednisolone in both 
treatment groups. Compared 
with conventional education at 
the baseline visit only 
Self-management education in 
both groups with addition of 
peak-flow based treatment 










consultations, courses of 





demonstrated an increase 
in the number of healthy 
days and lower total costs 
3-year follow-up. 
Improvements in FEVi and 
peak flow values. Lower 
risk ratio for the number 
of days with sickness. 
Lower average cost of 
primary care services and 
antibactenals 
After 1 year better 
perceived asthma control 
and self confidence. 2-
year follow-up: 
improvement in quality of 
life, peak-flow variability 
and number of outpatient 
visits No between-group 
differences 
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Self-management programs: essential contents 
Self-management programs revolve around shared responsibilities. The patient is 
responsible for dealing with asthma in everyday life. On the other hand, the health 
professional provides patients with the necessary knowledge, skills and attitudes 
needed for decision making, and coaches the patient into modifying their behaviour 
and autonomy. 
It is currently believed that interventional programs, using a combination of 
education, skills training and methods to modify behaviour, are needed to optimise 
management and improve the quality of life in patients with asthma22'23. Patient 
education alone does not reduce hospitalisations, doctor visits or medication use in 
asthma but may play a role in improving patients' perceptions of their symptoms24. 
Within this context, it is obvious that patient education should be tailored to the 
patients' individual needs and be preceded by a proper assessment of what these 
needs are. Systematically making an inventory of the patients' needs or concerns 
prior to each office visit has shown to improve patient-physician interaction25. 
Solely taking the patients' perspective into account can be too limited, as there may 
be a discrepancy between what the patient wants to know, on the basis of own 
interests or previous knowledge, and what the patient needs to know according to 
the health professional. It is the family physician's responsibility to increase patient 
awareness of the existence and importance of certain information and possibilities. 
This may depend on the relevance to the patient of the presented topic and whether 
they feel it deserves further attention or not, resulting in further integration of the 
patient's agenda and the medical perspective. 
The cornerstone of self-management is self-monitoring. It gives patients the 
opportunity to give feedback on decisions they make regarding their asthma and 
medications. There are two major sources of feedback: self-assessed symptoms and 
peak flow values. It is currently believed that waking at night due to asthma and 
increased use of bronchodilator provide the most sensitive measurements of clinical 
deterioration26. Another useful indicator of asthma control is the patient's peak flow. 
When related to the patient's best value, this parameter can provide information on 
both deterioration and control of asthma; the latter factor being the incentive for 
reducing or temporarily stopping inhaled steroids. There is ongoing debate as to 
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whether self-management should be symptom based, peak-flow based or a 
combination of both. A systematic review performed by the Australian National 
Asthma Campaign indicated that there was no difference between these two forms 
of self-monitoring, but available data on this topic were limited27"29. 
Role of the family physician 
Key elements of self-management are patient education and skills training, providing 
the patient with specific instructions on avoidance measures and when and how to 
take preventive and reliever medication. Most of these elements are already 
advocated in asthma care guidelines and should be part of routine clinical practice. 
The difference with asthma care described in guidelines and self-management, 
however, is the change in attitude of both health professionals and patients. Health 
professionals may need to learn to accept that patients will not always take the 
clinically most desired decision. However, as providers of healthcare, they remain 
responsible for optimising the circumstances under which patients can make these 
decisions; in other words, they need to enhance knowledge and self-efficacy. 
Patients, on the other hand, need to shift from relying on their physician as the 
person telling them what to do, towards feeling more responsible for their own 
choices and showing a willingness to explore their own possibilities. This does not 
mean that patients should be left on their own. Instead, self-management must be 
seen as a contemporary strategy for enhancing patient autonomy. 
Key elements of self-management are the use of tools to provide the patient with the 
necessary background to make daily decisions on how to deal with asthma. Self-
management thus becomes a process of ongoing 'problem-based learning' instead of 
mere compliance enhancement. Continuity of care and the possibility of regular 
review of patients are typical qualities of the primary-care setting, which may provide 
a perfect basis to continuously pursue better self-management in a patient-centered 
framework. On the other hand, the investment of time required to stepwise educate 
and train patients initially appears to be a prohibitive factor. But it is here that the 
chronicity of asthma works as an advantage. Asthma is considered to be a life-long 
disease and is usually clinically manufest for at least several years. This should be 
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kept in mind, when assessing the time investment. Education, training and coaching 
can take place over a number of consultations and need not be provided solely by 
the physician. Most of these required tasks may easily be delegated to practice 
nurses. It is the role of the family physician to ensure continuity of care in terms of 
offering the patient a consistent program in which all partners (physician, nurse, 
patient) share the same attitudes and principles. Setting up an asthma clinic where 
all of these partners are involved may provide the framework for such consistency. 
Conclusion 
Becoming more or less fully self-managing is an ongoing process that will inevitably 
take some time, but the long-term it is time saving. It is the responsibility of the 
health professional to elucidate this long-term perspective to patients and thus 
initiate growth of a patient-partnership towards a common agenda. To achieve 
patient's self-monitoring of signs and symptoms is also a crucial part. It allows self-
validation of the importance and meaning of these signs and symptoms in terms of 
their impact on daily life and their relationship to autonomous decision making. This 
will form the basis of actual self-intervention. Coaching directed at the 'therapeutic' 
implications of monitored signs and symptoms can highlight the agreement and 
discrepancies between the views of patients and professionals. 
Rearranging the organisation and delivery of asthma care into a mode of cooperation 
that aims at shared responsibilities and is patient-centered may very well be the key 
to bridge or narrow the gap between efficacy and effectiveness of asthma care. The 
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Aim and main results 
Main goal of the ZBA-study was to study to what extent self-management based on 
patient education, skills training and a written self-treatment plan results in more 
effective and efficient management of asthma with inhaled corticosteroids in general 
practice. Main findings from this study are: 
1. Self-management of asthma provides a safe basis for intermittent therapy with 
inhaled corticosteroids. 
2. Self-management lowers the burden of illness as perceived by patients and is at 
least equally effective in controlling asthma than conventional care. 
3. When the indirect costs are included, guided self-management is at least equally, 
but probably more efficient than conventional care when both are provided by 
GPs. 
4. Using materials for systematically taking into account the patients' needs may 
enhance shared decision-making by balancing the patients' and the GP's 
perspective in a more patient centered approach. 
5. When educating asthma patients an important role of the GP is to increase the 
patients awareness of issues possibly relevant for their asthma. 
6. Patients using low or intermediate dosages of inhaled steroids are predominantly 
treated in general practice. The acceptance-rate of guided self-management 
plans by patients in this category is sufficiently high to justify implementation of 
self-management of asthma in general practice. 
7. The acceptance-rate of self-treatment of asthma by GPs does not seem to be an 
obstacle for the implementation of such programmes. 
8. Both local and international evidence about benefits and applicability of self-
management justify a broader recommendation of self-management in the Dutch 
guidelines on the treatment of asthma in general practice. 
External validity 
Findings from this study provide important data on the applicability of self-
management in Dutch general practice. These findings are based on a sample of 
patients treated in general practice. Based on the initial dose of inhaled 
corticosteroids and the number of asthma attacks in the previous months patients 
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included in the ZBA study represent asthma patients with mild to moderate 
persistent asthma, which are predominantly treated at step 2 of the GINA-guidelines 
and the Dutch guidelines. 
In our study asthma appears to be well controlled in terms of baseline FEVi level and 
reversibility. However initial asthma control must be interpreted with caution. First of 
all patients with a smoking history of 15 packyears or more were excluded from the 
study. This was intended to reduce the risk of including patients with COPD, but may 
also have excluded a group of relatively poor controlled asthma patients. Moreover 
patients with a pre-bronchodilator FEVi less than 80% of predicted at the start of the 
study were pre-treated with 800 meg budesonide twice daily during a six weeks run 
in period. Interpreting asthma control in these groups based on baseline FEVi or 
FEVi-reversibility may give an overestimation of control as 23-35% required such 
pre-treatment (see chapters 6 and 7). This means that findings from our study are 
not externally valid per se: the results pertain to asthma patients with mild to 
moderate persistent asthma, provided that the initial step in providing asthma self-
management is optimisation of asthma control by the GP. 
Room for improvement 
As stated in the introduction emergency room visits and hospitalisations are relatively 
rare in asthma patients with mild to moderate persistent asthma, which is confirmed 
in chapter 7. In literature beneficial effects of self-management were mostly 
demonstrated in outpatient clinics and emergency room departments. Here self-
management programs are capable of reducing hospital admissions and emergency 
room visits. Days off work can be reduced and quality of life is improved1"12. One 
recent study by Abramson et al even demonstrated a reduction in asthma mortality13. 
In these settings asthma patients tend to have more severe asthma, leaving more 
room for improvement. Furthermore pulmonary departments often have the 
advantage of having specially trained personnel available. Findings in these settings 
can not be generalised on beforehand to general practice, where loss of asthma 
control occurs less frequently and there is lower impact on quality of life14. Thus far 
there are few randomised controlled trials to the effects of guided self-management 
programs in family practice. Hoskins et al showed reductions in morbidity in terms of 
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hospital admission, (emergency) consultations, oral steroid courses and emergency 
nebulisations. But due to possible selection bias superiority of self-management plans 
could not be proven15. Their results suggest that improvements in clinical and 
morbidity parameters are indeed less likely to occur in mild asthmatics. Jones et al 
also concluded this, but they may have failed to show results due to the small 
number of subjects16. In the light of this limited room for (clinical) improvement our 
hypothesis was that self-management of asthma had to be at least equally effective 
as usual care in order to provide an acceptable alternative. The additional value of 
self-management is the change to patients fully sharing responsibility of treatment 
with their caregivers (Chapter 8) based on a common frame of reference (Chapter 
9). This makes self-management of asthma an attractive strategy for enhancing 
patient autonomy. In addition to effects on lung function and costs, effects on 
patient-related parameters come in scope and have been taken into account in this 
thesis. 
Interpretation of results 
In chapter 6 of this thesis effects of self-management on asthma-control, quality of 
life, medication use and indicators of exacerbations have been studied in a 
randomised controlled trial in a general practice population. There were no 
statistically significant differences in the annual FEVi decline-rate and no between-
group differences in FEVi-reversibility and PC2o-histamine. In the self-management 
group asthma control improved in terms of a higher number of successfully treated 
weeks. This was associated with moderate improvements in quality of life. There was 
a clinically relevant improvement in the emotions domain. This indicates that patients 
in the self-management group felt less worried or insecure about the influence of 
their asthma on daily life. General practitioners did not diagnose more exacerbations, 
but the number of oral prednisolone courses was higher in the guided self-
management group. As described in chapter 6 this finding may have been the 
consequence of either registration bias, a baseline difference in asthma control or an 
effect of the self-management program itself. 
In the ZBA-project cost data were studied too. The economic consequences of our 
self-management program are described in chapter 7. In terms of quality of life and 
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successfully treated weeks self-management of asthma appears to be a dominant 
treatment strategy in comparison to usual care (i.e. better outcomes at less cost). 
But statistics in chapter 7 show that this may be entirely due to chance. From a 
societal perspective guided self-management is at least equally, but probably more 
efficient than conventional care when both are provided by GPs. 
As stated earlier in this discussion, patient-related outcomes also provide information 
about the usefulness of our self-management program. In chapter 5 we studied if 
patient-centered education was able to reduce information needs of patients in a 
satisfactory way. The use of a structured education program (appendix I) to support 
the GP and a feedback tool to support the patient (appendix II) resulted in a 
significant reduction of information needs of patients. Patient satisfaction increased, 
especially in items related to asthma management. These findings are consistent 
with the reduction in lost-activity days and the higher number of successfully treated 
weeks. Not only does this reduce the burden of illness as perceived by patients, but 
is also results in a reduction of disease related costs. The observed patient-related 
outcomes and their economic consequences are the outcomes in which self-
management of asthma distinguishes itself from usual asthma care, even under 
conditions where room for improvement initially seemed limited. 
Determinants of success 
Participating practices 
First of all GPs involved in this study were all in favour of self-management and had 
a positive attitude towards scientific research. It is therefor likely that they were 
highly motivated and have put a maximum effort in implementing the experimental 
self-management program. The finding that none of the GPs has dropped out due to 
loss of motivation illustrates this. All participating GPs were trained before 
implementing self management. Main goal of this training program was to provide a 
standardised self-management intervention. As is described in chapter 7 the 
intraduster correlation for practices was insignificantly low. These findings do 
support our hypothesis that the self-management program can be implemented in a 
standardised manner by GPs. It makes self-management of asthma a valuable 
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management strategy, regardless of differences in organisation or size of general 
practices. 
Participating patients 
As is demonstrated in chapter 5 and 6 a large number of patients has been invited to 
participate in the study. At least half of all invited patients refused to participate or 
did not respond to the invitation of their GP. Based on available data we concluded 
that the dosage of inhaled steroids is associated with willingness to participate. As is 
stated in chapter 4 this may have resulted in losing a group of patients that might 
have profited from self-management, resulting in a reduction in room for 
improvement and smaller effects. Willingness to participate was also relatively low in 
patients using higher daily dosages of inhaled corticosteroids. These patients may 
very well be the ones that were unable to reduce their dosage of inhaled 
corticosteroids in the past. So patients finally included in the study may have had 
positive experiences with stopping inhaled corticosteroids in the past. Patients 
included in the study thus may have been those patients in which intermittent 
therapy with inhaled steroids was possible on beforehand. The informed consent 
procedure may also have contributed to this selection. Patients were informed about 
the treatment strategy they were going to have during the study. Patients in the self-
management group were informed about the possibility of reducing or temporarily 
stopping inhaled corticosteroids. Their decision to participate in the study is more 
likely to be influenced by earlier experiences with (temporarily) stopping than for 
patients in the usual care group. This may explain the difference in willingness to 
participate between usual care and self-management (chapters 6 and 7). Based on 
our findings it cannot be concluded that intermittent treatment with inhaled steroids 
is feasible or effective for all asthma patients in general practice. On the other hand 
there is no harm in trying to reduce the dosage of inhaled medication. It is in 
accordance with recommendations in asthma management guidelines. The selection 
procedure presented in chapter 4 can be helpful to identify those patients that can 
reduce or stop inhaled steroids through self-management and those who need 
assistance of the GP first. 
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Elements of the self-management program 
The self-management program studied in this thesis consisted of three elements: 
patient education, skills training and a written self-treatment plan. Examining effects 
of our self-management program as a whole in a randomised controlled trial has the 
potential disadvantage of being unable to discriminate which of the program 
contents attributes to the final effects. We deliberately choose to examine this 'black 
box' as a whole for several reasons. First of all the effects of the individual 
components (e.g. training of peak flow measurement and educating patients) is 
limited or absent. Based on current insights, integration of education, skills training 
and a written self-treatment plan has the greatest potential of being effective. This 
approach has been acknowledged in two Cochrane reviews, published by Gibson et 
al.17'18. Choosing this integrated approach also has a pragmatic background. Handing 
out written guidelines for treatment adjustment based on peak-flow measurements 
and self-assessment of asthma symptoms is likely to fail on beforehand if patients 
are unable to measure their own peak-flow and are unaware of the relevance of 
symptoms monitored. 
Based upon our study-design we can only conclude that a combined self-
management program is beneficial and feasible in General Practice. It is still unclear 
which parts of the self-management program are the most effective and if there is a 
cumulative effect or synergism. Further clarification of the coherence of the program 
contents and the possibility of eliminating redundant or ineffective components may 
increase efficiency and cost-effectiveness of the program. 
Considerations for daily practice 
The essentials of the self-management program are more active involvement of 
patients through patient centered education and use of a self-treatment plan aiming 
at dose adjustment of inhaled steroids according to self-assessed levels of asthma 
control. 
In this thesis it is demonstrated that patient education, training of inhalation 
technique, peak flow measurement and written self-treatment guidelines applied in 
an integrated patient-centered approach are effective in terms of symptom 
reduction, reduction of lost activity days, reduction of inhaled corticosteroids and 
155 
improved quality of life. In our self-management program components of asthma 
management are incorporated in a coherent patient centered framework. As is 
demonstrated in chapter 7 self-management of asthma based on these elements is a 
more efficient treatment strategy than usual care from a health policy perspective. 
But these findings also confirm that implementation of self management is time and 
resource consuming. Time spent by GPs to educate and train patients was the main 
implementation expenditure. As this was identified as a possible barrier for 
implementation by GPs (chapter 3), this problem will need further attention when 
implementing self-management in general practice. Especially as GPs themselves will 
probably not directly notice the benefits resulting from their efforts. In the light of 
our findings several alternatives can be considered. First of all the introduction of 
nurse practitioners in Dutch general practice provides new opportunities. Educational 
tasks and skills training can be easily delegated to these health professionals and the 
gains are obvious. Nurse practitioners in general have more available time per 
patient at lower cost and have often better educational skills than GPs. 
Another more time efficient option is group wise patient education. Such an 
education strategy passes by individual information needs of patients and can as 
such be less patient-centered. However, data presented in chapter 5 demonstrate a 
substantial number of items that is of interest for most patients and some 
information items can be identified as obligatory knowledge for all patients. The 
latter was characterised as 'need to know' in chapter 5. Such items can easily be 
presented in group wise education sessions. Additionally the information checklist for 
patients can be used in individual GP-patients contacts to identify and discuss specific 
individual needs. As is shown in chapter 5 using such a checklist for systematically 
taking into account the patients' needs may enhance shared decision-making by 
balancing the patients' and the GP's perspective in a more patient centered 
approach19. 
Another third party that might be involved in providing self-management care is the 
occupational health physician. Reduction in lost-activity days is one of the main 
benefits of our self-management program. We did not measure the effect of the self-
management program on reduced-auJNïïy days. It is a known fact that patients often 
underestimate the relation between asthma and non-specific complaints like fatigue 
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and headache. Such complaints may lead to a reduction in quality of life, daily 
activities and productivity. Increasing the awareness of patients about these 
phenomena and teaching them to take appropriate action may further improve 
quality of life and reduce the perceived burden of illness. Occupational health 
physicians often have a good view on activity reducing factors and are able to 
elucidate unknown triggers in the work environment. As is discussed in chapter 7 
patients demonstrated high adherence in the area of healthy behaviour, so additional 
efforts in this area are likely to be beneficial. 
Finally willingness of GPs to start using self management of asthma needs to be 
addressed. Based on findings presented in chapter 4 the acceptance-rate of self-
management among GPs is sufficiently high, but there also is a substantial group 
that has doubts about the usefulness of self-management. Findings from our study 
may be helpful in changing these doubts. Ninety (90) percent of GPs who reported 
self-management to be useful is willing to apply this to their patients. Taking away 
doubts about the usefulness of self management thus is likely to increase the 
acceptance of self management in Dutch general practice. 
Recommendations and further research 
Based on our findings we conclude that our self-management program has been 
successful and we recommend implementation of this treatment strategy in Dutch 
general practice. Both local and international evidence about benefits and 
applicability of self management justify a broader recommendation of self-
management in the Dutch guidelines on the treatment of asthma in general practice. 
The introduction of self-management in Dutch general practice should not aim at 
replacing current management strategies. It is an at least equal alternative and 
provides a safe strategy when intermittent treatment with inhaled corticosteroids is 
required for whatever reason. The current recommendation in Dutch guidelines that 
asthma self-management should be at least for patients with severe asthma or 
frequent loss of asthma control or hospitalisations should be extended to patients 
with mild or moderately severe asthma. The decision model presented in chapter 4 
can be used for identification and assessment of asthma patients that are interested 
in self-management. 
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Further research is needed to elucidate if additional criteria or patient characteristics 
can be helpful in identifying or selecting those patients that will benefit most from 
self management. In addition possible improvements in the self-management 
program in terms of removing ineffective and redundant elements requires further 
attention. Part of the beneficial effects found in this study may be the consequence 
of following a well-described and controlled program. Consequently questions arise in 
which way patients will continue using their self-treatment program and to what 
extent the effects found remain or change in the long term. 
Rearranging the organisation and delivery of asthma care into a mode of co-
operation aiming at shared responsibilities and patient-centeredness has to some 
extent shown to be effective in narrowing the gap between efficacy and effectiveness 
of asthma care. Finding the answer to the still unanswered research questions 
mentioned above is no prerequisite for the introduction of self-management in Dutch 
General Practice, it can only optimise it. 
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Chapter 11 
Summary (in Dutch) - Samenvatting 
Hoofdstuk 1: inleiding 
De afgelopen decennia is het begrip over astma sterk toegenomen. Het inzicht dat 
chronische ontsteking van de bronchiaalboom het belangrijkste onderliggende 
mechanisme in de pathofysiologie van astma is, heeft geleid tot een brede acceptatie 
van inhalatiecorticosteroiden als hoeksteen van de medicamenteuze behandeling van 
astma. Hierdoor is ernstige astmagerelateerde morbiditeit voor veel astmapatiënten 
tot nul gereduceerd. Er is echter nog steeds veel ruimte voor verbetering. Astma is 
vaak minder goed onder controle dan de patiënt zelf denkt en er is nog steeds een 
aanzienlijk verlies van activiteiten en productiviteit als gevolg van astma. Veelal 
wordt gebrekkige therapietrouw als verantwoordelijke factor aangewezen. Hier staat 
tegenover dat het alsmaar harder aanmoedigen van therapietrouw niet tot 
aantoonbaar betere resultaten leidt. Ook is nog onduidelijk of een continue 
behandeling met inhalatiecorticosteroiden wel voor alle patiënten noodzakelijk is. Er 
zijn aanwijzingen dat inhalatiecorticosteroiden in veel gevallen intermitterend 
gebruikt kunnen worden of in ieder geval gereduceerd kunnen worden tot een 
minimale effectieve dosering. De uitdaging is het vinden van de optimale balans 
tussen overbehandeling en onderbehandeling. In dit proefschrift wordt beschreven in 
hoeverre individuele aanpassing van de behandeling door middel van 
zelfmanagement een veilig, efficiënt en kosteneffectief antwoord op deze uitdaging 
is. Het zelfmanagementprogramma dat is onderzocht (ZBA-project) rust op drie 
belangrijke pijlers: patiëntenvoorlichting, training van benodigde vaardigheden en 
een geschreven richtlijn voor zelfstandige aanpassing van de onderhoudsbehandeling 
met inhalatiecorticosteroiden. 
Hoofdstuk 2: de plaats van zelfmanagement 
In 1998 werd op het WONCA-wereldcongres een symposium gehouden over de 
toenmalige stand van zaken met betrekking tot de behandeling van astma en COPD. 
Nieuwe behandelingen en behandelstrategieën werden gepresenteerd. 
Therapietrouw werd erkend als een belangrijke beperkende factor voor de 
effectiviteit van nieuwe en bestaande therapieën. Zelfmanagement werd 
gepresenteerd als een patiënt-georiënteerd antwoord op dit probleem. Door grotere 
betrokkenheid en een duidelijkere eigen verantwoordelijkheid van de patiënt kunnen 
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belangen van patiënt en huisarts beter met elkaar in overeenstemming worden 
gebracht. Het belang van onderzoek naar de bruikbaarheid van dit concept werd 
expliciet onderkend door de deelnemers. 
Hoofdstuk 3: verwachtingen en ervaringen van huisartsen 
Om inzicht te krijgen in de specifieke eisen die het introduceren van zelfmanagement 
in de huisartspraktijk stelt aan de huisarts en aan de huisartspraktijk werd een 
onderzoek gedaan in een steekproef uit Britse en Nederlandse huisartsen. De eerste 
groep vanwege de reeds aanwezige ervaringen bij het toepassen van 
zelfmanagement, de tweede groep om verwachtingen en mogelijke barrières te 
inventariseren. De bereidheid om zelfbehandeling te gaan toepassen in de eigen 
praktijk was onder de totale groep van 287 geënquêteerde huisartsen 51% en dit 
liep op tot 90% onder de huisartsen die zelfmanagement als bruikbaar inschatten 
(75% van alle geënquêteerde huisartsen). Nederlandse huisartsen staan in het 
algemeen welwillend tegenover de invoering van zelfbehandeling, maar niet voordat 
er een aangetoonde meerwaarde is. Door de Nederlandse huisartsen werden vooral 
problemen verwacht op het gebied van beschikbare tijd, benodigde materialen en de 
hieraan gerelateerde kosten. Deze verwachtingen bleken goed overeen te komen 
met de ervaringen van de Britse collega's. Op basis van de bevindingen uit dit 
onderzoek kan geconcludeerd worden dat er een aantal herkenbare drempels 
bestaan voor de invoering van zelfmanagement. Ondanks de aanwezigheid van deze 
drempels is er voldoende draagvlak voor invoering van zelfmanagement in de 
Nederlandse huisartspraktijk. 
Hoofdstuk 4: bereidheid tot deelname van patiënten 
Op grond van argumenten als aversie en angst voor de bijwerkingen van 
inhalatiecorticosteroïden is het ogenschijnlijk logisch dat patiënten geïnteresseerd 
zijn in de mogelijkheid om hun onderhoudsbehandeling afte bouwen of te stoppen. 
Patiënten die baat hebben bij een onderhoudsbehandeling met 
inhalatiecorticosteroïden zijn anderzijds mogelijk huiverig om deze te stoppen als dit 
tot ongewenst controleverlies leidt. In hoofdstuk 4 wordt een studie beschreven naar 
de mogelijke rol die inhalatiecorticosteroïden spelen bij de bereidheid van patiënten 
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om zelfmanagement toe te gaan passen. Op grond van eerdere observaties werd 
daarnaast gekeken naar de rol van geslacht, leeftijd en de beroepsstatus. Van de 
283 onderzochte patiënten bleek 52% interesse te hebben in deelname aan een 
zelfmanagement programma. In de onderzochte groep kon geen duidelijke associatie 
tussen leeftijd en geslacht en de bereidheid tot deelname worden aangetoond. 
Patiënten zonder werk of studie hadden een relatief hoge bereidheid tot deelname. 
Dit gegeven bleek echter bij de huisarts vaak niet goed bekend. Op grond van deze 
bevindingen is het daarom niet mogelijk een algemene conclusie te trekken met 
betrekking tot de rol van de beroepsstatus en de bereidheid tot deelname aan een 
zelfmanagementprogramma. 
Er was een statistisch significante en onafhankelijke associatie tussen de bereidheid 
tot deelname en de hoeveelheid inhalatiecorticosteroïden die patiënten gebruikten. 
Patiënten die geen inhalatiecorticosteroïden gebruikten (terwijl ze dit op grond van 
selectie door de huisarts wel zouden moeten), hadden de laagste bereidheid tot 
deelname (43 van de 143, 30%). Ten opzichte van deze eerste groep hadden 
patiënten met lage doseringen inhalatiecorticosteroïden de hoogste bereidheid tot 
deelname (OR 10.59, 95% betrouwbaarheidsinterval 4.70-23.88). De bereidheid tot 
deelname nam af met de hoogte van de dosering inhalatiecorticosteroïden en was in 
de groep met de hoogste dosering inhalatiecorticosteroïden 18% (OR 3.06, 95% 
betrouwbaarheidsinterval 1.33 - 7.04). Op grond van deze bevindingen kan de 
huisarts gerichter zelfmanagement aanbieden aan astmapatiënten. Bij patiënten die 
geen inhalatiecorticosteroïden gebruiken, terwijl dit wel gewenst is, kan eerst het 
starten van een onderhoudsbehandeling en de therapietrouw worden besproken. Bij 
patiënten met relatief hoge doseringen inhalatiecorticosteroïden is het raadzaam om 
gezamenlijk de mogelijkheden voor dosisverlaging te exploreren. Pas als patiënt en 
huisarts ervaren hebben dat dit niet gepaard gaat met ongewenst controleverlies, 
kan de mogelijkheid om zelfstandig de onderhoudsbehandeling te variëren worden 
aangeboden. Astmapatiënten met een lage tot gemiddelde dosering 
inhalatiecorticosteroïden zijn zeer waarschijnlijk op voorhand bereid tot deelname 
aan zelfmanagement. 
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Hoofdstuk 5: de patiënt centraal 
Kerngedachte van het zelfmanagementprogramma is het delen van 
verantwoordelijkheden tussen huisarts en patiënt. De patiënt wordt meer 
nadrukkelijk verantwoordelijk voor het nemen van beslissingen met betrekking tot de 
dagelijkse omgang met astma. Hierbij staan thema's als het vermijden van 
uitlokkende factoren en een bewust gebruik van de verschillende astmamedicijnen 
centraal. De huisarts heeft in dit model de verantwoordelijkheid om de patiënt te 
voorzien van de benodigde kennis en vaardigheden om dergelijke beslissingen 
weloverwogen te kunnen nemen. Hierbij kan onderscheid gemaakt worden tussen 
astmagerelateerde informatie waarover de patiënt volgens de arts zou moeten 
beschikken en informatie waar de patiënt zelf behoefte aan heeft; 'willen weten' 
versus 'moeten weten'. Om deze discrepantie in de belangen van patiënt en huisarts 
te overbruggen, is gekozen voor een meer patiëntgerichte benadering. Door middel 
van het gebruik van gestructureerde feedback krijgen patiënten meer invloed op de 
inhoud van voorlichting en training die door hun huisarts gegeven wordt. In 
hoofdstuk 5 wordt onderzocht of en hoe het zelfmanagementprogramma aansluit op 
de informatiebehoefte van astmapatiënten en of dit ook leidt tot grotere 
tevredenheid. Voorlichting en instructie in het kader van het 
zelfmanagementprogramma werden gegeven in vier consulten over een periode van 
drie maanden. Vlak voor ieder voorlichtingsconsult werd door patiënten (n=98) een 
checklist ingevuld. Met behulp van deze checklist konden patiënten uit het totale 
aanbod van informatie over astma aangeven waarover ze zelf vragen hadden. 
Tijdens de voorlichtingsconsulten werd door de huisarts systematisch de 
informatiebehoefte van patiënten geïnventariseerd aan de hand van de checklist. 
Deze aanpak bleek te leiden tot een forse daling in de informatiebehoefte van 
astmapatiënten. Deze patiënten waren meer tevreden over de zorg van hun huisarts 
dan een controlegroep van 95 patiënten die gedurende dezelfde periode de 'gewone' 
astmazorg van hun huisarts ontvingen. Patiënten uit de zelfmanagementgroep 
oordeelden met name positief over de aandacht van hun huisarts voor de 
persoonlijke gevolgen van astma en de ondersteuning van de huisarts in het 
zelfstandig omgaan met astma. 
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Op grond van deze bevindingen kan geconcludeerd worden dat het zeer wel mogelijk 
is om gericht rekening te houden met wensen van patiënten, zonder daarbij te kort 
te doen aan de strikt medische belangen. Dit leidt tot meer betrokken en 
gemotiveerde patiënten. Het op een dergelijke manier delen van 
verantwoordelijkheden is dan ook een belangrijke voorwaarde voor de effectiviteit 
van zelfmanagement. 
Hoofdstuk 6: klinische effectiviteit van zelfmanagement 
In dit hoofdstuk wordt een gerandomiseerde gecontroleerde studie beschreven naar 
het effect van zelfmanagement op astmacontrole, kwaliteit van leven en de invloed 
van astma op het dagelijks functioneren. In deze studie werden 19 huisartspraktijken 
met in totaal 49 huisartsen willekeurig verdeeld over twee groepen: zelfmanagement 
en reguliere astmazorg. Astmapatiënten werden daarna door hun huisarts 
uitgenodigd om mee te doen aan het onderzoek. Op een longfunctielaboratorium 
werd gecontroleerd of geïnteresseerde patiënten voldeden aan alle criteria voor 
deelname. Uiteindelijk konden 214 patiënten aan de studie mee doen, waarvan 110 
in de zelfmanagement groep. Patiënten in de reguliere zorggroep kregen dezelfde 
astmazorg van hun huisarts als voor het onderzoek, dat wil zeggen de zorg zoals 
deze is omschreven in de richtlijn voor de behandeling van astma van het Nederlands 
Huisartsen Genootschap. Het zelfmanagementprogramma bestond uit 
patiëntgeoriënteerde voorlichting over astma, training van de piekstroommeting, 
periodieke controle en instructie van de inhalatietechniek en een geschreven richtlijn 
voor zelfbehandeling met inhalatiecorticosteroïden. Met behulp van deze richtlijn 
konden patiënten aan de hand van zelf gemeten piekstroomwaarden en 
alarmsymptomen zelfstandig de ontstekingsremmende behandeling bijstellen, 
variërend van volledig stoppen met inhalatiecorticosteroïden tot en met het 
zelfstandig starten van een Prednison stootkuur. 
Alle patiënten bezochten gedurende twee jaar ieder half jaar het 
longfunctielaboratorium voor meting van onder andere de longfunctie en de 
astmagerelateerde kwaliteit van leven. Daarnaast werd door de patiënt wekelijks een 
rapportage bijgehouden van de mate van kortademigheid en het aantal dagen 
waarop de dagelijkse activiteiten moesten worden verzuimd als gevolg van astma. 
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Alle weken waarbij de kortademigheid onder een individueel bepaald acceptabel 
niveau bleef, werden geteld als succesvol behandelde weken. Aan het eind van de 
studie waren er gemiddeld 81 (95% betrouwbaarheidsinterval 78-84) succesvol 
behandelde weken per patiënt in de zelfmanagementgroep en 75 (95% 
betrouwbaarheidsinterval 72-78) in de groep die reguliere astmazorg ontving. Een 
belangrijke bevinding bleek het verschil in het aantal dagen waarop patiënten als 
gevolg van astma hun reguliere activiteiten moesten verzuimen. In de 
zelfmanagementgroep was dit verzuim gemiddeld per patiënt 1.2 dagen (95% 
betrouwbaarheidsinterval 0.5-1.9), tegen 3.9 dagen (95% betrouwbaarheidsinterval 
2.5-5.4) in de groep die reguliere zorg ontving. Deze bevindingen werden 
weerspiegeld in de gemeten kwaliteit van leven in beide groepen. In de loop van 
beide onderzoeksjaren was de toename van kwaliteit van leven in de 
zelfmanagementgroep groter dan de toename in de groep die reguliere astmazorg 
ontving (p=0.055). Dit verschil in toename bleek met name verklaard te kunnen 
worden doordat er in de zelfmanagementgroep meer patiënten waren die minder 
angstig of bezorgd waren over de invloed van astma op hun dagelijks leven. 
Gemeten over twee jaar was er noch een verschil in het verloop van de longfunctie 
tussen beide groepen, noch in de het gebruik van luchtwegverwijders. Daarnaast 
bleek er een statistisch significante, besparing in het totaal aantal gebruikte 
inhalatiecorticosteroïden te zijn van 217 inhalaties, ten gunste van de 
zelfmanagementgroep. Geconcludeerd kan worden dat zelfmanagement een 
verantwoorde methode is voor intermitterende behandeling met 
inhalatiecorticosteroïden. De belangrijkste winst van zelfmanagement is de reductie 
van de door de patiënt ervaren hinder en symptomen. 
Hoofdstuk 7: kosten-effectiviteit van zelfmanagement 
In het ZBA-project zijn gegevens verzameld over kosten die in verband met, of als 
gevolg van astma gemaakt zijn. Ook werden, naast de metingen die zijn beschreven 
in hoofdstuk 6, op basis van de halfjaarlijkse metingen op het 
longfunctielaboratorium QALY's (Quality Adjusted Life Years) berekend. Met behulp 
van de uitkomstmaten uit hoofdstuk 6, de gemeten kosten en de QALY's wordt in 
hoofdstuk 7 beschreven hoe kosten en effecten bij astma zelfmanagement zich 
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verhouden tot kosten en effecten bij reguliere zorg. Een belangrijke bron van kosten 
zijn de kosten om het zelfmanagementprogramma in de huisartspraktijk te kunnen 
introduceren. Deze zogenaamde implementatiekosten bedroegen € 189 per patiënt. 
De belangrijkste kostenbronnen in relatie tot astmazorg waren astmamedicatie (met 
name budesonide), maatregelen gericht op allergeenreductie, huisartscontacten en 
verlies van productiviteit (bijvoorbeeld door arbeidsverzuim). De kosten voor 
budesonidegebruik en kortwerkende luchtwegverwijders waren significant lager voor 
zelfmanagement, met een besparing van € 75 per patiënt per twee jaar. In de 
zelfmanagementgroep werden opvallend vaker saneringsmaatregelen getroffen dan 
in de reguliere zorggroep (relatief risico = 1.7, 95% betrouwbaarheidsinterval 1.3-
2.2). Dit leidde tot een kostentoename van gemiddeld € 84 per patiënt. Zoals in 
hoofdstuk 6 beschreven, was het verlies van productiviteit in de 
zelfmanagementgroep significant lager dan in de reguliere zorggroep. Vertaald in de 
hieraan gerelateerde kosten leverde het zelfmanagementprogramma hierdoor een 
besparing op van € 213 per patiënt per twee jaar. De besparingen in deze 
kostencategorie bleken in het tweede jaar van de studie relatief groter dan in het 
eerste jaar. Na optelling van alle kosten (inclusief implementatiekosten) bedroegen 
de kosten per patiënt per twee jaar bij zelfmanagement van astma € 1084 (95% 
betrouwbaarheidsinterval 948-1228) en voor de reguliere astmazorg € 1097 (95% 
betrouwbaarheidsinterval 933-1260). Dit betekend dus dat zelfmanagement na twee 
jaar neutraal in kosten is in vergelijking met reguliere zorg, ondanks de 
implementatiekosten en het toegenomen aantal saneringsmaatregelen. Als de 
gevonden besparingen na twee jaar blijven bestaan of groter worden, zal 
zelfmanagement op termijn dus efficiënter zijn. 
Naast een vergelijking van kosten en besparingen wordt in hoofdstuk 7 ook een 
kosten-effectiviteitsanalyse beschreven. Met betrekking tot QALY's, aantal succesvol 
behandelde weken en het aantal patiënten met een relevante toename van de 
kwaliteit van leven lijkt het zelfmanagementprogramma dominant te zijn. Dat wil 
zeggen dat met zelfmanagement tegen lagere kosten méér effect op deze 
uitkomsten bereikt wordt. De stelligheid waarmee deze conclusie getrokken kan 
worden is echter beperkt als gevolg van een grote mate van spreiding in de 
bevindingen. Vanuit gezondheidseconomisch perspectief kan samenvattend 
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geconcludeerd worden dat het zelfmanagementprogramma minimaal even efficiënt is 
als de reguliere astmazorg. 
Hoofdstuk 8: richtlijn versus realiteit 
In 2000 werd in de British Medical Journal een studie gepubliceerd naar de 
opvattingen van Britse astmapatiënten, huisartsen en praktijkverpleegkundigen over 
zelfmanagement. Hoewel zelfmanagement in Britse behandelrichtlijnen nadrukkelijk 
wordt geadviseerd, blijkt de bereidheid en interesse om zelfmanagement toe te 
passen opvallend laag. Hoofdstuk 8 is een redactioneel commentaar dat in het kader 
van deze bevindingen is geschreven. In dit commentaar wordt uiteengezet dat brede 
acceptatie van zelfmanagement een belangrijke voorwaarde is voor het 
daadwerkelijk toepassen. Essentieel voor deze brede acceptatie is overeenstemming 
tussen patiënten en hulpverleners over de doelen van astmabehandeling en de 
mogelijkheden van alle betrokkenen. Belangen van hulpverleners kunnen 
gemakkelijk haaks op die van de patiënt komen te staan. Erkenning en acceptatie 
door hulpverleners van de eigen keuzes van patiënten en erkenning en acceptatie 
door patiënten van de medische aspecten zijn nodig om tot een gemeenschappelijke 
'agenda' te komen. Zelfmanagement is er op gericht de autonomie en de inbreng van 
de patiënt te versterken en zo de patiënt meer verantwoordelijkheid voor de omgang 
met zijn ziekte te geven. Juist door deze typische eigenschappen is zelfmanagement 
een zeer geschikte behandelstrategie om op basis van een meer gelijkwaardige 
samenwerking de (schijnbare) kloof tussen het medische en het persoonlijke 
perspectief te overbruggen. 
Hoofdstuk 9: de meerwaarde van zelfmanagement 
Dit proefschrift is het resultaat van een onderzoeksproject dat in 1995 gestart is. 
Gedurende dit project zijn zowel eigen inzichten als internationale inzichten gegroeid 
en veranderd. In hoofdstuk 9 wordt een overzicht gegeven van de kennis en 
inzichten ruim 5 jaar na de start van het onderzoeksproject. Uit een overzicht van 
een aantal belangrijke studies naar de effecten van zelfmanagement kan 
geconcludeerd worden dat zelfmanagement winst oplevert voor zowel patiënten als 
hulpverleners. Zelfmanagement leidt tot een reductie van ziekenhuisopnames en 
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Eerste Hulp bezoek. Ook werkverzuim als gevolg van astma neemt af en er zijn zelfs 
aanwijzingen dat het hebben van een zelfbehandelplan het risico op sterfte door 
astma reduceert. Vanuit maatschappelijk perspectief leidt zelfmanagement tot een 
verlaging van astmagerelateerde kosten. Deze bevindingen schetsen een zeer 
positief beeld over de mogelijkheden van zelfmanagement, maar enige relativering is 
op zijn plaats. De meeste studies zijn gedaan bij patiënten die werden behandeld 
door de longarts, frequent de Eerste Hulp bezochten of patiënten die nog geen goed 
georganiseerde astmazorg ontvingen. De studies die in huisartspraktijken gedaan zijn 
tonen aan dat aldaar behandelde astmapatienten in veel gevallen goed tot redelijk 
onder controle zijn, waardoor er veel minder ruimte voor verbetering is. Daardoor 
kunnen de beschreven positieve bevindingen vaak met of met goed worden 
bevestigd. Dit laat echter onverlet dat een zelfmanagementprogramma bestaande uit 
patientgeonenteerde voorlichting, training van noodzakelijke vaardigheden en een 
geschreven zelfbehandelplan een efficiente oplossing kan zijn om de belangen van 
de patient en de huisarts in een samenhangend programma te verenigen. 
Zelfmanagement onderscheidt zich hierbij met zozeer door de inhoud van het 
programma, maar door de benadering van de patient. Het vraagt een andere 
houding van de arts ten opzichte van de patient. De arts moet (leren te) accepteren 
dat patiënten vanuit medisch oogpunt met altijd de meest gewenste keuzes maken. 
De verantwoordelijkheid van de arts is gelegen in het creëren van de optimale 
omstandigheden voor zelfstandigheid van de patient. Zelfmanagement dient 
patiënten uit te dagen tot onafhankelijkheid van de arts, tot de bereidheid om 
zelfbewust en weloverwogen keuzes te maken en tot het exploreren van de eigen 
mogelijkheden om met astma om te gaan. In dit proces van 'probleemgericht' leren 
kan de arts als coach optreden. Laagdrempeligheid en de continuïteit van zorg zijn 
typische kwaliteiten van de huisartsgeneeskunde. Het zijn ook belangrijke 
randvoorwaarden voor de typisch patientgeonenteerde samenwerking die 
zelfmanagement kan zijn. Vanuit dit perspectief is er dan ook zeker een plaats voor 
zelfmanagement m de huisartspraktijk. Zoals in hoofdstuk 8 staat, is het dan met 
zozeer de vraag of zelfmanagement effectiever is dan de gangbare zorg, maar meer 
of zelfmanagement een methode kan zijn om de belangen van patient en arts op 
basis van gelijkwaardige samenwerking tot hun recht te laten komen. 
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Hoofdstuk 10: conclusies en aanbevelingen 
De belangrijkste bevindingen van het ZBA-project zijn: 
1. Astma zelfmanagement is een verantwoorde methode voor intermitterende 
behandeling met inhalatiecorticosteroïden. 
2. Bij astma zelfmanagement hebben patiënten minder last van hun astma, terwijl 
het behoud van longfunctie minstens even goed is als bij reguliere astmazorg. 
3. Met inbegrip van de indirecte kosten is astma zelfmanagement minstens even 
efficiënt en mogelijk efficiënter dan reguliere astmazorg. 
4. Het gebruik van hulpmiddelen om meer systematisch rekening te houden met de 
behoeften van patiënten, zorgt voor een betere balans tussen de belangen van 
patiënt en huisarts en een meer patiëntgeoriënteerde astmazorg. 
5. Bij het geven van voorlichting aan astmapatiënten is het van belang dat de 
patiënt zich meer bewust wordt van mogelijk relevante onderwerpen. Hierin heeft 
de huisarts een belangrijke taak. 
6. Astmapatiënten die in de huisartspraktijk behandeld worden gebruiken vaak lage 
tot gemiddelde doseringen inhalatiesteroïden. De acceptatiegraad van 
zelfmanagement in deze categorie patiënten is voldoende hoog om 
zelfmanagement in de huisartspraktijk te kunnen implementeren. 
7. De acceptatiegraad van astmazelfmanagement onder huisartsen is voldoende 
hoog om zelfmanagement te kunnen implementeren in de huisartspraktijk. 
8. Zowel nationaal als internationaal opgedane kennis over de meerwaarde en 
bruikbaarheid van astma zelfmanagement rechtvaardigen een bredere 
aanbeveling van zelfmanagement in de NHG richtlijn 'Astma bij volwassenen: 
behandeling'. 
De conclusies uit het ZBA-project gelden met name voor patiënten die door hun 
huisarts behandeld worden voor mild tot matig persisterend astma. Een eerste stap 
bij het toepassen van zelfmanagement is hierbij het zo optimaal mogelijk stabiliseren 
van astma door de huisarts. Toepassing van zelfmanagement vanuit deze basis 
maakt astma zelfmanagement een efficiënte methode om tot een meer 
patiëntgeoriënteerde behandeling van astma te komen. Zelfmanagement 
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onderscheidt zich in positieve zin van de gangbare astmazorg op de 
patiëntgerelateerde uitkomsten en de economische consequenties hiervan. 
Verschillen tussen huisartspraktijken qua organisatievorm en grootte zijn niet 
bepalend voor de toepasbaarheid en effectiviteit van zelfmanagement. De 
mogelijkheden voor zelfmanagement lijken eerder door de patiënt bepaald te 
worden. Niet alle patiënten kunnen of willen met zelfmanagement beginnen. Soms 
zal eerst gepraat moeten worden over de bereidheid om een noodzakelijke 
onderhoudsbehandeling te starten, soms zal eerst onder begeleiding van de huisarts 
de mogelijkheid om een ingestelde therapie af te bouwen moeten worden verkend. 
Het zelfmanagementprogramma dat in het ZBA-project gebruikt is, is gebaseerd op 
de toenmalige inzichten over zelfmanagement. Daarom is gekozen voor een 
programma waarin verschillende interventies in een logisch samenhangend geheel 
worden aangeboden: patiëntenvoorlichting, training van vaardigheden en een 
geschreven zelfbehandelplan. In hoofdstuk 10 worden een aantal mogelijkheden 
geschetst om de efficiëntie van dit programma verder te vergroten. De introductie 
van de praktijkverpleegkundige in de Nederlandse huisartspraktijk biedt een aantal 
veelbelovende kansen. Maar ook de ontwikkelingen als bijvoorbeeld de 
samenwerking tussen huisarts en bedrijfsgeneeskundige dienst bieden nieuwe 
mogelijkheden. 
In hoofdstuk 10 worden naar aanleiding van het ZBA-project de volgende 
aanbevelingen gedaan: 
- Op grond van de resultaten van het ZBA-project kan geconcludeerd worden dat 
het zelfmanagementprogramma dusdanig succesvol is geweest dat toepassing in 
de Nederlandse huisartspraktijk wordt aanbevolen. Zelfmanagement moet hierbij 
niet de reguliere astmazorg vervangen. Het is een volwaardig alternatief en een 
verantwoorde methode als intermitterende behandeling met 
inhalatiecorticosteroïden wordt overwogen of gewenst is. 
- De huidige aanbeveling in de NHG standaard 'Astma bij volwassenen: 
behandeling' om '....ten minste zelfbehandelingsadviezen (schriftelijk en 
mondeling) en een piekstroommeter te geven aan volwassenen met ernstig 
astma, aan diegenen met een wisselend patroon en diegenen die in een 
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ziekenhuis opgenomen zijn wegens astma' dient te worden uitgebreid naar alle 
patiënten die lage tot gemiddelde doseringen inhalatiecorticosteroïden (zouden 
moeten) gebruiken. Dit zijn in het algemeen patiënten met mild tot matig 
persisterend astma. Deze aanbeveling dient prominenter te zijn dan alleen een 
vermelding in het notenapparaat. 
- Er is verder onderzoek nodig om de vraag te beantwoorden of er meer specifieke 
patiëntkenmerken zijn die kunnen voorspellen of iemand wel of geen baat heeft 
bij zelfmanagement. 
- Het zelfmanagementprogramma kan wellicht nog verbeterd worden door 
overbodige of overlappende elementen te verwijderen, zodat alleen de meest 
effectieve onderdelen overblijven. Ook de eventuele toevoeging van zinvolle 
onderdelen verdient aandacht. 
- Wellicht kan een deel van de gevonden effecten worden toegeschreven aan het 
deelnemen aan een strak georganiseerd wetenschappelijk experiment. Op termijn 
kan wellicht de vraag beantwoord worden op welke manier patiënten doorgegaan 
zijn met zelfmanagement na het onderzoeksproject en of de gevonden effecten 
zijn gebleven. 
Aan het eind van deze samenvatting moge duidelijk zijn dat er nog mogelijkheden en 
onbeantwoorde vragen zijn, die de efficiëntie van zelfmanagement kunnen 
vergroten. Desondanks kan nu reeds geconcludeerd worden dat zelfmanagement 
van astma, gericht op gedeelde verantwoordelijkheid en patiëntgeorienteerde 
samenwerking, de efficiëntie van astmazorg doet toenemen. Het zoeken naar 
antwoorden op de nog openstaande vragen is dan ook geen reden om toepassing 
van zelfmanagement in de Nederlandse huisartspraktijk uit te stellen, het zal de 




GP manual for patient education: general instructions and 
example of first visit (both in Dutch) 
Algemene instructies 
Tijdens het ZBA-onderzoek ziet u de patiënt op zeven "geplande" consulten (1 t/m 
7). Voor elk van deze consulten vindt u een draaiboek in deze map "Materialen 
huisarts". Als u het draaiboek voor het betreffende consult van begin tot eind 
volgt tijdens het consult, verschaft u de patiënt stapsgewijs de informatie die hij of 
zij nodig heeft voor het uitvoeren van zelfbehandeling. De cursief gedrukte tekst 
kunt u desgewenst letterlijk 'voorlezen', maar u kunt ook alleen gebruik maken van 
de in HOOFDLETTERS weergegeven KERNWOORDEN. Vet gedrukte tekst geeft 
de dingen aan die u zelf moet doen. 
De inhoud van de patiëntenvoorlichting heeft als belangrijkste doelen de 
ondersteuning van het zelfbehandelingsplan en het motiveren van de patiënt. De 
opzet is om in eerste instantie beperkte informatie aan te bieden. Als de patiënt 
aangeeft behoefte te hebben aan meer voorlichting of advies over een specifiek 
onderwerp (bv. stoppen met roken, sanering), dan is het aan te bevelen om 
daarvoor extra tijd te reserveren. 
Het leren van het gebruik van de dag- en weekrapporten en het 
zelfbehandelingsplan gebeurt stapsgewijs. De opbouw van de consulten is hier op 
afgestemd. Het belangrijkste is steeds dat de patiënt zelf gaat oefenen. Trial en 
error is de beste leerschool voor een gecompliceerd behandelplan. Uw rol hierin is 
het adviseren en begeleiden van de patiënt bij het ontdekken van alle 
mogelijkheden en moeilijkheden. 
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Voorlichtingsconsult 1 
Geschatte duur 30 minuten 
VOORBEREIDING 
Materialen Neon uit de map 'Materialen patiënten' hel hele plastic 
mapje van de patiënt. 
Haal uit dit mapje: 
* De brochure Ontgaan met astma' 
* Hel 'Voorlichtin^egistratieronnulier war de 
huisarts' 
Pak een piekstroonuneter 
Pak twee dagboekjes. 
Roep de patiënt binnen 
UITLEG ZELFBEHANDELINGSONDERZOEK 
Inleiding Du consult is bedoeld om u uu te leggen WAT HET 
zelJbehandelingsONDERZOEK INHOUDT Tevens aillent 
vandaag een BEGIN MAKEN MET u te leren hoe u de 
zelßehandelutg kunt TOEPASSEN 
Bdang en doel Du onderzoek is opgezet door de KATHOLIEKE UNIVERSITEIT 
NIJMEGEN Onderzocht wordt of hel 'ZO NODIG GEBRUIK 
van de ontstekuigsrerrmer PULMICORT net zo goed is, of 
misschien wel beier, dan CONTINUE BEHANDELING met du 
middel 
Inhoud en duur Het onderzoek duurt TWEE JAAR In du onderzoek gaal u als hel 
ware een deel van mijn werk over nemen Aan de hand HUI een 
DAGRAPPORT gaat u zelf BIJHOUDEN hoe het ma uw asma 
gaat en zonodig de behandeling met Pulmicort aanpassen 
Willen stoppen Ik vind het als huisarts erg belangrijk dat astmapatibuen zelf hun 
behandeling op een goede manier kinnen aanpassen Vandaar 
dat ik hoop dat u het onderzoek helemaal af zult maken Mocht u 
echter loch tussentijds willen Sloppen met hel onderzoek, dan kan 
du altijd Neem dan wel even met mij coniaci op 
Materiaal Toon hel dagboekje aan de patiënt. 
DIT BOEKJE zuil u de komende twee jaar gaan gebruiken Ha is 
de BASIS VAN HET ONDERZOEK en HELPT Ubtjde 
zelfbehandelmg Ik zal u STRAKS MEER over du boekje 
venellen 
ALGEMENE VOORLICHTING OVER ASTMA 
Aard en oorsak van astma Asma is een LEVENSLANGE ZIEKTE ma een WISSELEND 
BELOOF Vaak is er een ERFELIJKE AANLEG. Asaiu wordt 
GEKENMERKT door VERNAUWING VAN DE LUCHTWEGEN. 
Dea vernauwing tan de volgende KLACHTEN vtworzaken: 
konademgheid (ui aanvallen) 
- piepen, zagen, brommen 
• Hoesten 
• 'volzuten ' 
• opgeven van slijm 
Prognose Astma is NIET TE GENEZEN, maar je huu wel KLACHTEN 
BEHANDELEN DU heeft een GUNSTIGE INVLOED op Het 
BELOOP van de ziekte 
Hyperreactiviteit en allergie 
allergietest 
Astmapaiiimen Hebben PRIKKELBARE LUCHTWEGEN. 
Luchtwegen worden geprikkeld door ALGEMENE PRIKKELS 
(hyperreaaivueit), wals: 









Als je gevoelig bent voor dergelijke prikkels ben je 
ALLERGISCH. 





KortademigHeid ontstaat door VERNAUWING VAN DE 
LUCHTWEGEN Cademen door een rietje'). Dit ontstaat door 
VERKRAMPING van de SPIERTJES om de luchtwegen en 
doordat de SLUMVLIEZEN OPZWELLEN en MEER SLUM gaan 
maken Du laatste noemen we ONTSTEKING van de luchtwegen. 
Gebruik eventueel de Illustratie hiernaast om bovenstaande 
voor de patlint te verduidelijken. 
10 Boekje Asma Fonds Geef het bodge 'Omgaan met astma' aan de patünt 
Wal ik u zojuist verteld heb hua u THUIS RUSTIG NALEZEN in 
dit boekje van het Astma Fonds 
LoDgfunctieonderzoek Venuinwig van de luchtwegen lam je meten Dà is de meting die 
| « al gehad heeft OP HET LONGFUNCTIE LABORATORIUM. 
Piekaroom en klachten De longfunctie kunt u op een EENVOUDIGE manier zelf in de 
gaten houden door THUIS de PIEKSTROOM en uw 
ASTMAKLACHTENbi] te houden in een DAGBOEK. Dit gaan 
we de komende TWEE WEKEN DAGELIJKS THUIS OEFENEN 
INSTRUCTIE VAARDIGHEDEN 
Inaniftif pieksroommeting Geef de patiënt een piekstroommeler 
Om uw longfunctie goed te hinnen meten is hel belangrijk dat u 
deze piekstroommeler op de GOEDE MANIER gebruUa. Dat 
gaan we nu OEFENEN 
• Zet het mondstuk op de meter (zie tekening) 
• Schuif de rode wijzer zo dicht mogelijk naar het 
toe 
• Houd de piekstroommeler vast zoals op de tekening 
• Ga staan en adem zo diep mogdijk in 
• Plaats het mondstuk van de meter tussen lippen e 
• Blaas kort en zo hard mogdijk in het mondstuk 
• Lees de stand van de wijzer af (zie tekening) 
• Herhaal de meting nog 2 keer en schrijf de hoogste waarde 
op 
Invullen dagrapport 
Uitleg un de patient 
U heeft nu met de patiënt geoefend. 
Schrijf op het DAGnpporI de hoogste genieten plrtitroom op 
In het grijze Talpe 'Uw beste waarde tot nu toe' 
BEPAAL de 80, 60 en 40% grenswaardes 
Vul op het DAGrapport In: 
tHTpm: de S M waaide, 
eent de 6* eo dan de M » waarde, 
o n t de 4 · α daa de « · » waarde, 
de 4 · » waarde. 
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Zet op de plekstroommeter: 
- het groen/gde schulQe op de 80% waarde 
- het geel/rode schulQe op de 60% waarde 
- het rood/lila schulQe op de 40% waarde 
Geef nu het Ingevulde boekje aan de patltnt. 
Ik heb nu de HOOGSTE PIEKSTROOMWAAXDE die u zojuist 
geblazen Heeft hier op uw dagrapport geschreven (WUS DE 
HOOGSTE WAAKDE ΑΛΝ) Deu vaarde noemen we de 
PERSOONLIJKE BESTE WAARDE. Daarna heb Ik berekend 
welke piekaroomuaardei in uw geval horen by de kleuren groen, 
geel. rood en lila. Deze KLEUREN GEVEN AAN hoe u arala uw 
ASTMA HET BESTE ZELF kunt BEHANDELEN, menner vertel 
ik u m HET VOLGENDE CONSULT meer 
Op uw PIEKSTROOMMETER hua u aan de GEKLEURDE 
PIJLTJES, die ik voor u heb ingesteld, de GROENE, GELE 
RODE EN UU ZONES herkennen. 
Invulinsmicue voor ik pauêm ik zou nu graag zun dat u THUIS S MORGENS EN 'S AVONDS 
\ uwptekstroom gaai MEIENEN OPSCHRIJVEN in uw 
dagrapport Meet uw piekst room steeds VOORDAT u uw 
ASTMAMEDICIJNEN INHALEERT' 
Meet net als wjuist. DRIEMAAL PER KEER en noteer de 
HOOGSTE WAARDE van deze dne metingen Noteer dat 
vaarde dan wil bij het GOEDE MOMENT van de dag en m de 
GOEDE GEKLEURDE BALK We zullen du nu eens samen 
oefenen 
Oefenen met de pautnt PieksDoom Stel, uw piekstroomMoardc van deze ochtend was 
Noem een pielutroomwaarde uit de (de zone (tulten de 60 en 
80%) 
Kunt u de DATUM VAN VANDAAG én deze PIEKSTROOM-
WAAMDE nu eens voor rmj in het boekje schrijven 
Controleer of: 
- de datum van vandaag boven aan by de Julttedat Tan de 
week en op de Juiste w^ze (dag-maand-Jaar) b Ingeruld, 
- de piekstroom In de kolom met de Juiste dag van de week 
(vandaag) staat, 
- de piekstroom In de kolom 'Ochtend' staal, 
- de piekstroom In de gele zone staal. 
Klachten 
Vul 1 i ouic η j 
hcoti |-i ai ir ir 










Naast het bijhouden van de piekstroom is ook het BIJHOUDEN 
VAN UW KLACHTEN van belang, om te zien hoe het met mi 
astma gaat Kruis ELKE A VOND hier aan of u de afgelopen dag 
last heeft gehad van Un afmeer van de genoemde klachten 
Wijs In het dagboek het onderdeel 'Klachten' aan met de 
groene, gele, rode en Illa zone. 
[Schrijr de naam van de door de patttnt gebruikte 
[ortwerkende luchtwegverwijder op In het vakje voor de rode 
>ne 
Laat de patlint aankruisen hoe deze zkh op dU moulent voelt 
Controleer of het kruide/de kruisjes in de kolom met de Juiste 
dag van de week (vandaag) staat/slaan. 
19 Astmamedtcijnen 
tb g « r i*v * 
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Ook is het de bedoeling dat u hier opschrijft hoeveel 
astmamedicijnen u dagelijks gebruikt 
Wijs in het dagboek het onderdeel 'AstmamedcUnen' aan en 
noleer daar de naam van de gebruikte luchtwegve-wyder(s). 
Laai de patiënt de gebruikte medicatie van vandaag invullen. 
Controleer· 
- of de gegevens In de kolom met de Juiste dag van de week 
(vandaag) staan, 
- of het 'aantal keer per dag' In het Juiste hokje b Ingevuld, 
- of het 'aantal puQes per keer' in het Juiste hokje is 
ingevuld. 
20 Symptomen 
Ct*i η ί« nltr« Bmauwdhe d 





Voor Λ« onderzoek willen we ook graag weien hoeveel last u 
heeft van benauwiBieid, piepende ademhaling en hoesten Geef 
du IEDERE DA G met behulp van de 'Klachtenscore ' aan 
Wije In het dagboek bet onderdeel 'Symptomen' aan en wUa 
hdemaal aan de rechterzyde aan waar de 'Klachtenacore' 
Laat de patlint alle drie de symptomen TOOT vandaal acoren. 
Controleer: 
- of de scores in de kolom met de juiste dag van de «eek 
(vandaag) staan» 
- of by dk symptoom een score Is Ingevuld. 
21 Invullen basisgegevens 
Pitientnummer f 2 3 4 £" 
Geboortedatum 4 % _ Q f _ £ 2 
Vul nu zélf op het dagrapport in: 
- patlëntnunumr 
- geboortedatum (dag-nuand-jaar) 
Laat de patiënt de gegevens op de voorflap invullen. 
AFRONDING CONSULT 
22 Nieuwe afspraak Geef de patlint een tasje van het Astma Fonds om alle 
materialen in Ie bewaren. 
Laai de paliint bij de assistente een NIEUWE AFSPRAAK 
van 20 minuten - DUBBEL CONSULT- plannen voor over 
TWEE WEKEN. Wijs de patünt er op dal dem licb 10 
minuten vòdr dit consult bij de aslstente mddl am alvast 
een formulier in te vullen. ('Astma voorlicbungsregistratie-
formuher voor de pallini') 
Wijs erop, dal de patünt bij het volgende consult opnieuw 
de dagboefcj«, piekstroommeler, Turbuhaler en 
informatiebrochure meeneemt 
De patiënt kan nu vla de assistente naar huis. 
CONSULTREGISTRATIE 
23 Geboortedatum: 12.13 0 1 a l ? ' 
Consulten: 
I 2 3 4 ι S 
15" 
D a t u m consult: \ί 
Vul hel 'Astma voorllchtlngmglstraliefonnuUer voor de 
huisarts' in. Kruis daarvoor de voorlkbtliigdtems, die In 
dn consult aan bod zijn geweest, aan In de kokm van 
consult 1. Vergei niet onderaan de DUUR VAN HET 
CONSULT te noleren. 
Scheur hierna de achterste doorslag van dit formulier af 
en stuur ALLEEN DEZE DOORSLAG met een portvrije 
retouimvdop naar Nijmegen. 
Slop de rest van dit formulier terug In hel piastk maple 
van de patiënt, in de map 'Materialen patiënten'. 
HET EERSTE CONSULT IS NU KLAAR 
182 
Dankwoord 
Dit proefschrift gaat over zelfmanagement, een kwaliteit die ook voor een 
promovendus geen overbodige luxe is gebleken. Toch heb ik dit proefschrift niet 
alleen gemaakt. Het is voor mij dan ook vanzelfsprekend dat een dankwoord aan 
iedereen die bij het ZBA project betrokken is geweest, integraal onderdeel van dit 
proefschrift moet zijn. 
Voor mij begon het ZBA project in het najaar van 1995. Het project heette toen 
'Zelfbehandeling van astma voor patiënten met inhalatiecorticosteroïden in de 
huisartspraktijk'. Een titel die voor een kortademige astmapatiënt natuurlijk niet uit 
te spreken is en waarvoor dan ook al snel het acroniem ZBA werd bedacht. Bij het 
organiseren van het ZBA project zijn veel mensen betrokken geweest. In de 
beginfase van het project zijn er twee mensen die ik speciaal wil bedanken. Dit zijn 
Lud Beijers en Ivo Smeele. Het opzetten van de logistiek van dit onderzoeksproject 
was voor mij pionieren. Gelukkig was er altijd de inbreng en kritische toets van Lud, 
waardoor de hele logistiek tot in detail kon worden uitgewerkt. Lud, jouw inbreng in 
deze fase van het project heeft er zeker toe geleid dat ZBA ook in logistieke zin een 
succes is geworden. Ik kijk dan ook met plezier op onze samenwerking terug en 
verheug me op eventuele nieuwe projecten, waarin we kunnen samenwerken. Ook 
Ivo wil ik in de context van het opzetten van het project speciaal bedanken. Jij was 
altijd de pragmatische toets die er voor waakte dat het zelfmanagement programma 
voor huisartsen en patiënten waardevol en uitvoerbaar bleef. Daarnaast bleef je in 
de verdere loop van het project een waardevolle toetssteen voor mijn ideeën. Maar 
vooral onze gesprekken over de balans tussen werk en gezin heb ik als een zeer 
waardevolle steun gevoeld bij het maken van mijn eigen keuzes. 
Toen het project geleidelijk aan zijn vorm begon te krijgen, bleken er bergen werk 
verzet te moeten worden. De binnenkomst van Tjard (toen nog als 
onderzoeksassistent) bleek een gouden greep. Tjard, je bleek niet alleen een zeer 
goede steun bij al het werk van ontwerpen, drukken, sorteren en verspreiden van 
boekjes en formulieren. Je was daarnaast ook een gezellige collega om mee samen 
te werken. Dit is altijd zo gebleven, maar de manier waarop je in de loop van de 
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afgelopen jaren ook inhoudelijk bij het project betrokken bent geraakt, was voor mij 
van onschatbare waarde. Naast een prachtige kosten-effectiviteits analyse (of ΚΕΑ, 
voor de kortademigen) ben je voor mij altijd degene die me methodologisch op het 
rechte en objectieve pad wist te houden. Het was en is de basis voor een vruchtbare 
samenwerking. 
De basis van het ZBA-project was natuurlijk het eigenlijke experiment. De 
hoofdrolspelers die ik zeker niet over wil slaan in dit dankwoord zijn dan ook de 
deelnemende patiënten en hun huisartsen. Met zeer veel toewijding en geduld 
werden vele vragenlijsten bijgehouden, waarvan de 18.388 dag- en weekrapporten 
en de 859 consultformulieren nog maar het topje van de spreekwoordelijke ijsberg 
vormen. Zonder de wijze waarop de huisartsen invulling hebben gegeven aan hun 
astmazorg en de loyaliteit waarmee patiënten vragenlijsten en dagboekjes hebben 
bijgehouden, was dit onderzoek nooit gelukt. Er zijn een paar mensen en praktijken 
die ik in deze context speciaal wil bedanken. Dit zijn allereerst de 
longfunctieassistentes die alle metingen hebben gedaan: Lilian, Vicky, Maria en 
Lisette. Bedankt voor de altijd correcte en toch zeer persoonlijke bejegening van de 
patiënten, jullie voortvarendheid bij het plannen van alle afspraken en de hoge 
kwaliteit van de verzamelde data. Er is ook een praktijk die ik speciaal wil bedanken, 
het 'Gezondheidscentrum Stratum'. Als 'pilotpraktijk' waren jullie vanaf het prille 
begin betrokken bij het testen van alle procedures en protocollen. Dit vond ik zeer 
waardevol. Naast de altijd gastvrije ontvangst met soms een vleugje Koot en Bie zijn 
jullie daardoor voor mij altijd een speciale praktijk gebleven. 
Ook in Nijmegen is het project door vele mensen ondersteund. Twanny en Lea, jullie 
hebben vele klussen voor het project gedaan. Zo zijn er bijvoorbeeld 911 
Turbuhalers geteld en van alle formulieren die deels door Harry en deels door jullie 
zijn ingevoerd, ben ik de tel kwijt geraakt. In deze context wil ik ook Reinier 
bedanken voor zijn bijdrage. Het organiseren en analyseren van al het materiaal 
vond ik erg leuk en interessant. Maar als het moeilijk werd, dan mocht jij het 
overnemen. De meest ingewikkelde analyses waren dan altijd in een oogwenk weer 
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gedaan en na jouw uitleg kon ik ze nog interpreteren ook. Je hebt dan ook een 
onmisbare bijdrage geleverd aan het analyseren en interpreteren van alle gegevens. 
Binnen het project hebben diverse studenten en assistenten meegelopen. Marielle, 
Marie-José, Manon, Elke, Edith en Zineta, in jullie stages hebben jullie deelvragen 
van het project beantwoord, waarvoor de gegevens vaak met veel monnikenwerk 
moesten worden uitgezocht. Dat jullie dit telkens tot een goed eind brachten is een 
compliment waard. Ik hoop dat jullie veel binnen het project geleerd hebben en net 
zoveel plezier van de stages hebben gehad als ikzelf. Op deze plaats wil ik ook 
Marjolein, Chantal en Miranda bedanken. Dankzij jullie assistentie hebben we in een 
korte tijd veel bruikbare gegevens beschikbaar gekregen. 
De inhoudelijke ondersteuning van het project door Onno van Schayck en Richard 
Grol bleek een goede combinatie. Onno, jij liet me zeer zelfstandig werken binnen 
het project. Dat gaf mij de kans om me het project in een vroege fase echt eigen te 
maken. Ik kon echter altijd voor overleg bij je terecht en je vertrouwen in de goede 
afloop van het project was een steun in de rug. Na je vertrek naar Maastricht vond ik 
het een stuk lastiger om de inhoudelijke voortgang van het project te blijven 
afstemmen. Dank zij de moderne communicatiemiddelen en enkele gezamenlijke 
congressen bleek het echter opgelost te kunnen worden en ik ben blij dat je tot het 
eind van het project inhoudelijk betrokken bent gebleven. Richard, ook jou wil ik hier 
als promotor speciaal bedanken. Je had vaak een rol die ik in eerste instantie best 
lastig vond. Als ik dingen even snel wilde regelen of dacht alles netjes opgeschreven 
te hebben, dan trok jij vaak aan de rem. Dit was echter nooit zonder reden. Je 
inhoudelijke commentaren en correcties sneden hout en ik merk dat ik daardoor 
kritischer naar mijn eigen schrijfstijl ben gaan kijken. Je hebt daarmee zowel aan 
mijn eigen groei, als aan de kwaliteit van het project een belangrijke bijdrage 
geleverd. 
Naast beide promotores kende het ZBA project ook een begeleidingscommissie 
bestaande uit: Chris van Weel, Cees van Herwaarden, Johan Molema, Hans 
Folgering, Gijs Bleijenberg, Henk van den Hoogen, Ivo Smeeie, Guido van den Boom 
en Joost den Otter. Vele plannen en versies van mijn protocol en publicatieplan 
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hebben jullie gewillig aanhoord en hier is dan het uiteindelijke product! Dank voor 
jullie bijdrage en gewaardeerde expertise. Een paar leden van de 
begeleidingscommissie wil ik nog speciaal bedanken, namelijk Chris van Weel en 
Guido van den Boom. Jullie wisten beiden in een cruciale fase van het project met 
zeer verfrissende inzichten en ideeën mijn output weer op stoom te krijgen. Guido, 
jouw analytische manier van kijken heeft mij weer een heel andere manier van 
schrijven geleerd. Je was een goede 'sparringpartner' om mijn gedachten helder te 
krijgen en scherp in de artikelen te formuleren. Bedankt daarvoor. 
Iemand die ik aan het eind van dit proefschrift ook speciaal wil bedanken is André 
Knottnerus. André, je bent niet bij dit onderzoek betrokken geweest, maar je stond 
wel aan de wieg van mijn wetenschappelijke carrière. Door de manier waarop jij mij 
kennis hebt laten maken met wetenschappelijk onderzoek in de 
huisartsgeneeskunde, ben ik er voor altijd aan verknocht geraakt. Ik vond en vind 
het zeer bijzonder dat je door alle jaren heen ook precies bleef weten waar ik mee 
bezig was en heb je welgemeende en persoonlijke belangstelling altijd zeer 
gewaardeerd. 
Het laatste deel van mijn dankwoord heb ik voor een paar zeer speciale mensen 
gereserveerd. Om te beginnen zijn dit mijn kinderen: Maarten, Wouter, Vera en 
Anne. Het doen van een promotie onderzoek heeft mij niet alleen dit proefschrift 
opgeleverd. Jullie zijn er ook bijgekomen. Dankzij jullie komst heeft de 
totstandkoming van dit proefschrift wat langer geduurd. Het is er alleen maar beter 
van geworden. Jullie hartverwarmende afleiding zorgde ervoor dat ik mijn vaderrol 
niet uit het oog hoefde te verliezen. En dat was maar heel af en toe tegen wil en 
dank! 
Ook mijn ouders en schoonouders verdienen een speciale plaats in dit dankwoord. 
Jullie ondersteuning, zeker gedurende de laatste drie jaar is zeer bijzonder geweest. 
Zonder deze steun had ik het nooit gered en dit proefschrift is daarmee ook een 
beetje jullie proefschrift. Ik benoem jullie daarom tot doctor in de mantelzorg! Ook 
Tante Riet verdient een speciaal woord van dank. De energieke wijze waarop jij er 
bent voor onze kinderen en de zekerheid dat de kinderen bij jou in goede handen 
zijn, is een grote steun. 
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Désirée, de laatste tijd vroegen we ons wel eens gekscherend af waarvoor ik je zou 
gaan bedanken. We waren het er over eens dat het niet hoefde te gaan over de 
opvang van de kinderen of het geduldig tolereren van afwezigheid. En toch wil ik je 
hier speciaal bedanken. Ik wil je bedanken omdat je er was en voor de manier 
waarop we samen dit punt hebben bereikt. Zeker met de komst van 'de drieling' 
werden onze toekomstplannen behoorlijk op de proef gesteld. Samen moesten en 
moeten we opnieuw onze weg bepalen en er voor knokken. Deze promotie is voor 
mij niet alleen de bekroning van de 'wetenschappelijke proeve van bekwaamheid'. 
Het is ook de bevestiging dat we samen veel kunnen bereiken. 'Love lifts us up 
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Nijmegen, 16 oktober 2002 
1. Bij zelfmanagement van astma hebben patiënten minder last van hun astma, terwijl het 
behoud van longfunctie gelijkwaardig is aan de reguliere astmazorg (dit proefschrift). 
2. Met inbegrip van de indirecte kosten is zelfmanagement van astma minstens even 
efficiënt en mogelijk efficiënter dan reguliere astmazorg (dit proefschrift). 
3. Het gebruik van hulpmiddelen om meer systematisch rekening te houden met de 
behoeften van patiënten, zorgt voor een betere balans tussen de belangen van patiënt 
en huisarts en een meer patiëntgeoriènteerde astmazorg (dit proefschrift). 
4. Bij het geven van voorlichting aan astmapatiënten is het van belang dat de patiënt zich 
meer bewust wordt van mogelijk relevante onderwerpen. Hierin heeft de huisarts een 
belangrijke taak (dit proefschrift). 
5. Astmapatiënten die in de huisartspraktijk behandeld worden, gebruiken vaak lage tot 
gemiddelde doseringen inhalatiesteroiden. De acceptatiegraad van zelfmanagement in 
deze categorie patiënten is voldoende hoog om zelfmanagement in de huisartspraktijk te 
kunnen implementeren (dit proefschrift). 
6. De acceptatiegraad van zelfmanagement van astma onder huisartsen is voldoende hoog 
om zelfmanagement te kunnen implementeren in de huisartspraktijk (dit proefschrift). 
7. Op grond van de resultaten van het ZBA-project kan geconcludeerd worden dat het 
zelfmanagementprogramma dusdanig succesvol is geweest dat toepassing in de 
Nederlandse huisartspraktijk wordt aanbevolen. Zelfmanagement moet hierbij niet de 
reguliere astmazorg vervangen. Het is een volwaardig alternatief en een verantwoorde 
methode als intermitterende behandeling met inhalatiecorticosteroiden wordt overwogen 
of gewenst is (dit proefschrift). 
8. De huidige aanbeveling m de NHG standaard 'Astma bij volwassenen: behandeling' om 
' .ten minste zelfbehandelmgsadviezen (schriftelijk en mondeling) en een 
piekstroommeter te geven aan volwassenen met ernstig astma, aan diegenen met een 
wisselend patroon en diegenen die in een ziekenhuis opgenomen zijn wegens astma' 
dient te worden uitgebreid naar alle patiënten met mild tot matig persisterend astma. 
Deze aanbeveling dient prominenter te zijn dan alleen een vermelding in het 
notenapparaat (dit proefschrift). 
9. Roken is een verslavmgsziekte. 
10. Doctor - patient consultations are all too often driven by the heath professional and with 
excellent medications available it is not surprising that consultations tend to be 
prescription orientated (Dr M Partridge, UK National Asthma Campaign, 2000). 
11. A long time ago in a galaxy far, far away .. 
12. If it's just us, that would be an awful waste of space. 
13. God heeft de wereld rond gemaakt, zodat we met te ver vooruit kunnen kijken (Isak 
Denissen, Deens schrijver). 
14. Het zijn met de godsdiensten zelf die aanzetten tot haat en intolerantie, maar de mensen 
die ze belijden. 
Bart Thoonen 

